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ABSTRACT 
There has been tremendous amount of effort focused on the development and 
improvement of genome editing applications over the decades. Particularly, the 
development of programmable nucleases has revolutionized genome editing with regards 
to their improvements in mutagenesis efficacy and targeting feasibility. Programmable 
nucleases are competent for a variety of genome editing applications. There is growing 
interest in employing the programmable nucleases in therapeutic genome editing 
applications, such as correcting mutations in genetic disorders.  
Type II CRISPR-Cas9 bacterial adaptive immunity systems have recently been 
engineered as RNA-guided programmable nucleases. Native CRISPR-Cas9 nucleases have 
two stages of sequence-specific target DNA recognition prior to cleavage: the intrinsic 
binding of the Cas9 nuclease to a short DNA element (the PAM) followed by testing target 
site complementarity with the programmable guide RNA. The ease of reprogramming 
CRISPR-Cas9 nucleases for new target sequences makes them favorable genome editing 
platform for many applications including gene therapy. However, wild-type Cas9 
nucleases have limitations: (i) The PAM element requirement restricts the targeting range 
of Cas9; (ii) despite the presence of two stages of target recognition, wild-type Cas9 can 
cleave DNA at unintended sites, which is not desired for therapeutic purposes; and (iii) 
there is a lack of control over the mutagenic editing product that is procuded.  
In this study, we developed and characterized chimeric Cas9 platforms to provide 
solutions to these limitations. In these platforms, the DNA-binding affinity of Cas9 protein 
from S. pyogenes is attenuated such that the target site binding is dependent on a fused 
   vii 
programmable DNA-targeting-unit that recognizes a neighboring DNA-sequence. This 
modification extends the range of usable PAM elements and substantially improves the 
targeting specify of wild type Cas9. Furthermore, one of the featured chimeric Cas9 
variants developed in this study has both robust nuclease activity and ability to generate 
predictable uniform editing products. These superior properties of the chimeric Cas9 
platforms make them favorable for various genome editing applications and bring 
programmable nucleases one step closer to therapeutic applications. 
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CHAPTER I: Introduction 
1.1 Introduction on understanding the genetic code  
The information defining the heritable characteristics of living beings is stored in 
their genetic material, their genome. For the majority of organisms, the genome is 
constituted of deoxyribonucleic acid (DNA). The stored genetic information within DNA 
is encoded as an alphabet with four letters, bases: Adenine, Thymine, Guanine, and 
Cytosine. Throughout time, cellular machineries have evolved to compile, execute, restore, 
and reproduce the encoded genetic information. 
Understanding the functions of genes—the basic unit of heredity—in the context 
of physiology or disease is a fundamental scientific interest. Since Mendel’s first pea 
hybridization experiments, geneticists have been working hard to deconvolute the meaning 
of the genetic code. Early research into gene function has relied upon forward genetic 
approaches, where a gene is associated with an observed phenotype caused by a random 
loss of function mutation. Technological advancements such as development of DNA 
sequencing and polymerase chain reaction (PCR) led to the rise of reverse genetics to 
decrypt the genetic code. In the genomics age, with the combination of information 
technologies and modern genetics it is possible to read the whole genome of various 
organisms (including humans) fast and accurately. Researchers can now access large 
datasets to discover the function of genes and other regulatory genomic regions, associate 
the variations and mutations with physiological processes and diseases. Two patients with 
a similar disease phenotype may possess different types of underlying mutations or gene 
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variations that alter how they respond to a conventional therapy. Accumulation of deeper 
datasets is shaping the future of medicine towards personalized treatment options. 
1.2 Rise of genome engineering via programmable nucleases 
As researchers have been deciphering the genetic code, scientific curiosity and the 
quests of geneticist began to shift into editing the genetic code. Gene targeting—the 
ancestor phrase of genome editing—allows sequence-specific alterations of a genomic 
locus via homologous recombination1. Such alterations are useful to study the function of 
a gene by generation of null mutants or insertion of reporters to regulate its expression 
spatially or temporally2. Beyond understanding gene function, gene targeting has the 
potential to revert mutations that are underlying genetic disorders. In complex genomes 
such as humans, homologous recombination is extremely rare event such that its frequency 
is less than one in a million somatic cells1. Presence of a double strand break at a particular 
genomic site stimulates the gene targeting for this site by orders of magnitude3, 4. Therefore, 
generation of intentional double strand breaks (DSB) at a defined DNA sequence became 
the interest genome engineering efforts. 
In order to create a DSB at a defined site in genome, researchers use programmable 
nucleases. These nucleases are composed of a sequence-specific DNA targeting unit and a 
catalytic unit; the activity of the latter depends on success of former. There are four types 
of programmable nucleases: Meganucleases, zinc finger nucleases, TALENs, and 
CRISPR-Cas system5. The first three nucleases use protein-DNA interactions to achieve 
sequence-specific DNA targeting. Whereas, CRISPR-Cas system is an RNA-guided 
nuclease platform. The utility of genome editing via programmable nucleases is 
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revolutionizing biomedical research. Over the last two decade, there has been tremendous 
progress in the development of programmable nucleases and their creative applications. 
Programmable nucleases can be employed on research models (cell lines and model 
organisms) to study biological processes or disorders, economically important plants and 
livestock to improve the quality of products and choose desired traits, and therapeutic 
genome editing applications6. Among these various applications, therapeutic genome 
editing requires serious considerations, such as the efficacy, safety, and successful delivery 
of the nucleases7, 8. The center work of this thesis is to assess and improve the specificity 
(safety) of CRISPR-Cas9 nucleases for future therapeutic genome editing applications. 
1.3 Mechanism of programmable nucleases-directed genome editing 
In common to all programmable nucleases, the outcome of genome editing depends 
on cellular events. Once a nuclease docks on the genome and finds its target site, it 
generates a double-strand break. A genomic double strand break is a serious threat to cells’ 
well-being.  Therefore, cells respond to a DSB by triggering two primary types of DNA-
repair pathways: Non-homologous end joining (NHEJ) and homology-directed repair 
(HDR)9 (Figure 1.1a). Mammalian cells predominantly respond to a DSB via canonical 
NHEJ. Depending on the conformation of the broken ends NHEJ machinery ligates the 
ends of broken DNA strands differently. For blunt ended DSBs, the ends are preferentially 
ligated precisely10, 11.  Such ligation may restore the nuclease target site and leads to another 
round of nuclease cleavage and DSB formation. During the repair of DSBs with staggered 
ends, NHEJ machinery may insert or delete a few random bases at the site of a DSB (indels) 
prior to the ligation of the broken ends10, 11. Indel mutations may cause gene disruption due 
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to changes in the open reading frame. If two separate DSBs occur on the genome 
simultaneously, more complex genomic arrangements may occur: such as deletion or 
inversion of the intervening sequence if the breaks are on the same chromosome12, or 
translocations if the breaks are on different chromosomes13. Homology-directed repair of 
a DSB requires a template DNA that has homology to the flanking sequences around the 
both ends of the broken DNA. The template DNA can either be another non-cut allele in 
the genome or an exogenously supplied donor, which can be double stranded or single 
stranded8, 9, 14. Double stranded donors utilize a Rad51-dependent homologous 
recombination pathway, whereas HDR with single stranded donors is Rad51 
independent15. Both HDR pathways with exogenous donors lead to tailored site-specific 
alterations in the target genome including gene correction, insertion or deletion. 
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Figure 1. 1 Overview of programmable nuclease-directed genome editing 
a) Schematic view of nuclease-directed genome editing. Once a programmed nuclease docks on 
the target site (blue rectangle), both strands of the DNA get cleaved. Typically, NHEJ or HDR 
machineries involve in the repair the DSB. NHEJ-mediated repairs may generate small indels at 
the target site. In the presence of a template DNA that has homology to the target site (such as 
exogenous donor DNA), HDR may occur. b) Schematic of three most commonly used 
programmable nuclease platforms: ZFNs, TALENs, CRISPR-Cas9. Both ZFNs and TALENs use 
programmable DNA-binding domains for sequence-specific DNA recognition. ZFNs dock on the 
antiparallel to the sequence; 5’ end of the target sequence is with C-terminal of the protein and 3’ 
end of the target sequence is with N-terminal of the protein. In contrast, TALENs dock on the DNA 
parallel to the sequence. Both ZFNs and TALENs use the nuclease domain of FokI. If two pairs 
ZFN and TALEN monomer binds on DNA in correct orientation and spacing, FokI domains of 
each monomer can dimerize and cleaves DNA. CRISPR-Cas9 is an RNA-guided nuclease 
platform. 5’ end of the sgRNA is programmed for sequence-specific DNA recognition. Cas9 
proteins have intrinsic DNA binding feature against a short motif downstream of the sgRNA target 
site.  
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1.4 Programmable DNA-binding domains 
Both zinc finger nucleases and TALENs employ programmable DNA-binding 
domains (pDBD) to achieve sequence-specific DNA targeting. The pDBDs of zinc finger 
nucleases and TALENs are Cys2His2 zinc finger proteins and transcription activator-like 
effectors respectively. 
1.4.1 Cys2His2 Zinc Finger Proteins (ZFP) 
Cys2His2 ZFPs are the largest class of transcription factors found in metazoan 
genomes16. More than three decades ago, the first member of Cys2His2 ZFP family was 
identified as the tandem repeats of about 30 residues within the TFIIIA protein sequence 
from Xenopus17. As additional studies characterized more and more zinc finger protein 
sequences, their alignment reveal a consensus motif: (F/Y)-X-C-X2−5-C-X3-(F/Y)-X-X-X-
X-X-Ψ-X-X-H-X3−5-H, where X is any amino acid and Ψ is a hydrophobic residue18. 
Nuclear magnetic resonance structures reported that in the presence of zinc these residues 
fold into a ββα motif and coordinate zinc tetrahedrally19, 20. This zinc coordinated, compact, 
conserved ββα motif is referred as “finger”. The crystal structure of three-finger Zif268 
bound to DNA provided insight on its DNA recognition21-23. These studies featured Zif268 
as model system to study ZFP-DNA interaction. ZFPs fit into the major groove of the target 
DNA in modular fashion meaning that the positioning of each finger on the DNA is similar. 
The docking of ZFP to the target DNA is anti-parallel such that the N-terminal finger docks 
along the 3’ end and the C-terminal finger is with 5’ end of the primary DNA strand that 
is recognized. The surface residues of the α-helix of each finger contact bases in the major 
groove of the target DNA. The amino acids at positions -1, 3, 6 of the α-helix of each finger 
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contact three consecutive bases on the same DNA strand (primary strand). The amino acid 
at position 2 of the α-helix may contact to a base on the complementary strand21-23. 
Therefore, in canonical form, each finger is considered have specificity against a triplet 
DNA sequence. Mutations in the DNA contact residues of the recognition helix can alter 
(reprogram) the finger specificity against a target triplet DNA sequence24-27. Over the last 
two decades, numerous studies aimed to select and identify novel ZFP-DNA binding 
patterns28-38. In a single finger format, all 64 possible triplet DNA sequences can be 
targeted37. However, in a ZFP array, addition of a consecutive finger does not always mean 
concatenation of the recognition sequence of the added finger due to context dependencies. 
The incompatibility of the residues at the finger-finger interface or recognition overlap of 
the adjacent fingers can account for the context dependency36. 
1.4.2 Transcription activator like (TAL) effectors 
In nature, bacterial pathogen Xanthomonas secrete transcription activator like 
(TAL) effectors to infect plant cells. Once injected into the host cell, TAL effectors bind 
to promoters of target plant genes and activate their expression to facilitate the spreading 
of the infection39, 40. Typically, a TAL effector is composed of three major domains: the N-
terminal domain contains signaling motif required for secretion, the central domain is a 
tandem array of multiple highly conserved repeat modules, and the C-terminal domain 
carries nuclear localization sequences (NLS) and transcriptional activation domains41. The 
central repeat modules account for sequence specific DNA recognition42. Each repeat 
module is 34 amino acid long, and its sequence composition is highly conserved except the 
positions 12th and 13th, which are termed the repeat variable diresidue (RVD)43. The 
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number of repeat modules and the composition of RVDs are distinct for each TAL effector. 
Computational and empirical approaches decrypted sequence-specific DNA recognition 
code of the TAL effectors. Each repeat module involves in the recognition of a single base 
pair whose specificity is determined by the composition of the RVD. These studies 
suggested the use of four primary RVDs for construction of novel TAL effectors for each 
base: NI for A, HD for C, NN for R (G or A), and NG for T44, 45. 
Structural studies indicated that a TAL effector dock on major grove of B form 
target DNA and wrap around in a right-handed superhelical architecture. In contrast to 
ZFPs, TAL effectors bind on the target DNA strand in parallel to the sequence such that 
N-terminal repeat module recognizes 5’ end and C-terminal repeat module recognizes 3’ 
end of the target DNA sequence. Each 34 amino acid long repeat module forms a two-helix 
bundle structure, where the RVD locate within the loop connecting the helices. In each 
repeat module, the 12th residue stabilizes the 13th to make the contact with the 
corresponding DNA base46, 47. In addition to the compatible RVD composition, TAL-
effectors also require the presence of a 5’ Thymine base (T) at the N0 position of a target 
DNA sequence44, 45. Crystal structure also confirmed the recognition of the N0 T by the N-
terminal domain46, 47. Structure-guided directed evolution of the N-terminal domain 
eliminated requirement N0 Thymidine at the target DNA site48. Therefore, theoretically it 
is possible to design and construct a TAL-effector array against any given DNA sequence. 
1.5 FokI endonuclease 
FokI is a type IIs restriction endonuclease naturally found in Flavobacterium 
okeanokoites bacteria. FokI binds to 5´-GGATC-3´ sequence and cleaves the duplex DNA 
   9 
at 9 and 13 nucleotides downstream of its recognition sequence by generating 4 nucleotides 
5’ overhang49. Proteolytic and structural studies revealed that FokI consist of two domains: 
N-terminal DNA-binding domain, and C-terminal non-sequence specific nuclease 
domain50, 51. Researchers harnessed the modular nature of FokI to substitute the DNA-
binding domain with other natural DNA-binding domains52-56. Mutational analysis shows 
that FokI utilizes a single catalytic center to cleave a target DNA57. Although FokI is 
present as monomer in a solution or docked on a target DNA58, 59, biochemical and 
structural studies reported that the nuclease domain of FokI requires homo-dimerization to 
cleave the substrate DNA60, 61. Either two FokI monomers bound on the same DNA 
molecule or—at very high concentrations—one DNA bound FokI monomer and another 
one in the solution must dimerize to produce a DSB60, 61. In vitro DNA cleavage 
experiments point out that on a target DNA molecule with two FokI site some distance 
from each other, two FokI monomers can dimerize by forming a loop architecture62. 
1.6 Zinc Finger Nucleases (ZFNs) 
Zinc finger nucleases (ZFNs) are the chimera of a Cys2His2 zinc finger protein 
(ZFP), and the nuclease domain of the FokI type IIs restriction endonuclease. ZFNs 
function as a pair where each monomer of ZFN binds to 9-18 base pairs of DNA. When 
two ZFN monomers recognize nearby DNA sequence in correct orientation and spacing 
(Figure 1.1b), FokI from each ZFN can dimerize and cleave both strands of the DNA63. In 
a random genome of 3 billion base pairs, about a 16 base pair-long DNA sequence should 
be unique. However, site-specific targeting within a complex genome is a challenging task. 
The target site must be distinguished from a number of similar sequences—including 
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paralogues and pseudogenes—effectively and reproducibly. To reduce off-target cleaves 
of ZFNs, multiple approaches focused on different components of the ZFNs are described. 
One of the approaches is to select from a library of engineered of ZFPs with different DNA 
recognition residues for those better target site specificity28-38. For example, a recent study 
described a reporter system to distinctively select target but not off-target site specific ZFP 
arrays on therapeutically relevant genomic sites64. However, there is no easy formula to 
construct high fidelity ZFNs without site-specific selection. Increasing the number of 
fingers in a zinc finger array can bring more specificity but also create a mismatch between 
the helical periodicity of the ZFP and the DNA18, 65. When a ZFP docks on the target DNA, 
the inter finger linker generates rigid conformation for the two adjacent fingers to contact 
successive DNA triplets21. Zif268-templated engineered ZFPs usually contain evolutionary 
conserved canonical 5 amino acid (TG[E/Q]KP) linker21, 66. Mutations in the residues of 
the canonical linker reduce the DNA binding affinity of the ZFP67, 68. Addition of non-
canonical linkers in between every two or three fingers brings the helical periodicities of 
the ZFP and the DNA to a match and allows construction of longer ZFPs69-71. 
Another level of targeting specificity can be provided to ZFNs by engineering of 
the FokI nuclease domain. Structural and biochemical studies revealed the dimer interface 
between two FokI monomers60, 61. Harnessing the structural information, three studies 
reported the generation of obligatory heterodimeric FokI variants. ZFNs constructed with 
these heterodimeric FokI variants displayed reduced the levels of off-target activity-
associated toxicity in comparison to canonical ZFNs72-74. Another strategy is to use 
ZFNickases. This approach also uses obligatory FokI heterodimers, where one of the 
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monomers is catalytically inactive due to a point mutation (D450A)75, 76. ZFNickases 
cleave one of the strands (nick) at its target site and compatible with homology-directed 
repair. Although ZFNickases display lower activity, reduction of random indels at the 
target site can be considered as improved specificity. After all these years of engineering 
efforts, now it is possible to produce highly active and specific ZFNs. Yet, the construction 
of ZFNs still requires technical expertise. 
1.6.1 Applications of ZFNs 
Following the identification of the modular architecture of FokI, a stream of proof-
of-principle studies reported the development of functional chimeric restriction 
endonucleases, where the nuclease domain of FokI is fused to naturally occurring DNA-
binding domains52-54. One of these studies reported the first functional ZFN as the fusion 
of CP-QDR or Sp1-QNR zinc finger proteins to the nuclease domain of FokI53. In early 
2000s, ZFNs were used in living cells. Carroll and Chandrasegaran laboratories applied 
ZFNs to induce homologous recombination in Xenopus laevis oocytes77. A number of 
studies followed this and reported ZFN-mediated genome editing in cell lines78-80, plants81, 
82, and model organisms including fruit fly83, 84, zebrafish34, and mice85 (reviewed in Urnov 
et al.63). These studies not only suggested the broad utility of programmable nucleases but 
also helped researchers to answer basic biological questions. Beyond the biomedical 
laboratory usage, ZFNs also edited the genomes of non-model systems for development of 
biotechnology applications in agriculture81, 86 and livestock87-89. 
The goal of therapeutic genome editing existed since the early days of 
programmable nucleases. As researchers gained insight on how these nucleases edit 
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genomes and developed improved nuclease architectures, more and more applications are 
being reported. Any nuclease-based therapeutic genome editing strategy has to utilize 
cellular DSB repair pathways such as NHEJ or HDR8. Disruption of a therapeutically 
relevant gene is relatively easier since NHEJ is the predominant cellular response to a DSB, 
yet applicable disease contexts are limited. For example, individuals carrying naturally 
occurring 32bp deletion in HIV-1 entry co-receptor CCR5 gene (CCR5del32) display 
resistance to HIV-1 infection with no serious health issues90, 91. Harnessing this 
phenomenon, ZFNs were used to inactivate the CCR5 gene in CD4+ T cells and CD34+ 
hematopoietic stem and progenitor cells (HSPCs)92, 93. Clinical trials are ongoing to 
evaluate the therapeutic potential of the autologous transplantation of the nuclease treated 
cells against HIV-1 infection94. In addition to offering treatment for infectious diseases, 
nuclease based genome editing should be useful for monogenic disorders. In sickle cell 
disease (SCD), the underlying cause is a point mutation in the adult β-globin gene, which 
causes the polymerization of hemoglobin in erythrocytes with a sickled conformation95. 
One of the proposed therapeutic approaches is to induce the expression of fetal γ-globin 
gene in red blood cells95, 96. ZFN-directed disruption of the erythroid lineage specific 
enhancer element in BCL11A gene97, 98 in CD34+ HSPCs induces the expression of fetal γ-
globin gene in differentiated red blood cells99.  
Therapeutic genome editing via HDR requires an exogenous donor template that 
has homology to the nuclease target site. Nuclease directed HDR is compatible for both 
gene correction and gene replacement applications. These methods are more challenging 
than gene disruption strategies since HDR rates are typically lower than NHEJ, which can 
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introduce other undesired mutations at the target site and confound the outcome8, 100. An 
example of a gene correction approach is to revert the β-globin point mutation that causes 
SCD. In CD34+ HSPCs, ZFN induced DSBs in the presence of donor DNA corrected the 
mutation within fraction of the treated population101. Such direct gene correction is not 
feasible for wide range of monogenic diseases, where there can be multiple types of the 
underlying mutations and each of them require customized nuclease and donor 
construction. Gene replacement approaches provide an alternate solution to this problem. 
This strategy aims to integrate a repair cassette containing the corrected open reading frame 
of the gene of interest (cDNA) into either the non-coding region of the same gene (e.g. 
introns) or a safe harbor locus in human genome such as AAVS1 intron 1102, 103. In ex vivo 
therapeutics setting, ZFN driven gene replacement strategy has been applied on patient 
isolated CD34+ HSPCs for two X-linked diseases: chronic granulomatous disease (X-
CGD)104 and severe combined immunodeficiency (SCID-X1)105, 106. AAV6 (adeno 
associated virus serotype 6) donor template carrying functional cDNA of CYBB gene with 
homology arms for AAVS1 site restored the genetic deficiency in X-CGD104. For a 
prospective SCID-X1 treatment, ZFNs drove site-specific integration of IDLV (integration 
deficient lentivirus) donors carrying either full length IL2RG cDNA with homology arms 
against either AAVS1 or partial IL2RG cDNA with homology arms against the intron of the 
endogenous gene105, 106. In common to all of studies editing CD34+ HSPCs, the rate of HDR 
is lower for long term progenitors—hematopoietic stem cells—than the bulk population. 
This is possibly due to the quiescent nature of these cells. In addition to these ex vivo 
approaches, ZFNs have also been used for in vivo gene replacement therapeutics. In 
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hemophilia B, the blood coagulation factor IX deficiency mutations are located in F9 gene. 
In mouse hemophilia B model, tail vein injection of AAV vectors carrying the ZFN 
expression cassettes and the donor (promoterless functional factor IX cDNA) leads donor 
cDNA incorporation into F9 or Albumin locus in the liver cells107-109. 
1.7 Transcription activator-like effector nucleases (TALENs) 
Similar to ZFNs, transcription activator-like effector nucleases (TALENs) are also 
a chimera of a programmable DNA binding domain (TAL effectors) and FokI nuclease 
domain (Figure 1.1b). Shortly after the decryption of sequence specific DNA recognition 
via TAL-effectors44, 45, three studies reported the development of TALENs55, 56, 110. 
Importantly, these studies identified critical functional parameters such as required domain 
architectures and optimal spacing between each TALEN monomer target site55, 110. In 
contrast to its simplicity of reprogramming, the repetitive nature of TAL effectors presents 
challenges with regards to the construction of the designer TALENs. Most commonly a 
golden gate cloning system, which takes advantage of type IIs restriction enzymes, is used 
to build TALENs within few days111, 112. Another approach is to stitch together modules 
with longer homology arms in ligation independent manner113. For higher throughput 
assemblies, solid support-based module ligation generates functional TALENs within a 
day114. Repetitive TALEN sequences impact the stabilities of the lentiviral expression 
constructs of these nucleases115. Re-coding of the TAL effectors to minimize sequence 
repetition provided a solution to this problem116. Typically, designer TALENs use 15-20 
base pair DNA recognition provide sufficient site specificity. However, several studies 
reported that TALENs display off-target activity in human genome at relatively low 
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levels117-121. Altering the RVD compositions or reducing the excess positive charge in non-
sequence specific DNA contacts provide improved specificity and on target activity of 
TALENs120, 121. Another approach is to truncate the C-terminal domain to restrict spacing 
requirement between two monomer binding sites110, 121, 122. Beyond the engineering of the 
DNA binding domain, usage of the heterodimeric FokI architectures can provide an 
additional level of targeting accuracy72-74, 120. Overall, TALENs can provide accurate and 
efficient targeted genome editing with reduced designing efforts relative to ZFNs. 
1.7.1 Applications of TALENs 
Over many years, applications of ZFNs determined the ground work for 
development and application of other programmable nucleases. Because of this existing 
knowledge and the simplicity of the TAL effector programming, many researchers 
interested in developing and applying TALENs for various biomedical questions. 
Immediately after deciphering the TAL effector DNA recognition code44, 45, number of 
studies reported TALEN-directed successful genome editing in cell lines110, 117 and 
organisms including yeast55, 56, worms123, zebrafish124, 125, rat126, fruit fly127, and more 
(reviewed by D. Carroll6). Some studies suggest that TALENs can edit genomes in more 
complex manner beyond small indels; such as complex chromosomal deletions, inversions 
and translocations12, 13, 128. High-throughput production of designer TALENs opened up 
novel applications to study gene function129. These include construction of TALEN 
libraries for a small set of human genes involve in cancer/epigenetic regulation or targeting 
18740 protein-coding genes114, 122. In addition to protein-coding genes, a library targeting 
human miRNAs has also been reported130. In combination with induced pluripotent stem 
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cells (hIPSCs), TALENs can be used to develop cellular disease models131-133. Applications 
of TALENs extend beyond basic science. Currently, TALENs are often being used in 
agriculture and livestock to improve the quality of products and select desirable traits89, 134-
137. 
Similar to ZFNs, therapeutic genome editing via TALENs also involve gene 
disruption or correction or replacement strategies. TALENs can disrupt genes to provide 
protection against infectious diseases; such as targeting CCR5 gene for HIV-1 infection 
resistance or depletion of hepatitis B virus from human genome110, 138-140. In monogenic 
disorders context, TALENs have also been used to perturb the erythroid-lineage specific 
enhancer element in BCL11A gene95-98 within CD34+ HSPCs141. TALEN induced gene 
correction reverted the disease-causing mutations in Douchenne muscular dystrophy142, 
epidermolyisis bullosa118, and sickle cell anemia143. Finally, TALENs have been utilized 
to incorporate gene replacement donors for β-Thalassemia144 and X-linked chronic 
granulomatous disease145. Beyond the utility of programmable nucleases, TAL-effectors 
have been fused with other effector domains to generate site specific transcription 
regulation, and epigenetic modifications146-150. 
1.8 Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) and 
CRISPR-associated (Cas) systems 
CRISPR-Cas systems provide RNA-guided adaptive immunity in bacteria and 
archaea against infectious genetic material (e.g. phages, plasmids etc.). To date, two classes 
and six types of CRISPR-Cas systems have been identified. Classification of CRISPR-Cas 
systems is done according to the organization of the CRISPR loci and the presence and 
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composition of Cas (CRISPR-associated) proteins151, 152. The CRISPR locus is an array of 
multiple short repetitive sequences interspersed by non-repetitive spacer sequences in a 
repeat-spacer-repeat format. The sequence of a spacer corresponds to the genetic material 
of a species infectious to the host organism153-155. Therefore, the CRISPR loci represent the 
immunization record of the host to previously encountered infectious nucleic acids. The 
composition of Cas genes varies among different CRISPR-Cas system. In class 1 systems 
(types I, III and IV), multiple proteins are employed to form an effector complex, whereas 
in class 2 systems (types II, V, and VI), a single multidomain effector protein is sufficient 
for immune response151, 152, 156, 157. Even though class 1 systems account for vast majority 
of the all known CRISPR systems157, the simplicity of class 2 systems makes them 
favorable for development of biotechnology applications.  
In nature, CRISPR-Cas mediated adaptive immunity occurs in three stages: 
adaptation (acquisition), expression and processing, and interference158. In the adaptation 
stage, Cas1-Cas2 protein complex incorporates new pieces of infectious foreign genetic 
material (protospacer) into the CRISPR loci159-161. The presence of 2 to 4 nucleotide long 
protospacer adjacent motif (PAM) is crucial in protospacer acquisition to distinguish self 
versus foreign genetic material162-164. The next stage is expression and processing of the 
CRISPR RNA (crRNA) from the transcribed locus. The CRISPR locus of a host genome, 
which contains several spacers in between the repeat sequences, is typically transcribed as 
a long RNA molecule, named precursory CRISPR RNA (pre-crRNA). In order to generate 
an active crRNA-Cas effector ribonucleoprotein (RNP) complex, the pre-crRNA needs to 
be processed into a mature crRNA form156, 165. The crRNA processing in class 2 systems 
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can either be done by the cognate Cas effector166, 167, or require the involvement of trans-
activating crRNA (tracrRNA) and RNase III168. In the final interference stage, functional 
crRNA loaded Cas effectors locate and cleave the target nucleic acid site-specifically155, 
169-171. 
Class 2 CRISPR-Cas systems have been repurposed for various biotechnological 
applications5, 172. Particularly, the type II (Cas9) and type V (Cas12-a, Cpf1) effectors are 
revolutionizing the genome editing applications173, 174. Recently, type VI effector (Cas13-
a, C2c2) has been described as an RNA-guided RNA targeting effector that can knockdown 
or edit the target RNA175, 176. It is reasonable to anticipate the development of novel 
applications as new Cas effectors are identified. The next section focuses on the Cas9 
effectors (nucleases) in the context of defining and improving their DNA targeting 
specificity. 
1.9 Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery 
The simplicity of site-specific genome targeting by type II clustered, regularly 
interspaced, short palindromic repeat (CRISPR)-Cas9 nucleases, along with their robust 
activity profile, has changed the landscape of genome editing. These favorable properties 
have made the CRISPR-Cas9 system the technology of choice for sequence-specific 
modifications in vertebrate systems. For many applications, whether the focus is on basic 
science investigations or therapeutic efficacy, activity and precision are important 
considerations when one is choosing a nuclease platform, target site and delivery method. 
Here we review recent methods for increasing the activity and accuracy of Cas9 and 
assessing the extent of off-target cleavage events. 
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1.9.1 Overview on CRISPR-Cas9 systems and their applications 
Type II CRISPR-Cas9 systems are found in only a small fraction of bacterial 
species152, 177. These adaptive defense systems employ a single, large multisubunit 
endonuclease (Cas9) and a pair of RNAs that as a complex facilitate sequence-specific 
target cleavage of foreign DNA158. In 2012, the critical components required to program 
the Streptococcus pyogenes ribonucleoprotein complex to cleave a specific DNA sequence 
were defined and streamlined by engineering a single guide RNA (sgRNA) that could 
subsume all the RNA-based structural and recognition functions170. Based on lessons from 
other artificial nuclease platforms43, 63, the insights provided by this in vitro study were 
rapidly translated in early 2013 to Cas9-sgRNA expression and delivery systems that 
facilitated sequence-specific genome editing in mammalian cell lines173, 178-180 and model 
organisms181, 182.  These and other investigations probed and improved aspects of nuclear 
localization, and sgRNA design and expression173, 178, 180, 183 that rapidly culminated in a 
reliable S. pyogenes Cas9-based nuclease system that is revolutionizing biological studies 
and holds promise for therapeutic applications7, 184, 185.   
The Cas9-sgRNA nuclease system (Figure 1.1b and Figure 1.2) is more 
straightforward to program than prior artificial nuclease platforms because sequence-
specific targeting resides primarily within the associated sgRNA, which is simple to 
recode. This attribute has permitted a proliferation of Cas9-based genome editing 
applications that harness the generation of a site-specific double-strand break (DSB) for 
targeted gene inactivation or modification. The ease of expressing many distinct sgRNAs 
within a cell (sgRNA multiplexing) facilitates the simultaneous targeting of multiple 
   20 
genes173, 181, 186-191 or the creation of larger genomic alterations between pairs of DSBs, 
such as segmental deletions173, 192, 193, inversions193, 194, and translocations195-198. Cell lines 
or organisms can be “preloaded” with Cas9199-203 such that editing requires only the 
delivery of the desired sgRNAs. Lentiviral delivery of libraries of sgRNAs into Cas9 
expressing cells permits genome-wide gene-inactivation screens that can identify 
participating genes in a cellular process of interest199-202. Similarly, a Cre-dependent Cas9 
knock-in mouse model combined with viral-mediated sgRNA and Cre delivery facilitates 
tissue or cell-type specific gene modification203, such as the analysis of regulatory networks 
in primary immune cells204.  
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Figure 1. 2 Structural overview of SpCas9 
a) Schematic view of the domain organization of SpCas9, where domains that are formed from 
discontinuous sequence elements are numbered. b) X-ray crystal structure of SpCas9 with sgRNA 
(blue - guide and red – constant sequence) and the target DNA (black)205. In this structure, 
sgRNA:DNA heteroduplex divides the Cas9 protein into two lobes connected by the bridge helix 
(green): the recognition lobe consist of the Rec1 (light grey) and Rec2 (dark grey) domains; and 
the nuclease lobe with RuvC (cyan), HNH (purple), and the PAM-interacting domain (wheat). Two 
Arginines (R1333 and R1335; magenta) within the PID make the primary contacts to the guanines 
within the PAM. c) Schematic view of the Cas9-sgRNA complex, upon R-loop formation cleavage 
of the DNA occurs 3 bp from the edge of the PAM element.  
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The Cas9-sgRNA system has proven to be similarly effective in promoting the 
targeted insertion of a desired DNA sequence through homology-directed repair (HDR) 
utilizing either exogenously supplied duplex DNA templates173, 178, 192, 206, single stranded 
oligonucleotides116, 181, 192, 207-213 or viral encoded templates203, 214-217. The efficiency of 
HDR events is cell-type dependent and typically occurs at a lower frequency than the rate 
of insertions or deletions (indels) created via non-homologous end joining (NHEJ)-
mediated imprecise repair of the Cas9-generated DSB218.  However, HDR rates can be 
increased in some cell types through cell cycle synchronization209 or small molecules or 
proteins that interfere with alternate DNA repair pathways219, 220. In sum, Cas9-based 
technological advances have dramatically simplified the creation of modified vertebrate 
cell lines and animal models for the investigation of gene function during development and 
disease progression194, 207, 221-232. Similar revolution is being realized by the use of nuclease-
dead Cas9 (dCas9) to deliver effector domains to perturb gene expression and chromatin 
modification states 233.  
Therapeutic applications for CRISPR-Cas9 are also being actively explored. Cas9-
mediated ex vivo gene editing in primary cells189, 191, 208, 210, 213, 217 or induced pluripotent 
stem cells145, 234, 235 provides a potential pathway for the creation of autologous cell-based 
therapies. In vivo correction of dystrophin gene mutations that are associated with Douchne 
muscular dystrophy holds therapeutic promise236-238. Another therapeutic level of Cas9-
mediated in vivo gene correction was recently demonstrated in a mouse model of 
fumarylacetoacetate hydrolase (Fah) deficiency207, 239. In parallel, viral delivery systems, 
such as adeno-associated virus (AAV), for the tissue-specific delivery of Cas9-sgRNA are 
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being developed240. The limited cargo capacity of AAV (~4.7 kb)241 creates challenges for 
packaging expression cassettes for S. pyogenes Cas9 (SpCas9, ~4.2 kb) and its sgRNA in 
a single vector187. More compact CRISPR-Cas9 systems—such as Cas9 orthologues from 
Neisseria meningiditis (NmCas9), Staphylococcus aureus (SaCas9), and Campylobacter 
jejuni (CjCas9)—have been developed242-245 to overcome this problem. One such system, 
SaCas9244, achieved efficient gene editing within the mouse liver when delivered via a 
single AAV construct. These proof-of-principle experiments highlight the promise of Type 
II Cas9 nucleases for therapeutic gene correction or gene replacement if compatible 
delivery systems can be realized and collateral damage to the genome can be minimized. 
1.9.2 Licensing a DNA sequence for cleavage 
Whether utilizing programmable nucleases for editing cell lines, model organisms 
or therapeutic applications, nuclease precision is an important consideration. Pioneering 
gene therapy efforts using gamma-retroviruses in hematopoietic stem cells were stymied 
by the insertional mutagenesis inherent with these gene delivery vectors, which led to 
oncogenic transformation in a subset of patients246, 247. Likewise, the generation of DNA 
breaks at unintended (off-target) sites by imprecise nucleases has the potential to alter gene 
expression and function through direct mutagenesis or the generation of genomic 
rearrangements. Understanding the series of events associated with the “licensing” of a 
DNA sequence for cleavage by the Cas9-sgRNA complex should permit the accurate 
prediction of potential cleavage sites and the development of Cas9-sgRNA variants with 
improved precision. A molecular and mechanistic description of target site recognition and 
cleavage has been provided by biochemical170, 248-251 and structural studies205, 252-255, 
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buttressed by nuclease activity assays in cell culture173, 256-258 and data on the function of 
Cas9 in adaptive bacterial immunity158. Mechanistic analyses suggest that a DNA sequence 
is licensed for cleavage through two stages of recognition: 1) Cas9 binding to a favorable 
Protospacer Adjacent Motif (PAM) element, and 2) sgRNA-mediated interrogation of the 
neighboring DNA sequence via Watson-Crick base pairing to allosterically switch Cas9 
into an active state (Figure 1.3.a).  
Single molecule and bulk biochemical assays indicate that the residence time of a 
Cas9-sgRNA complex on a DNA sequence during target acquisition is dependent on the 
presence of a compatible PAM element248. This PAM-dependence provides kinetic control 
over the sampling of target sequences by restricting DNA-sgRNA heteroduplex (R-loop) 
formation249. This preference is observed in ChIP-seq experiments on dCas9, where the 
vast majority of occupied sequences contained an optimal PAM element250, 259. In the case 
of SpCas9, an NGG PAM element is strongly preferred1704, although NAG and NGA 
PAMs are inefficiently recognized in some contexts256, 260, 261.  
sgRNA interrogation of the DNA sequence initiates next to the PAM element 
through Watson-Crick pairing in a 3ʹ to 5ʹ direction relative to the guide sequence (20 
nucleotides [nt] for SpCas9)248, 249. Progressive R-loop formation is a passive process248, 
254, 262 in which mismatches within the seed region are more likely to abrogate nuclease 
activity170, 171, 173, 248, 250, 259. Data analysis from large-scale screens utilizing libraries of 
sgRNAs suggests that there is an optimal level of heteroduplex stability for efficient target 
cleavage199, 263, 264 and that other sequence features in the guide199, 258, 263-266 and 
neighboring the canonical PAM element263, 264, 266 can influence nuclease efficiency. Using 
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these data, researchers have developed algorithms that predict Cas9-sgRNA activity as a 
function of these parameters258, 264-267. Chromatin architecture also influences the binding 
of Cas9-sgRNA complexes at suboptimal (non-cognate) sequences within the genome250, 
259, but the extent that it impacts nuclease activity remains uncertain258, 268. As more aspects 
of the mechanism of site licensing for cleavage by Cas9-sgRNA are defined, they should 
facilitate the creation of advanced predictive models describing sequence cleavage 
efficiency as a function of the guide sequence. These algorithms should enable the 
identification of efficient nuclease target sequences that have few compatible off-target 
sequences within the genome. 
1.9.3 Cas9 promiscuity in cell lines, primary cells and model organisms 
Precision is an enigma that has dogged the therapeutic application of all artificial 
nuclease platforms. There is abundant evidence that SpCas9-based nucleases in 
transformed cell lines can tolerate imperfections within the sgRNA-DNA heteroduplex170, 
173, 198, 256, 257, 261, 269, 270. Analysis of the activity profiles of guides encoding one or more 
mismatches to a target site has shown that the number, position and type of base 
mismatches256, 257, 261 can affect the activity level (for example, a G:U mismatch is better 
tolerated than a G:A mismatch)256. Heteroduplex sequence composition also influences 
tolerance to the number and position of the substitutions between the guide and target 
sequence257, 261. Reassuringly, deep sequencing of potential off-target sites (defined via 
computational prediction198, 256, 257, ChIP-seq of dCas9 bound regions250, 259 or in vitro 
library analysis269) within populations of nuclease-treated cells did not identify indels at 
the majority of these sequences. The absence of indels at most bound regions shown by 
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ChIP-seq 250, 259 indicates that nuclease activity is not merely a function of Cas9-sgRNA 
residence time. Notably a subset of off-target sites display nuclease activity198, 250, 256, 257, 
259, 269, with up to four or five mismatches between the guide and genomic sequence 
tolerated257, 269. This degree of potential promiscuity is a concern with respect to therapeutic 
applications, as thousands of sequences with four or five mismatches to a 20-nt guide 
sequence can typically be found in the human genome198, 257. In some instances Cas9-
sgRNA complexes can also tolerate a ‘bulge’ between the guide and a noncognate sequence 
(a base flipped out of one component of the heteroduplex)270, which further complicates 
the genome-wide prediction of nuclease activity as a function of guide sequence. These 
studies provided impetus for efforts to engineer Cas9-sgRNA systems with improved 
performance (described below). 
Although studies of SpCas9-sgRNA-treated transformed cell lines have provided 
evidence of modest nuclease promiscuity, a more nuanced perception has emerged from 
the studies of Cas9-based editing in stem cells and model organisms. Sequence-capture 
characterization of a population of nuclease-treated CD34+ cells at two to three dozen 
computationally predicted off-target sites detected significant indels at only a single off-
target site for one of five active guides189. Importantly, stem cells facilitate the expansion 
of single nuclease-treated clones for direct comparison with the parental line via whole 
genome sequencing (WGS) in a nominally ‘normal’ cellular environment with regards to 
DNA repair. These comparative analyses revealed a large number of sequence alterations 
between the parental and nuclease-derived clones, but none could be ascribed to off-target 
cleavage by the nuclease235, 271, 272. Similar results were observed for exome sequencing in 
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a number of nuclease-treated clonal haploid cell lines273. These results, although promising 
must be interpreted cautiously, because WGS is most likely to detect only those active off-
target sites that are cleaved with efficiency similar to that of the target site273, 274. Because 
lesions at most off-target sites are low-frequency events, the likelihood of a single clone 
containing an off-target lesion at a specific site is low. Similarly, analysis of Cas9-sgRNA-
treated vertebrate embryos have occasionally identified a small number of active off-target 
events in the offspring of treated founder animals192, 275-277. These off-target sites typically 
have only one or two mismatches to the guide sequence, implying that they might have 
activity similar to that of the target site. The lower rate of Cas9-induced off-target lesions 
in stem cells and model organisms relative to transformed cell lines might be due in part to 
the higher propensity for imprecise DNA repair in transformed lines. In sum, these studies 
show that Cas9-edited stem cell lines or model organisms can be obtained without 
unwanted nuclease-based genomic modification, but the propensity for Cas9 off-target 
activity in transformed cell lines highlights the need for the evaluation of nuclease precision 
in therapeutic applications. 
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Figure 1. 3 Stages of target-site recognition by Cas9 
a) The SpCas9-sgRNA complex proceeds through two stages of licensing prior to DNA cleavage. 
In the first stage target acquisition proceeds through recognition of the neighboring PAM sequence 
(nGG preferred for SpCas9). If 3’ end of the programmed guide is complementary with the DNA 
sequence neighboring the PAM element an R-loop is initiated. Guide complementarity throughout 
the DNA sequence is assessed through extension of the R-loop, which once confirmed results in 
the allosteric activation of the RuvC and HNH nuclease domains resulting in a DSB (blue triangles). 
b) Only a small fraction of guide sequences have no near cognate sequences with the genome. [left 
stacked bar] Genome-wide CRISPRseek278 assessment of the distribution of guide sequences for 
SpCas9 that have high quality off target sites. A representative set of 124,793 guide RNAs targeting 
human exons sequences are binned based on the off-target site with the fewest mismatches to the 
guide sequence. A “perfect match” indicates the presence of an off-target site perfectly 
complementary to the guide sequence (red segment), which would be anticipated to be an active 
site for cleavage. 98.4% of these guide sequences have at least one off-target site with 3 or fewer 
mismatches to the guide sequence. The remaining 1.6% of guides (light green segment) would be 
the best candidates for precise genome editing. [Right stacked bar] Guides within the light green 
segment were binned based on those with or without a single base bulged off-target site270 but with 
no other mismatches (gray- absence of bulged off-targets, black- one or more bulged off-targets).  
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1.9.4 Lessons from unbiased methods for assessing nuclease fidelity 
Before the development of unbiased methods for the characterization of nuclease 
off-target activity, computational algorithms based on guide-sequence similarity were the 
primary method for identifying potential off-target sites. Whereas these algorithms 
originally focused on binning off-target sites on the basis of the number of mismatches in 
the target sequence, more recent algorithms incorporate a scoring function whereby the 
position and type of mismatch are used to further stratify the ranking of these potential off-
target sites182, 256, 267, 268, 278-285 (Table 1.1). This information can be utilized to identify 
guide sequences with a low probability of off-target activity. However, even simple 
filtering based on excluding guides with near-cognate matches in the genome leads to a 
sizable decrease in the density of available target sequences (Figure 1.3.b), suggesting that 
alternative approaches to improve nuclease precision will be important. Currently the 
limited data on genome-wide Cas9-sgRNA off-target activity preclude the training robust 
predictive models that can accurately rank the relative cleavage rate of sites with multiple 
guide-target mismatches286. Consequently, although existing computational methods can 
identify active off-target sites for a guide sequence, the specificity of these predictions is 
poor. 
Improving future computational models requires ‘unbiased’ genome-wide 
assessments of nuclease activity for a panel of different sgRNAs.  A new suite of off-target 
detection methods have recently been described that can identify sites with low cleavage 
activity244, 273, 286-290. These methods focus on one of two approaches to identify the 
genomic positions of nuclease-induced DSBs: 1) direct capture of DSBs or 2) the detection 
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of surrogates associated with DSB repair activity. These methods have different strengths 
and weaknesses and vary in their sensitivity, expense and ease of implementation (sections 
1.9.7 and 1.9.8). 
Digenome-seq273 (in vitro Cas9-digested whole-genome sequencing) and 
BLESS244, 291 (direct in situ break labeling, enrichment on streptavidin and next-generation 
sequencing) identify off-target sites through the detection of Cas9-induced DSBs within 
the genome. BLESS directly labels unrepaired DSBs in fixed cells via ligation of a biotin-
labeled adapter, which allows the purification and sequencing of these genomic regions. 
Digenome-seq uses in vitro Cas9-sgRNA digestion of purified genomic DNA followed by 
WGS to identify the locations of DSBs as interruptions in mapped sequencing reads. 
Digenome-seq seems to be more sensitive than BLESS, as the latter only detected off-
target sites with indel rates ≥1 %. Recently, SITE-seq289 (selective enrichment and 
identification of tagged genomic DNA ends) and CIRCLE-seq290 (circularization for in 
vitro reporting of cleavage effects by sequencing) used enrichment strategies to reduce the 
background and thereby improve the sensitivity of Digenome-seq.  
The second class of off-target identification methods (integrase-defective lentiviral 
vector (IDLV) capture 288, 292, HTGTS287 (high-throughput, genome-wide translocation 
sequencing)  and GUIDE-seq286 (genome-wide, unbiased identification of double-strand 
breaks enabled by sequencing)) rely on erroneous NHEJ-mediated DNA repair (exogenous 
DNA capture or translocation) to identify Cas9-induced breakpoints within the genome. 
IDLV-capture288, 292 tags nuclease-induced DSBs via the insertion of exogenously supplied 
IDLV DNA, whereas GUIDE-seq286 utilizes the insertion of modified blunt-ended duplex 
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oligonucleotides at DSBs.  The tagging of DSBs by oligonucleotides is more efficient than 
that by IDLV, which enabled GUIDE-seq to identify off-target sites that were undiscovered 
by IDLV-capture with identical sgRNAs. Finally, HTGTS287 captures off-target sites as 
genomic rearrangement events with a target locus. For a common sgRNA (VEGFa site 1) 
HTGTS identified a repertoire of off-target sites concordant with the GUIDE-seq method: 
all off-target sites identified by GUIDE-seq (21 total) were identified by HTGTS (38 total) 
and the ranked order of activity for the top 5 off-target sites was identical.  
Together the data from these studies demonstrate that different sgRNAs display 
variability in the number of active off-target sites and the frequency of DSBs at those sites. 
Some sgRNAs led to promiscuous activity at more than 100 off-target sequences, whereas 
others were not associated with any detectable off-target events286. In general there is an 
anticorrelation between a genomic site’s number of mismatches to a guide sequence and 
the likelihood that the site will be cleaved by Cas9, which is consistent with activity 
assays256, 257. Nonetheless, the parameters that define active noncognate sequences remain 
nebulous, as sites with up to six mismatches273, 286 or a single base bulge244, 286 between the 
guide and target sequence show activity. The availability of unbiased techniques for whole-
genome surveys of nuclease activity provides an opportunity to construct more highly 
parameterized computational models of guide-target interactions to achieve the accurate 
prediction of functional off-target sequences for any given sgRNA. 
1.9.5 Methods to enhance Cas9-sgRNA precision 
Because of the imperfect precision of the wild-type SpCas9 nuclease, a number of 
strategies have been developed to increase the fidelity of sequence cleavage within the 
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genome (Figure 1.4 and section 1.9.9).  These methods range from careful target-site 
selection and guide design to variations in Cas9 function that restrict conditions for DSB 
formation. These are discussed as independent approaches, but in some cases they could 
potentially be combined. 
Perhaps the most straightforward approach is to use the growing number of 
computational tools to predict guide sequences that will have the fewest off-target sites182, 
256, 267, 268, 278-285 (as described above; Table 1.1). Careful choice of the guide can have a 
dramatic impact on the number of active off-target sites244, 273, 286-288. Modification of the 
guide sequence has also proven advantageous.  Truncation of the guide from 20 nt to 17 nt 
or 18 nt (tru-gRNA) preserves nearly full activity of the SpCas9-tru-gRNA nuclease at the 
majority of target sites268, 286, 293 while reducing activity at many off-target sites286, 293. 
Alternately, appending two extra guanine nucleotides on the 5ʹ end of the guide sequence 
has been shown to improve nuclease precision198, 273.  In addition, delivering Cas9 and its 
sgRNA as a ribonucleoprotein complex (RNP) limits its temporal activity thereby 
improving its precision208, 209, 294-297.  
Modifications to the Cas9 nuclease have also proven effective in improving 
precision.  Inactivation of one of the two nuclease domains in Cas9 generates a nickase 
(Cas9n) that cleaves only a single strand of the target sequence170. By programming Cas9 
nickases with two different sgRNAs targeting neighboring sites on opposite DNA strands, 
one can generate a DSB198, 261, 276, 298. The combinatorial requirement for two active 
proximal nickases to generate a DSB reduces the likelihood of off-target DSBs198, 261, 287, 
298. However, at some sites in transformed cell lines individual nickases can yield high rates 
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of single base mutations (~10 %), although the precise mechanism is undefined190, 299. A 
related strategy mimicking ZFN and TALEN platforms, uses a catalytically inactive Cas9 
(dCas9) as a DNA-recognition platform for the site-specific delivery of the FokI nuclease 
domain190, 299, 300. FokI-dCas9 offers improved precision relative to standard Cas9 because 
of the requirement for FokI dimerization for the efficient generation of a DSB. However, 
single FokI-dCas9 monomers can generate a low level of mutagenic activity at some 
sequences190, 299. Another strategy relies on the attenuation of non-sequence specific DNA 
contact residues to reduce the overall binding energy of Cas9 to the DNA. Three variants 
(enhanced specificity Cas9301, high-fidelity Cas9302, and hyperaccurate Cas9303) improved 
the targeting accuracy of SpCas9 substantially. 
One can also modulate Cas9 activity by manipulating the Cas9 PAM-interacting 
domain (PID; Figure 1.2). Structural and biochemical studies identified the location of 
PID and demonstrated that PAM specificity could be switched by substituting PIDs from 
orthologous Cas9s205, 253. Recently, selection-based approaches were used to identify 
mutations in the PID that generate SpCas9 and variants with distinct PAM preferences304.  
Not only these SpCas9 variants not only expand the targeting range of SpCas9, but some 
variants also show improved precision on the basis of genome-wide activity analysis. 
Similar approach has been extended to select SaCas9 variants with different PAM 
preferences305. In an alternate approach, mutations in the PID that attenuate the DNA-
binding affinity of Cas9 can render its function dependent on DNA recognition by an 
attached programmable DNA-binding domain (pDBD). The resulting Cas9MT-pDBD 
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system, which is the focus of this thesis, provides improved precision by adding an 
additional specificity determinant to target site recognition306.  
Exerting temporal control over nuclease activity is another appealing method for 
improving precision. One can regulate nuclease activity by breaking the Cas9 protein into 
two independent components (split-Cas9)307-310 or adding an allosteric switch311 or an 
interrupted sequence (intein-Cas9)310, 312 in which assembly or intein excision, 
respectively, can be exogenously regulated. The switch to an active state can be driven 
through the delivery of a small molecule308, 311, 312 or light of a suitable wavelength309.  
Finally, there are a multitude of Type II CRISPR-Cas9 systems244, 313, only a small 
number of which have been characterized in any detail242, 244, 245, 314. In addition, Type V 
CRISPR-Cas systems152 that use Cpf1 (Cas12-a) instead of Cas9 as the nuclease effector 
also show promise for editing eukaryotic genomes174, 315-319.  Some of these alternative 
systems have more favorable characteristics for the precise editing of vertebrate genomes 
owing to differences in PAM stringencies and sgRNA mismatch sensitivities320-322.  
Looking forward, it seems likely that the preferred editing platform, in particular for 
therapeutic applications, will be a more compact nuclease (Cas9 or Cpf1 orthologue) with 
improved targeting range (for example, a simple PAM element) and greater sensitivity to 
mismatches within its recognition site. This system likely does not exist in a native form, 
but will be improved through design and selection approaches to achieve the desired goal 
of robust activity and high precision. 
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Table 1.1 Computational programs for sgRNA off-target analysis. 
Algorithm Name Off-target search features 
CRISPRseek278 
 
Allows discovery of non-cognate sites with user-defined 
maximum number of mismatches; Scoring based on number 
and position of mismatches; Available as a Bioconductor 
package; Search and scoring parameters can be modified by 
the user and program can be included in computational 
pipelines. 
Cas-OFFinder279 
 
Allows discovery of non-cognate sites with up to 9 
mismatches and up to 2 DNA and RNA bulges; does not 
score/rank off-target sites; Program is available for download. 
CRISPR Design Tool256 
  
Allows discovery of non-cognate sites with up to 4 
mismatches; Scoring based on number and position of 
mismatches;  
No user-defined features. 
COSMID280 
 
Allows discovery of non-cognate sites with up to 3 
mismatches and up to 2 DNA and RNA bulges; Scoring based 
on number and position of mismatches. 
CropIT281 
 
Allows discovery of non-cognate sites with up to 9 
mismatches; Scoring based on number and position of 
mismatches; Incorporates DNase hypersensitivity profiles 
from the ENCODE dataset for ranking off-target sites within 
the human genome; limited user-defined parameters. 
CasFinder282 
 
Allows discovery of non-cognate sites with user defined 
number of mismatches; Scoring based on number and 
position of mismatches; Available as a perl package; 
parameters can be modified by the user. 
E-CRISP283 Allows discovery of non-cognate sites with up to 7 
consecutive mismatches at the 5’ most end and up to 1 
mismatch in the remaining 13 positions or up to 3 mismatches 
total; Scoring based on number of mismatches, genomic 
location of the off-target site and its sequence composition; 
limited user-defined parameters. 
ChopChop267 Allows discovery of non-cognate sites with up to 2 
mismatches; Lists off-target sites by number of mismatches. 
ZiFiT182, 284 
 
Allows discovery of non-cognate sites with up to 3 
mismatches, where the position and type of mismatch are 
indicated. 
CasOT285 Allows discovery of non-cognate sites with up to 6 
mismatches; Program is available for download.  
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1.9.6 Practical considerations for the design of Cas9-based editing experiments 
There are a multitude of factors (Cas9 platform, sgRNA target site, etc.) to consider 
during the design phase of Cas9-based projects. Below we suggest some strategies that 
may be useful in design of nuclease-based experiments. 
Importantly, not all guide sequences can program Cas9 for highly efficient genomic 
cleavage.  The use of SpCas9 for genome-wide gene-inactivation screens199-202, 268 is 
producing a large amount of activity data that can be used to train computational models 
to predict the most favorable sequences for Cas9 cleavage258, 264, 266, 268. Algorithms that 
predict sgRNA activity ( for example, sgRNA Designer264, Sequence Scan for CRISPR266, 
sgRNA Scorer258 or CRISPRscan268) can be used with their built-in off-target assessments 
or in combination with algorithms that evaluate additional aspects of off-target sites for 
promising guide sequences (for example, heteroduplex bulge by COSMID280; Table 1.1) 
to identify targets that are highly active and have few potential off-target sites.  The activity 
of the chosen guides can then be verified in the appropriate biological system323. 
When targeting protein-coding genes to generate null alleles, the most robust 
method to achieve a null is targeting an exon containing a critical domain for protein 
function324.  Simply targeting an early coding exon can prove ineffective, as alternate 
transcriptional start sites or alternative splicing may allow the generation of functional 
transcripts that bypass the Cas9-induced lesions. For non-coding RNAs or regulatory 
elements, complete excision of the genomic segment128, 325-329 may provide the greatest 
likelihood that a loss-of-function allele is generated.  
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The targeted insertion of DNA through HDR-based approaches also has important 
caveats. Optimal lengths of homology arms for single-stranded oligonucleotides116, 209 
(ssODN) and duplex DNA donors206, 218 have been defined in certain systems, but these 
parameters may vary in different biological settings. Importantly, these insertions do not 
always occur via precise HDR; depending on the type of donor, they can also occur through 
NHEJ-mediated pathways at one end (or both ends) of the donor insertion site109, 206, 214, 330, 
331. The ratio of NHEJ-generated indels relative to HDR-mediated insertions at the target 
site in a population of treated cells or embryos can be quantified directly via SMRT 
sequencing218 or Illumina sequencing when an ssODN is used as a HDR donor. In addition, 
for large donor DNAs, Southern blotting or linear amplification-mediated (LAM)-
PCR332—whichever is more appropriate for the biological system—should be standard 
practice to verify the absence of random donor integration in the genome. 
The tolerance for the level of nuclease promiscuity will obviously depend on the 
application. Researchers using Cas9 nucleases for the genomic alteration of model 
organisms or cell lines for basic science investigations will be more comfortable with low-
frequency, in contrast to nucleases destined for therapeutic applications involving the 
modification of millions to billions of stem or progenitor cells. In basic science 
investigations, concerns about observed phenotypes resulting from collateral genomic 
damage can be alleviated by the use of two or more independent cell lines or animal 
models, ideally generated using different sgRNAs that target the same locus. When 
possible, genetic complementation can be used to validate the phenotype-genotype 
association. For therapeutic applications, in-depth unbiased off-target analysis of nuclease 
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activity should be carried out on the relevant cell type(s). Once a baseline of nuclease 
precision is established, off-target analysis can be used to optimize the nuclease dose and 
the delivery method to identify the conditions that produce the most favorable activity 
profiles with high precision. 
The nuclease field is advancing at a breathtaking rate. Translating this newfound 
technical ability into the creation of breakthrough therapeutics that profoundly alter disease 
outcomes for patients is no longer science fiction; in fact, it is likely that this will be 
accomplished in the foreseeable future. Achieving this goal will require continued 
improvements in nuclease precision, the ability to detect unintended insults to the genome, 
and our understanding of the complexities of DNA repair. The result of these efforts, if 
advanced prudently, will enable the deployment of exciting gene- and cell-based 
therapeutics that will radically improve treatment options for a number of diseases. 
1.9.7 Unbiased methods for off-target analysis 
1.9.7.1 Whole Genome Sequencing (WGS) 
The most exhaustive method to assess changes to the genome. It is only feasible to 
analyze a small number of nuclease-treated clones (or animals), which limits the ability to 
extrapolate this data to off-target lesion rates in a population of nuclease-treated cells. 
1.9.7.2 Direct DSB capture 
These methods directly identify DSBs generated by the Cas9. 
Digenome-Seq273: This method allows the dose dependent in vitro assessment of 
Cas9-sgRNA activity, which permits identification of weakly active off-target sites. 
Genomic loci with mapped sequencing reads that have aligned 5ʹ ends are characteristic of 
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potential off-targets. Digenome-seq cannot capture the influence of local chromatin 
structure or folding on Cas9 activity258, since it is performed in vitro. 
BLESS244, 291: This method labels unrepaired DSBs in fixed nuclei of treated cells 
via ligation of a biotinylated adaptor.  This tag allows solid support based enrichment of 
these loci for deep sequencing analysis. Overall there is a good correlation between 
measured lesion rates and the DSB score assigned based on BLESS analysis.  The 
persistence of DSBs prior to repair, if short, may limit the sensitivity of this approach.  
SITE-seq289: This method also uses in vitro digestion of genomic DNA with Cas9-
sgRNA RNP complexes. High molecular weight genomic DNA is treated with an RNP to 
generate blunt end DSBs. The ends are 3’ adenylated and ligated with biotinylated P5 
adaptors. Then, the DNA is fragmented, end repaired, and ligated to a P7 adaptor. Next, 
biotin selection and PCR amplification is applied to enrich the with Cas9 activity related 
DNA pieces. Similar Digenome-seq, Site-seq also cannot capture the influence of local 
chromatin structure or folding on Cas9 activity. 
CIRCLE-seq290: This method also uses in vitro digestion of genomic DNA with 
Cas9-sgRNA RNP complexes. Fragmented genomic DNA is circularized via intra-
molecular ligation. The circular DNA is treated with an RNP and then adaptors are ligated 
to the broken ends for deep sequencing. Although CIRCLE-seq is very sensitive method, 
the influence of local chromatin structure or folding on Cas9 activity also cannot be 
assessed. 
1.9.7.3 Repair based methods 
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These methods exploit erroneous NHEJ-mediated repair to tag DSBs through either 
exogenous DNA capture or genomic rearrangements. 
IDLV-capture288, 292: This method uses NHEJ-mediated integration of IDLV DNA 
to tag DSBs.  IDLV integration sites are detected by LAM-PCR332138 followed by deep-
sequencing. This method has been successfully used for ZFNs, TALENs, and Cas9 but due 
to low sensitivity it cannot capture inefficient off-target sites (<1% indel frequency). 
GUIDE-seq286: This method uses NHEJ-mediated integration of 
phosphorothioate-protected double stranded oligonucleotides to tag genomic DSBs that are 
then enriched by PCR and deep-sequenced. The modified oligonucleotides can achieve 
high insertion frequencies in some cell lines (20-50 % of total indel frequency), which 
enhances its sensitivity relative to IDLV capture. Off-target sites with indel rates >0.1 % 
can be detected. There is a good correlation between the indel rate and GUIDE-seq 
oligonucleotide insertion rate. Across analyzed sgRNA datasets, the majority of off-target 
sites with two base mismatches and a subset of three base mismatches were active.  This 
method works preferentially with blunt DSBs, so it is less sensitive when used with Cas9 
nickases or FokI-dCas9 fusions286, 299. 
HTGTS287: This method combines LAM-PCR and genome-wide translocation 
sequencing333 to capture genomic rearrangements caused by improper ligation of DSBs 
between the nuclease target and a spatially proximal off-target site. The target site is used 
as the ‘bait’ to capture off-target ‘prey’ sites, although highly active off-target sites can 
also be used as the ‘bait’ affording a similar distribution of genomic DSBs. HTGTS is both 
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sensitive and applicable to other Cas9 variants that improve precision (Cas9 nickases or 
FokI-dCas9). 
1.9.8 Discussion on unbiased methods for off-target analysis 
With a number of methods available for performing unbiased off-target analysis, 
end-users must choose the most appropriate method for their experimental application. The 
choice of off-target detection method depends on many factors including: (i) its sensitivity 
and specificity, (ii) its ease of implementation and data analysis, (iii) the Cas9 variant 
employed, and (iv) the cell type.  
Among these methods, GUIDE-seq286 and HTGTS287 perform similarly with both 
giving the most comprehensive list of off-target sites and the highest levels of sensitivity. 
Although GUIDE-seq was shown to be highly accurate, sites obtained in HTGTS were not 
validated in detail. Digenome-seq273 can also be highly sensitive but can also miss many 
off-target sites (for VEGFa TS1, 7 of 21 GUIDE-seq sites and 24 of 38 HTGTS off-target 
sites were missed) and requires a much higher depth of sequencing. Reduction of the 
background during the library preparations of SITE-seq289 and CIRCLE-seq290 make them 
very sensitive platforms to assess off-target cleavages. However, the presence of in cellulo 
off-target activities may require confirmation. 
There is some background that is associated with both Digenome-seq and 
BLESS244, as less than 50% of the identified off-target sites withstand validation. The data 
analysis for BLESS and GUIDE-seq requires filtering to remove DSB hotspots within the 
genome. GUIDE-seq had a higher rate of validated sites, but the data processing identifying 
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peaks also involved pre-filtering sequences based on the similarity to the target sequence 
(up to 8 base mismatch was allowed). 
Although most methods should be relatively easy to perform, the LAM-PCR step 
used in HTGTS287 and IDLV-capture288 methods may require more technical expertise. A 
JOVE video is available describing the LAM-PCR technique292. Importantly 
computational analysis of the Illumina sequencing data can be challenging for some of 
these approaches.  In particular for HTGTS287 where translocation sequences will contain 
elements that map to two different sites within the genome. Users will likely require 
bioinformatics support for the data processing from these approaches.  
Although all of the unbiased off-target analysis methods work with wild-type Cas9, 
some methods may be insensitive to Cas9 variants that do not leave blunt DSBs. For 
example GUIDE-seq has low sensitivity to Cas9-nickases or FokI-dCas9 dimers as they 
produce DSBs with overhangs upon cleavage299. However, WGS, Digenome-seq, SITE-
seq, CIRCLE-seq and HTGTS should remain sensitive to Cas9 variants.  
Since Cas9 binding250, 259 and hence activity can potentially be influenced by 
chromatin architecture, the repertoire of off-target sites can vary between different cell 
lines286.  Consequently, off-target analysis should be performed in the relevant cell type in 
which the nuclease will be applied. Although methods like WGS, BLESS244, Digenome-
seq273, SITE-seq289, and CIRCLE-seq290 in principle, can be performed for any cell line, 
the efficiency of other methods may be cell line dependent. For example, the cell-type 
sensitivity of GUIDE-seq may depend on both the efficiency of the insertion of GUIDE-
seq oligonucleotides and the accommodation of the introduction of foreign DNA.  The 
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latter may induce innate immune responses in some cell types such as T-cells334, 335. 
Likewise, some cell types may be more tolerant and amenable to translocations than others, 
which could impact the sensitivity of HTGTS output. Thus, choosing the best method for 
off-target identification will be both user and application dependent. 
1.9.9 Additional information on methods to enhance Cas9-sgRNA precision 
These methods can be categorized into four primary strategies: 
1.9.9.1 Computational selection of the best guides 
Computational tools can be used to choose guides that are predicted to have high 
on-target and low off-target activity (Table 1.1). This filtering inherently reduces the 
density of Cas9 targets within the genome (Figure 1.3.b), which may prove problematic 
for editing applications that have a limited sequence window. 
1.9.9.2 Modification of the guide sequence 
Truncated guides (tru-gRNA286, 293): Truncating guides from 5ʹ end (17 or 18nt) 
improves precision by reducing the stability of the Cas9-sgRNA complex254, 255, 336, 
possibly although the exact mechanism remains unclear. GUIDE-seq analysis indicates a 
dramatic reduction in off-target activity for Cas9-tru-gRNAs relative to full-length Cas9-
sgRNAs286.  Nonetheless, residual nuclease activity persists at a small number of off-target 
sites.  
5ʹ Guanine198, 273: In addition to standard 20nt guide for SpCas9, two guanine 
nucleotides are added on to the 5ʹ end of the guide sequence.  This modification appears to 
function in part through nuclease attenuation, which can impact activity at both the target 
and off-target sites268, 273, 277. 
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1.9.9.3 Delivery of the Cas9-sgRNA ribonucleoprotein complex 
The delivery of Cas9 nuclease and the sgRNA via plasmid transfection or viral 
transduction typically results in expression of the Cas9-sgRNA complex beyond that 
needed to achieve target site DSB formation294, which increases the potential for off-target 
activity289. In contrast, delivery of Cas9 and sgRNA as a ribonucleoprotein complex191, 208, 
209, 294-297 or within a lipid nanoparticle239 can more readily control the cellular 
concentration of Cas9-sgRNA and restrict the time window of its activity. 
1.9.9.4 Modification of the Cas9 nuclease 
Dual Cas9 nickases (Cas9n198, 261, 276, 298): The strand that is nicked is determined 
by the nuclease domain (RuvC or HNH) that is inactivated170, 253.  When used with a pair 
of guides to generate nicks on both strands that leave 5ʹ overhangs, DSBs are generated 
that stimulate NHEJ or HDR261, 298. Although single nicks are much less mutagenic than 
DSBs, they can lead to mutagenesis in the context of some sequences190, 198, 276, 300. The 
requirement for two neighboring Cas9 sites reduces the density of targetable sequences by 
dual nickases with the genome. 
FokI-dCas9190, 300: Both the RuvC and HNH nuclease domains of Cas9 are mutated 
yielding a catalytically inactive Cas9 (dCas9) to deliver the nuclease domain of FokI to 
specific sites of the genome. FokI-dCas9 can be used in combination with tru-gRNAs to 
increase nuclease precision299. Like Cas9n, FokI-dCas9 has reduced targeting density 
because a pair of neighboring compatible binding sites is required for DSB formation.  
However, unlike the nickases, the relative spacing of FokI-dCas9 dimers is much more 
restricted. 
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SpCas9 PAM variants304: New PAM variants that target NGAG and NGCG were 
identified through mutagenesis and selection.  Notably, the NGCG SpCas9 variant displays 
few off-target sites based on GUIDE-seq analysis.  In addition a D1135E mutant was 
identified that increases the stringency of SpCas9 for the standard NGG PAM, which 
improves its precision. 
eSpCas9_v1.1301, SpCas9-HF1302, HypaSpCas9303:  In these variants, non-
sequence specific DNA recognition residues of SpCas9 is mutated to reduce its excess 
binding energy to the DNA. Mechanistically these mutations extend the period of SpCas9 
to stay on the inactive state. Therefore, nuclease activities at some sites are reduced in 
comparison to wild type SpCas9.  
SpCas9MT-pDBD306: In this system, Cys2-His2 zinc finger arrays or transcription 
activator-like effector (TALE) domains are engineered to deliver the mutant Cas9 to a 
desired target site in the genome. Target site recognition by the pDBD is necessary for 
nuclease activity, which reduces the number of active off-target sites. 
Base editors337-339: In this system, the Cas9 is either nuclease dead or a D10A 
nickase, and fused to a cytosine deaminase effector. Base editors convert a PAM distal 
cytosine into uracil, thereby a C:G base pair to T:A337, 338. This utility is particularly useful 
for gene correction based therapies where the underlying cause is a point mutation. 
Recently, directed evolution based study described the development of adenine deaminase, 
which converts a PAM distal adenine into inosine, thereby a A:T base pair to G:C339. 
Split307-310- or Intein-Cas9310, 312: Due to the bilobed architecture of Cas9, it can 
be divided (or interrupted) into two inactive segments, where reassembly (or intein 
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excision) restores activity to the complex.  The association of the two domains split-Cas9 
can be regulated through the introduction of drug-dependent308 or light-dependent309 
dimerization domains.  Likewise, intein excision can be regulated through drug-dependent 
control312.  Besides temporal control, dividing SpCas9 into two fragments allows its 
packaging in two separate AAV vectors310. 
Allosterically-regulated Cas9311: Another way to inducible nuclease activity is 
to add an allosteric switch to Cas9. This is achieved by insertion of estrogen receptor-α 
ligand-binding domain (ER-LBD) at a hotspot (residue 231) of the SpCas9 protein. This 
insertion blocks the nuclease activity of SpCas9. Upon addition of a small molecule ligand, 
the ER-LBD undergoes conformational change and reactivates the SpCas9. 
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Figure 1. 4 Schematic of SpCas9 variants with improved precision 
a) Truncated sgRNA where the guide is reduced to 17-18nt in length. b) Addition of two Guanines 
to the 5’ end of the guide. c) Dual Cas9 nickases (Cas9n) where one of the catalytic domains has 
loss-of-function mutation.  When used in pairs with the proper orientation of sites the nickases 
generating a DSB with 5’ overhangs. d) FokI-dCas9 fusions where the catalytically inactive 
SpCas9 acts as programmable DNA-binding unit. Two FokI-dCas9 complexes must bind with the 
proper orientation and spacing to allow dimerization of FokI and DSB formation. e) Cas9MT-pDBD 
where a programmable DNA-binding domain (pDBD) is fused to a Cas9 that has attenuated DNA-
binding affinity through a PID mutation. Consequently, nuclease activity requires DNA recognition 
by the pDBD as well as a compatible PAM and sgRNA recognition sequence. f) SpCas9-HF1, 
eSpCas9_v1.1, HypaSpCas9 variants are generated through mutations in non-sequence specific 
DNA interaction residues of SpCas9 (red circles). These mutations reduce the DNA-binding energy 
of SpCas9 and extend its inactive confirmation time to improve. g) Split-Cas9 where the SpCas9 
is divided into two catalytically inactive segments fused to a (inducible) dimerization domain. Upon 
stimulus, dimerization occurs to reunite the components of SpCas9 and restore nuclease activity. 
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CHAPTER II: DNA-binding-domain fusions enhance the targeting 
range and precision of Cas9 
The CRISPR-Cas9 system is commonly used in biomedical research; however, the 
precision of Cas9 is suboptimal for applications that involve editing a large population of 
cells (for example, gene therapy). Variations on the standard Cas9 system have yielded 
improvements in the precision of targeted DNA cleavage, but they often restrict the range 
of targetable sequences. It remains unclear whether these variants can limit lesions to a 
single site in the human genome over a large cohort of treated cells. Here we show that by 
fusing a programmable DNA-binding domain (pDBD) to Cas9 and attenuating Cas9’s 
inherent DNA-binding affinity, we were able to produce a Cas9-pDBD chimera with 
dramatically improved precision and an increased targeting range. Because the specificity 
and affinity of this framework can be easily tuned, Cas9-pDBDs provide a flexible system 
that can be tailored to achieve extremely precise genome editing at nearly any genomic 
locus. 
2.1 Introduction 
The CRISPR-Cas9 genome engineering system is revolutionizing biological 
sciences owing to its simplicity and efficacy 185, 340, 341. The most commonly studied Cas9 
nuclease (SpCas9) originates from Streptococcus pyogenes 170. SpCas9 and its associated 
guide RNA license a DNA sequence for cleavage on the basis of two stages of sequence 
interrogation 170, 205, 248, 249, 254 (Figure 2.1a): (1) compatibility of the protospacer-adjacent 
motif (PAM) element with the specificity of the PAM-interacting domain, and (2) 
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complementarity of the guide RNA sequence to the target site. As it is straightforward to 
program Cas9 to cleave a desired target site through the incorporation of a complementary 
single guide RNA (sgRNA) 170, the primary constraint on Cas9 targeting is the presence of 
a compatible PAM element 170, 190, 256. The PAM-interacting domain of wild-type SpCas9 
preferentially recognizes an NGG element 170, although it can inefficiently utilize other 
PAM sequences (for example, NAG and NGA) 256, 260. The simplicity of the SpCas9-
sgRNA system allows facile editing of genomes in a variety of organisms and cell lines 185, 
340, 341. 
The precision of SpCas9 is suboptimal for most gene therapy applications involving 
editing of a large population of cells 184, 342. Numerous studies have demonstrated that 
SpCas9 can cleave the genome at unintended sites 256, 257, 269, 270, 273, 286-288, with some guides 
acting at more than 100 off-target sites 286. Recent genome-wide analyses of SpCas9 
precision indicate that the majority of genomic loci that differ from the guide RNA 
sequence at two nucleotides and a subset of genomic loci that differ at three nucleotides 
are cleaved with moderate activity 273, 286-288. For some guides, off-target sites that differ 
by up to six nucleotides can be inefficiently cleaved 273, 286-288, and bulges can be 
accommodated in the sgRNA:DNA heteroduplex 270. In this light, we assessed the general 
frequency of potential off-target sites with three or fewer mismatches for SpCas9 guide 
RNAs in exons or promoter regions using CRISPRseek 278, 343. We found that the vast 
majority of guides (~98% in exons and ~99% in promoters) had one or more off-target 
sites with three or fewer mismatches (Figure 2.1b-e) and thus were likely to have some 
level of off-target activity. Because off-target breaks have the potential to cause both local 
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mutagenesis and genomic rearrangements 286, 287, 344, 345 (for example, segmental deletions, 
inversions and translocations), the resulting collateral damage from SpCas9 treatment 
could have adverse consequences in therapeutic applications. 
Decreased off-target cleavage rates have been associated with several 
modifications to the structure or delivery of the CRISPR-Cas9 system, such as changes to 
the guide sequence length and composition 198, 293, the use of a pair of Cas9 nickases 198, 261, 
298 or FokI-dCas9 nucleases 190, 300, inducible assembly of split Cas9 307-309, 312, Cas9 PAM 
variants with enhanced specificity 304 and the delivery of Cas9:sgRNA ribonucleoprotein 
complexes 294, 295, 297. However, it remains unknown whether these variations can restrict 
cleavage to a single site in the human genome over a large cohort of treated cells 274, 342. In 
addition, some of the most promising approaches (for example, paired nickases and dimeric 
FokI-dCas9) restrict the targetable sequence space by requiring the proximity of two 
sequences compatible with Cas9 recognition. 
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Figure 2. 1 Overview of potential SpCas9 off-target sites in the human genome 
(a) Schematic of the SpCas9:sgRNA system and the two sequential stages of licensing required for 
cleavage: Stage 1 – PAM recognition (nGG is highly preferred) and Stage 2 – complementary R-
loop formation between the 20 nucleotide guide RNA and the interrogated DNA sequence. (b) 
Genome-wide analysis using CRISPRseek278 of the potential off target sites for a representative set 
of 124,793 guide RNAs targeting human exons sequences. Guides were binned based on the 
predicted off-target site with the smallest number of mismatches to the guide sequence. A perfect 
match indicates the presence of an off-target site with a perfect guide match (magenta wedge). Only 
1.6% of these guide sequences do not have an off-target site with 3 or fewer mismatches to the 
guide sequence (teal wedge). This subset would be the best candidates for precise genome editing. 
The vast majority of guides typically have many potential off-target sequences with 3 or fewer 
mismatches. (c) Genome-wide analysis of the minimum number of mismatches in off-target sites 
for a representative set of 55,687 guide RNAs targeting human promoter regions (binned as 
describe above). Only 1% of these guide sequences do not have an off-target site with 3 or fewer 
mismatches to the guide sequence (teal wedge). (d,e) Guide RNAs targeting gene exons (d) or 
promoters € with no predicted off-targets with <= 3 mismatches (teal wedge from b,c) are analyzed 
for off-target sites with potential bulges in the sgRNA:DNA heteroduplex270. Magenta wedges 
indicate the fraction of guides that have one or more off-target sites that have perfect 
complementarity with the exception of a single bulge.  
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We envisioned an improved Cas9 platform in which the precision of target 
recognition was augmented by the incorporation of pDBDs such as Cys2-His2 zinc-finger 
proteins 63 (ZFPs) or transcription activator–like effectors 43 (TALEs) (Figure 2.2). Both 
of these pDBD platforms can be programmed to recognize nearly any sequence in the 
genome 37, 43, 63, 346. Indeed, pDBDs have been used with great success as targeting domains 
for programmable nucleases through the incorporation of nonspecific FokI nuclease 
domains (zinc-finger nucleases 63 and TALE nucleases 43) or sequence-specific nuclease 
domains (e.g., megaTAL 347). One favorable characteristic of pDBDs is their inherent 
modularity whereby specificity and affinity can be rationally tuned by adjustments to the 
number and composition of incorporated modules and the linkage between modules 348, 349. 
Here we demonstrate that the fusion of a pDBD to a mutant SpCas9 with attenuated DNA-
binding affinity generated a chimeric nuclease with a broader sequence-targeting range and 
dramatically improved precision. This SpCas9-pDBD platform has favorable properties for 
genome engineering applications. In addition, our analysis of these SpCas9-pDBD 
chimeras provides new insights into the barriers involved in licensing target-site cleavage 
by a SpCas9:sgRNA complex. 
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Figure 2. 2 Overview of the SpCas9-pDBD designs 
a) Schematic of the SpCas9:sgRNA system fused to a pDBD (orange) that recognizes a binding 
site 3’ to the PAM. b) A hybrid model containing the structure of SpCas9205 (grey, PAM recognition 
residues magenta) with an sgRNA (20 nucleotide guide region cyan, remaining nucleotides red) 
and complementary target DNA (black) with the structure of Zif26822 (orange) placed with a 
binding site 11 bp from the PAM recognition sequence (Watson strand), where the two structures 
were superimposed on a B-DNA model constructed using 3DNA350. In parallel with the spacing 
parameter analysis in Figure 2.3, the structural model suggests that there is ample room for a ZFP 
to dock proximally to SpCas9 downstream of the PAM element.  
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2.2 Materials and Methods 
2.2.1 Plasmid constructs: 
Our SpCas9-pDBD experiments used the following plasmids: All sgRNAs were 
expressed via a U6 promoter from pLKO1-puro351. All SpCas9 and SpCas9-DBD fusions 
were expressed via pCS2-Dest gateway plasmid under chicken β-globin promoter352. ZFPs 
were assembled as gBlocks (Integrated DNA Technologies) from finger modules on the 
basis of previously described recognition preferences35, 36. ZFPs were cloned into a pCS2-
Dest-SpCas9 plasmid backbone cloned thorough BspEI and XhoI sites. TALEs were 
assembled via golden gate assembly111 into our JDS TALE plasmids353. Assembled TALEs 
were cloned into BbsI digested pCS2-Dest-SpCas9-TALEntry backbone through Acc65I 
and BamHI sites. Key plasmids of this study will be deposited at Addgene for distribution 
to the community. Plasmid reporter assays of nuclease activity used the restoration of GFP 
activity through single-strand annealing (SSA)-mediated repair of an inactive GFP 
construct using the M427 plasmid developed by the Porteus laboratory354. SpCas9 target 
sites were cloned into plasmid M427 via ligation-independent methods after SbfI digestion. 
Mutations in the PAM-interacting domain of SpCas9 were generated by cassette 
mutagenesis. 
2.2.2 Cell culture assay 
HEK293T cells obtained from our collaborator M. Green (UMass Medical School, 
Worcester, Massachusetts, USA) were cultured in high-glucose DMEM with 10% FBS and 
1% penicillin-streptomycin (Gibco) in a 37 °C incubator with 5% CO2. These cells were 
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not verified or tested for mycoplasma contamination. For transient transfection, we used 
early to mid-passage cells (passage numbers 5–25). Approximately 1.6 × 105 cells were 
transfected with 50 ng SpCas9-pDBD–expressing plasmid, 50 ng sgRNA-expressing 
plasmid and 100 ng mCherry plasmid with Polyfect transfection reagent (Qiagen) in a 24-
well format according to the manufacturer’s suggested protocol. For the SSA-reporter 
assay, 150 ng M427 SSA-reporter plasmid was also included in the cotransfection mix. 
2.2.3 Western blotting 
HEK293T cells were transfected with 500 ng Cas9 and 500 ng sgRNA-expressing 
plasmid in a six-well plate with Lipofectamine 3000 transfection reagent (Invitrogen) 
according to the manufacturer’s suggested protocol. 48 h after transfection, cells were 
harvested and lysed with 100 l of RIPA buffer. 8 l of cell lysate was used for 
electrophoresis and blotting. The blots were probed with anti-hemagglutinin (Sigma, 
H9658) and anti–α-tubulin (Sigma, T6074) as primary antibodies, and then with 
horseradish peroxidase–conjugated anti-mouse IgG (Abcam, ab6808) and anti-rabbit IgG 
as secondary antibodies, respectively. For visualization we used Immobilon Western 
Chemiluminescent HRP substrate (EMD Millipore, WBKLS0100). 
2.2.4 Flow cytometry reporter assay 
48 h after transfection, cells were trypsinized and collected in a microcentrifuge 
tube. Cells were centrifuged at 500g for 2 min, washed once with 1× PBS, recentrifuged at 
500g for 2 min and resuspended in 1× PBS for flow cytometry (Becton Dickinson 
FACScan). For FACS analysis, 10,000 events were counted for each sample. To minimize 
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the effect of differences in the efficiency of transfection among samples, cells were initially 
gated for mCherry expression, and the percentage of EGFP-expressing cells (nuclease-
positive events) was quantified in mCherry-positive cells. All of the experimental 
replicates were performed in triplicate on different days; data are reported as mean ± s.e.m. 
2.2.5 Genomic targeting analysis with T7EI 
72 h after transfection, cells were harvested and genomic DNA was extracted using 
a DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s suggested 
protocol. 50 ng of input DNA was PCR-amplified using T7EI primers that were specific 
for each genomic region (Appendix 1) with Phusion High Fidelity DNA Polymerase (New 
England BioLabs): (98 °C, 15 s; 67 °C, 25 s; 72 °C, 18 s) for 30 cycles. 10 l of PCR 
product was hybridized and treated with 0.5 l of T7EI (New England BioLabs) in 1× NEB 
Buffer 2 for 45 min12. The samples were run on a 2.5% agarose gel and quantified with 
ImageJ software355. Insertion-deletion percentages were calculated as previously 
described12. Experiments for T7EI analysis were performed in triplicate on different days; 
data are reported as mean ± s.e.m. 
2.2.6 Targeted deep-sequencing-based off-target analysis for SpCas9-pDBDs 
For the generation of each amplicon, we used two-step PCR amplification to first 
amplify the genomic segments and then install the barcodes and indexes. In the first step, 
we used ‘locus-specific primers’ bearing common overhangs with tails complementary to 
the TruSeq adaptor sequences (Appendix 1). 50 ng of input DNA was PCR amplified with 
Phusion High Fidelity DNA Polymerase (New England BioLabs): (98 °C, 15 s; 67 °C 25 
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s; 72 °C 18 s) for 30 cycles. 5 µl of each PCR reaction was gel-quantified by ImageJ355 
against a reference ladder, and equal amounts from each genomic-locus PCR were pooled 
for each treatment group (15 different treatment groups). The pooled PCR products from 
each group were run on a 2% agarose gel, and the DNA from the expected product size 
(between 100 and 200 bp) was extracted and purified with a QIAquick gel extraction kit 
(Qiagen). In the second step, we amplified the purified pool from each treatment group 
with a ‘universal forward primer’ and an ‘indexed reverse primer’ to reconstitute the 
TruSeq adaptors. 2 ng of input DNA was PCR amplified with Phusion High Fidelity DNA 
Polymerase (New England BioLabs): (98 °C, 15 s; 61 °C, 25 s; 72 °C, 18 s) for nine cycles. 
5 µl of each PCR reaction was gel-quantified by ImageJ355, and then equal amounts of the 
products from each treatment group were mixed and run on a 2% agarose gel. Full-size 
products (~250 bp in length) were gel-extracted and purified with a QIAquick gel 
extraction kit (Qiagen). The purified library was deep-sequenced using a paired-end 150-
bp MiSeq run. 
Sequences from each genomic locus in a specific index were identified on the basis 
of a perfect match to the final 11 bp of the proximal genomic primer used for locus 
amplification. Insertions or deletions in the SpCas9 target region were defined on the basis 
of the distance between a ‘prefix’ sequence at the 5’ end of each off-target site (typically 
10 bp) and a ‘suffix’ sequence at the 3’ end of each off-target site (typically 10 bp)356, 
where there were typically 33 bp between these elements in the unmodified locus. 
Distances that were greater than expected were binned as insertions, and distances that 
were shorter than expected were binned as deletions. Reads that did not contain the suffix 
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sequence were marked as undefined. For some loci, the background sequencing error rate 
was high. For example, for OT2-1 a homopolymer sequence in the guide region led to a 
high error rate. 
All statistical analyses were performed using R, a system for statistical computation 
and graphics357. Log-odds ratios of lesions were calculated for the on-target and off-target 
sites of each individual Cas9 treatment group versus the untreated control for each of the 
three independent experiments. A t-test was applied to assess whether the log-odds ratio 
was significantly different from 0, that is, whether there was a significant difference in 
lesion odds between each individual Cas9 treatment group and the untreated control for the 
on-target and off-target sites. We obtained odds ratios and their 99% confidence intervals 
by taking the exponents of the estimated log-odds ratios and their 99% confidence 
intervals. These analyses were also applied to the sum of the lesion rates across all three 
replicates (combined). To adjust for multiple comparisons, we adjusted P values using the 
Benjamini-Hochberg method358. Only loci that had significant Benjamini-Hochberg–
adjusted P values in the combined data for the treatment group relative to the control were 
considered significant. 
2.2.7 GUIDE-seq off-target analysis for SpCas9-pDBDs 
We performed GUIDE-seq with some modifications to the original protocol286. 
Importantly, there is an error in the original publication with regard to the GSP1 and GSP2 
primer sets, which list incompatible combinations. It was necessary to properly sort the 
primer sets for the positive (+) and negative (–) strands to achieve successful library 
amplification. 
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Nuclease_off_+_GSP1 
GGATCTCGACGCTCTCCCTGTTTAATTGAGTTGTCATATGTTAATAAC +  
Nuclease_off_–_GSP1 
GGATCTCGACGCTCTCCCTATACCGTTATTAACATATGACA – 
Nuclease_off_+_GSP2 
CCTCTCTATGGGCAGTCGGTGATTTGAGTTGTCATATGTTAATAACGGTA + 
Nuclease_off_–_GSP2 
CCTCTCTATGGGCAGTCGGTGATACATATGACAACTCAATTAAAC – 
In addition, our protocol differed from the published protocol286 in the following 
manner: in a 24-well format, HEK293T cells were transfected with 250 ng of Cas9, 150 ng 
of sgRNA, 50 ng of GFP and 10 pmol of annealed GUIDE-seq oligonucleotide using 
Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer’s 
suggested protocol. 48 h after transfection, genomic DNA was extracted with a DNeasy 
Blood and Tissue kit (Qiagen) according to the manufacturer’s suggested protocol. Library 
preparations were done with original adaptors according to protocols described by Joung 
and colleagues286, with each library barcoded for pooled sequencing. The barcoded, 
purified libraries were deep-sequenced as a pool using two paired-end 150-bp MiSeq runs. 
Reads containing identical molecular indices and identical starting 8-bp elements 
on read 1 were pooled into one unique read. The initial 30 bp and the final 50 bp of the 
unique read 2 sequences were clipped for removal of the adaptor sequence and low-quality 
sequences and then mapped to the human genome (hg19) using Bowtie2. Peaks containing 
mapped unique reads were identified using the pile-up program ESAT 
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(http://garberlab.umassmed.edu/software/esat/) with a window of 25 bp with a 15-bp 
overlap. Neighboring windows that were on different strands of the genome and less than 
50 bp apart were merged using Bioconductor package ChIPpeakAnno359, 360. Peaks that 
were present with multiple different guides (hot spots286) or that did not contain unique 
reads for both sense and antisense libraries286 were discarded. The remaining peaks were 
searched for sequence elements that were complementary to the nuclease target site using 
CRISPRseek278. Only peaks that harbored a sequence with fewer than seven mismatches 
to the target site were considered potential off-target sites. These regions are reported in 
Appendix 2, and the numbers of reads from the sense and the antisense libraries were 
combined into the final read number. 
2.2.8 CRISPRseek analysis of potential off-target site for SpCas9 sgRNAs 
Human hg19 exon and promoter sequences were fetched using Bioconductor 
packages ChIPpeakAnno359, 360 and TxDb.Hsapiens.UCSC.hg19.knownGene. A subset of 
16,500 exons and 192 promoter sequences of 2 kb each were selected for sgRNA searching 
and genome-wide off-target analysis using Bioconductor package CRISPRseek278, 343 with 
the default settings (both NGG and NAG PAMs were allowed), except BSgenomeName = 
BSgenome.Hsapiens.UCSC.hg19, annotateExon = FALSE, outputUniqueREs = FALSE, 
exportAllgRNAs = “fasta” and fetchSequence = FALSE. After sgRNAs with on-targets 
or/and off-targets in the haplotype blocks had been excluded, there were 124,793 unique 
sgRNAs from exon sequences and 55,687 unique guide RNAs from promoter sequences 
included in the analysis. Each guide was binned on the basis of either the off-target site 
with the fewest mismatches to the guide sequence or the sum of the off-target scores for 
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the top ten off-target sites. The fraction of guides in each bin for exons or promoters is 
displayed as a pie chart (Figure 2.1). 
2.3 Results 
2.3.1 Defining the properties of the SpCas9-pDBD framework 
To define the parameters necessary for the function of a SpCas9-pDBD chimera, 
we assayed the cleavage of a Cas9:sgRNA target site with a suboptimal NAG PAM using 
a plasmid reporter assay354 (Figure 2.3). We examined the ability of a pDBD fused (ZFP 
or TALE) to SpCas9 to enhance nuclease activity when the pDBD binding sites were 
located at different positions and orientations relative to the Cas9 target site (Figure 2.4a). 
In pilot experiments, we observed the most robust activity when we used a C-terminal 
fusion of a ZFP or a TALE to SpCas9 when the pDBD binding sites were positioned 3’ to 
the PAM element (M.F.B. and S.A.W., unpublished results). Both SpCas9-ZFP and 
SpCas9-TALE proteins increased nuclease activity on an NAG PAM target to a level 
similar to the activity of wild-type SpCas9 on an NGG PAM (Figure 2.4a) while being 
expressed at similar levels (Figure 2.4b). SpCas9-pDBD nuclease activity remained 
dependent on the length of the guide sequence (Figure 2.4c), confirming that the chimera 
retained the guide-dependent licensing stage for sequence cleavage. To define the 
functional PAM elements for SpCas9-pDBD, we examined activity at each of the 16 
possible sequence combinations. In contrast to wild-type SpCas9, SpCas9-pDBD 
demonstrated high activity for NAG, NGA and NGC as well as for the standard NGG PAM 
(Figure 2.4d-e). Accounting for reverse complements of the functional PAM elements, the 
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SpCas9-pDBD chimeras recognized 7 of the 16 possible dinucleotide sequence 
combinations. The increased targeting range for SpCas9-pDBDs was also observed at 
genomic target sites (Figure 2.5). Because of the smaller size of SpCas9-ZFPs relative to 
SpCas9-TALEs, which confers advantages for certain viral-delivery systems361, we 
focused primarily on SpCas9-ZFP chimeras for the immediate development of this 
platform. 
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Figure 2. 3 Schematic overview of plasmid-based nuclease activity reporter assay 
The reporter plasmid carriers broken EGFP expression construct. A programmable 
nuclease target site is cloned in between two repeated sequences (indicated by “F”). Once 
the nuclease creates a double-strand break at the target site on the plasmid DNA, the DSB 
is repaired via cellular single-strand annealing pathway. This results in functional 
restoration of the EGFP reporter gene. 
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Figure 2. 4 Development of an SpCas9-pDBD framework 
a) Top, schematic of the pDBD binding-site orientation and spacing parameters examined. The 
position and 5’-to-3’ orientation of the pDBD binding site relative to the PAM element of the 
SpCas9 binding site are represented by orange arrows (Watson (W) and Crick (C)). Bottom, activity 
profiles of SpCas9 (blue, on an NGG or NAG PAM), SpCas9-Zif268 (red, NAG PAM) and 
SpCas9-TAL268 (brown, NAG PAM) in the GFP reporter assay on a common sgRNA target site. 
The pDBD-site orientation was either W or C, and spacing was 5, 8, 11 or 14 bp from the PAM. b) 
HEK293T cells are transfected with the indicated Cas9 plasmid (see methods for details), which 
has triple HA-tag. (Top) Full length protein is probed with anti-HA antibody. (Bottom) Alpha-
tubulin is used as loading control (Neg. CT; negative control). C) Activity profile of SpCas9 (blue) 
and SpCas9-Zif268 (red) in the GFP reporter assay354 with sgRNAs of various lengths truncated 
from the 5’ end of the guide and an nGG PAM target site. d) Activity profile of SpCas9 (blue) and 
SpCas9-Zif268 (red) in the GFP reporter assay on a common target site with different PAM 
sequences and a neighboring Zif268 site. e) Activity profile of SpCas9 (blue) and SpCas9-TAL268 
(brown) in the GFP reporter assay with sgRNAs of 20nt vs 16nt lengths on nGG, nAG, nGA, nGC 
PAM target sites. Data are from three independent biological replicates performed on different days 
in HEK293T cells. Error bars indicate ±s.e.m (standard error of the mean).  
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Figure 2. 5 Activity profile of SpCas9-pDBDs at target sites with different PAMs 
a) Top, SpCas9 or SpCas9-Zif268 programmed independently with four different sgRNAs 
targeting four different genomic sites with neighboring Zif268 binding sites (highlighted in orange). 
Bottom, SpCas9 cut efficiently only at the target site with an NGG PAM, but SpCas9-Zif268 cut 
efficiently at additional target sites with NAG, NGA and NGC PAMs. b) Genomic regions were 
PCR amplified, and lesions (indicating cleavage and mutagenic non-homologous end joining) were 
detected by T7EI assay. Data are from three independent biological replicates performed on 
different days in HEK293T cells. Error bars indicate ±s.e.m.  
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2.3.2 Attenuating the DNA-binding activity of SpCas9 
The fusion of a pDBD to SpCas9 should increase nuclease precision if target 
cleavage is dependent on DNA recognition by the pDBD. To test this, we attenuated the 
DNA-binding affinity of SpCas9 by independently mutating the key PAM recognition 
residues205 (Arg1333 and Arg1335) to either lysine or serine (Figure 2.6a). In the plasmid 
reporter assay, all four mutations decreased the nuclease activity of SpCas9 to background 
levels. A ZFP fusion in the presence of a complementary binding site restored nuclease 
activity in all mutants except R1335S (SpCas9MT4) (Figure 2.6b). We found that R1335K 
(SpCas9MT3) lacked activity with the NAG PAM even as a SpCas9-ZFP fusion. This 
prompted a broader assessment of PAM specificity for the three active SpCas9-ZFP 
mutants, which revealed a preference for alternate PAMs that preserved the remaining 
arginine-guanine interaction205 (i.e., R1333 mutants preferred NNG PAMs, whereas the 
R1335K mutant preferred NGN PAMs; Figure 2.6c). The activity of each SpCas9 mutant 
was also characterized on compatible genomic target sites with an NGG PAM. R1333K 
(SpCas9MT1) retained independent activity on a subset of target sequences, whereas 
R1333S (SpCas9MT2) and R1335K (SpCas9MT3) showed only background activity, which 
could be restored to wild-type levels in the presence of a ZFP fusion (Figure 2.7 and 
Figure 2.8). To confirm that the ZFP-dependent restoration of activity was general, we 
assessed the nuclease activity of three additional SpCas9MT3-ZFP fusions, two of which 
restored nuclease function (Figure 2.9 and Table 2.1). Thus, altering the affinity of PAM 
recognition through mutation generated SpCas9 variants that were dependent on the 
attached pDBD for efficient function. This pDBD dependence established a third stage of 
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target-site licensing for our SpCas9MT3-pDBDs, which we believed would increase their 
precision. 
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Figure 2. 6 Attenuating the nuclease activity of SpCas9 
a) Left, four PAM-interacting amino acids neighboring the NGG PAM (magenta) in the structure 
of SpCas9205. Arginines at positions 1,333 and 1,335 were mutated to attenuate the DNA-binding 
affinity of SpCas9. Right, local sequences of the PAM interacting domain mutants at positions 1333 
or 1335 of SpCas9 examined in this study. b) Activity profiles of SpCas9 (blue) and SpCas9-Zif268 
(red) bearing lysine and serine substitutions at positions 1,333 and 1,335 in the PAM-interaction 
domain in comparison to wild-type (WT) SpCas9. b) Analysis of SpCas9 mutant activity on 
different nGn or nnG PAM-containing target sites in the GFP reporter assay. Mutations that alter 
the interaction of R1333 with its guanine contact (nGn, teal) reveal modest activity at nnG PAMs. 
Correspondingly, mutations that alter the interaction of R1335 with its guanine contact (nnG, 
magenta) reveal modest activity at nGn PAMs. Reporter assays were performed in HEK293T cells. 
Bars represent means from three independent biological replicates performed on different days. 
Error bars indicate ±s.e.m. 
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Figure 2. 7 Genomic activity profile of SpCas9 mutants 
a) Analysis of the genomic activity profile of SpCas9 mutants (MT1, MT2, MT3 & MT4) 
independently and as SpCas9-Zif268 fusions at the PLXNB2 locus at a target site with an nGG 
PAM and a Zif268 binding site 11 bp away on the Watson strand. T7EI assay data from PCR 
products spanning the target site in three independent biological replicates (Rep1, Rep2, Rep3) 
performed on different days in HEK293T cells. Cleaved products are indicated by magenta 
arrowheads. b) Quantification of average T7EI-based lesion rates. Bars represent means from three 
independent biological replicates. Error bars indicate ±s.e.m.  
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Figure 2. 8 Analysis of the genomic activity profile of SpCas9MT1 
T7EI assay data from PCR products spanning the target site in three independent biological 
replicates (Rep1, Rep2, Rep3) performed on different days in HEK293T cells. Cleaved products 
are indicated by magenta arrowheads. 
  
   74 
 
Figure 2. 9 Analysis of the genomic activity of other SpCas9MT3-ZFPs 
Activity of SpCas9MT3-ZFPDCLK2 and SpCas9MT3-ZFPF9 at DNAJC6 and PLXDC2 sites 
respectively. These sequences have compatible binding sites for the DCLK235 and Factor IX107 
ZFPs. T7EI assay data from PCR products spanning the target site from single experiment done in 
HEK293T cells. Cleaved products are indicated by magenta arrowheads. Similar analysis of 
SpCas9MT3-ZFPHEBP2 (targeting a compatible binding site for the HEBP2 ZFP36) at GPRC5B did 
not detect any lesions for this SpCas9MT3-ZFP fusion (data not shown).  
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Table 2.1: Summary of the SpCas9MT3-pDBDs tested in this study. 
7 out of 8 ZFPs and 1 out of 3 TALEs are able to restore nuclease activity to the SpCas9MT3 mutant 
when fused to the C-terminus. Genomic nuclease activities are measured by T7EI assay. 
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2.3.3 Assessing the precision of SpCas9MT3-ZFP fusions 
Next we compared the precision of SpCas9MT3-ZFPs to that of SpCas9 using 
sgRNAs with previously defined off-target sites257, 293. We programmed three different 
four-finger ZFPs to recognize 12-bp sequences neighboring sgRNA target sites 2, 3 and 4 
(TS2, TS3 and TS4, respectively) for use as SpCas9MT3-ZFP fusions (Figure 2.10a). The 
activity of SpCas9, SpCas9MT3 and SpCas9MT3-ZFP with the corresponding sgRNA was 
compared at each target site. In all cases SpCas9MT3 dramatically decreased the cleavage 
efficiency, which was restored by the cognate ZFP fusion (Figure 2.10b). The activity of 
SpCas9MT3-ZFP was dependent on the presence of both a cognate sgRNA and a cognate 
ZFP (Figure 2.10c). Consistent with the dependence on ZFP binding, truncation of one 
zinc finger from either end of ZFPTS3 decreased the activity of SpCas9MT3-ZFPTS3 at TS3, 
and the removal of two zinc fingers abrogated activity (Figure 2.11). The additional stage 
of target-site licensing supplied by the pDBD dramatically increased the precision of 
SpCas9MT3-ZFPTS3 relative to that of wild-type SpCas9; lesion rates for sgRNATS3 at off-
target site 2 (OT3-2), the most active off-target site, were 22% by T7 endonuclease I (T7EI) 
assay with wild-type Cas9 but were undetectable with SpCas9MT3-ZFPTS3 (Figure 2.10c). 
We also programmed two TALE arrays to target SpCas9MT3 to TS3 and TS4 (TALETS3 and 
TALETS4). Nuclease activity at TS3, but not at TS4, was restored by the related SpCas9MT3-
TALE fusion (Figure 2.12). 
To examine the catalytic tolerance of the SpCas9MT3-ZFPTS3:sgRNA complex for 
mismatches between the guide and a target sequence, we used a set of guides that 
progressively shifted blocks of two base mismatches from the 5’ to the 3’ end of the guide 
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sequence. SpCas9MT3-ZFPTS3 had a lower tolerance for mismatches between the guide and 
target site than did wild-type SpCas9 (SpCas9WT), whereas SpCas9WT-ZFPTS3 seemed to 
have a modestly increased tolerance for mismatches (Figure 2.10d). SpCas9MT3-ZFPs also 
exhibited decreased activity with truncated sgRNAs293 (Figure 2.13), consistent with the 
requirement for a higher degree of guide–target site complementarity to achieve efficient 
cleavage. 
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Figure 2. 10 SpCas9MT-ZFP chimeras have improved precision 
a) Sequences of TS2, TS3 and TS4 for the SpCas9:sgRNAs described by Joung and colleagues257, 
293. The 12-bp ZFP binding sites for TS2, TS3 and TS4 are highlighted in cyan, red and teal, 
respectively, with arrows indicating the bound strands. b) Lesion rates determined by T7EI assay 
for SpCas9, SpCas9MT3 and SpCas9MT3-ZFP at TS2, TS3 and TS4. Data are from three independent 
biological replicates performed on different days in HEK293T cells. c) Representative T7EI assay 
comparing lesion rates at TS3 and OT3-2293 for various SpCas9-chimera:sgRNA combinations. 
The activity at the target site for SpCas9MT3-ZFP was dependent on the cognate sgRNA and ZFP, 
where SpCas9MT3-ZFPTS3 was able to discriminate between TS3 and OT3-2. Cleaved products are 
indicated by magenta arrowheads. d) Genomic target-site cleavage activity by SpCas9, SpCas9WT-
ZFPTS3 and SpCas9MT3-ZFPTS3 in response to dinucleotide mismatches placed at different positions 
in the guide sequence targeting the TS3 site. Top, T7EI assay data from PCR products spanning 
the TS3 site in three independent biological replicates performed on different days in HEK293T 
cells. Bottom, schematic indicating the position of the dinucleotide mismatches across the guide 
sequence. SpCas9MT3-ZFPTS3 demonstrated superior discrimination relative to SpCas9 for 
dinucleotide mismatches in the sgRNA recognition sequence. Error bars indicate ±s.e.m. 
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Figure 2. 11 Effect of the number of zinc fingers on SpCas9MT3-ZFPTS3 activity 
Both Cas9WT and SpCas9MT3-ZFPTS3 with four fingers (F1-4) achieve efficient target cleavage. 
Removing a single finger from either end of the zinc finger array (F1-3 or F2-4) dramatically 
reduces the activity of the SpCas9MT3-ZFP chimera. Cleaved products are indicated by magenta 
arrowheads. The bar graph displays the mean lesion rate in three independent biological replicates 
(Rep1, Rep2, Rep3) performed on different days in HEK293T cells.  Error bars indicate standard 
error of the mean. 
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Figure 2. 12 Activity profiles of SpCas9MT3-TALETS3 and SpCas9MT3-TALETS4 
An arrow indicates the strand (Watson) of the highlighted sequence that is bound by the TALE. 
Two different TALE repeat lengths (9.5 and 15.5) were examined at each target site. T7EI assay 
data from PCR products spanning the target site in three independent biological replicates (Rep1, 
Rep2, Rep3) performed on different days in HEK293T cells. Cleaved products are indicated by 
magenta arrowheads. 
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Figure 2. 13 Activity profile of SpCas9MT3-ZFPTS3/TS4 with tru-sgRNAs 
a) Nuclease activity based on T7EI assay for SpCas9WT and SpCas9MT3-ZFPTS3 with a 17 
nucleotide truncated guide at the TS3 target site. b) Nuclease activity based on T7EI assay for 
SpCas9WT and SpCas9MT3-ZFPTS4 with an 18 nucleotide truncated guide at the TS4 target site. 
Cleaved products are indicated by magenta arrowheads. c) Target sites for the TS3 and TS4 tru-
sgRNAs and graph showing the average activity at each target site in three independent biological 
replicates performed on different days in HEK293T cells. Error bars indicate standard error of the 
mean. For both TS3 and TS4, the SpCas9MT3-ZFP chimera is more sensitive to the truncation of the 
guide sequence, which is consistent with the greater sensitivity of this system to guide mismatches. 
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2.3.4 Deep-sequencing analysis of off-target activity 
To more broadly assess improvements in precision, we deep-sequenced PCR 
products spanning previously defined off-target sites for sgRNATS2:TS3:TS4 257, 293, as well 
as several additional genomic loci with favorable ZFPTS2:TS3:TS4 recognition sites and some 
complementarity to the TS2, TS3 or TS4 guide sequences. We compared the nuclease 
activity of SpCas9, SpCas9MT3, SpCas9WT-ZFPTS2:TS3:TS4 and SpCas9MT3-ZFPTS2:TS3:TS4 at 
these off-target sites and found that SpCas9MT3-ZFPTS2:TS3:TS4 dramatically increased the 
precision of target-site cleavage (Figure 2.14a). In most cases, using SpCas9MT3-
ZFPTS2:TS3:TS4 decreased lesion rates at off-target sites to background levels, resulting in up 
to 150-fold improvements in the specificity ratio (Figure 2.14b). Only one off-target site 
(OT2-2), which had a neighboring sequence similar to the expected ZFPTS2 recognition 
sequence (Figure 2.15a), still had high lesion rates. One other site (OT2-6) showed some 
residual activity for both SpCas9MT3 and SpCas9MT3-ZFPTS2 that was above the background 
error rate in our sequencing data. Overall, these data demonstrate a dramatic enhancement 
in precision for SpCas9MT3-ZFPs relative to that of standard SpCas9 at previously defined 
active off-target sites. 
One potential advantage of the SpCas9-pDBD system over other Cas9 platforms is 
the ability to rapidly tune the affinity and specificity of the attached pDBD to further 
optimize its precision. Consequently, we sought to improve the precision of SpCas9MT3-
ZFPTS2 by truncating the ZFP to reduce its affinity for target site OT2-2. Constructs with a 
truncation of either of the terminal zinc fingers showed high activity at the target site 
((Figure 2.14c). However, these truncations decreased or eliminated off-target activity at 
   83 
OT2-2, reflecting a profound improvement in the precision of SpCas9MT3-ZFPTS2 (Figure 
2.14c and Figure 2.15b-c). Similarly, utilization of a ZFP (TS2*) that recognized an 
alternate sequence neighboring the TS2 guide target site also abolished off-target activity 
at OT2-2, confirming that cleavage by SpCas9MT3 at this off-target site was ZFP dependent 
(Figure 2.14c). Given the improvements in precision realized through these simple 
adjustments in the composition of the ZFP, it should be possible to achieve even greater 
enhancements in precision via more focused modification of the ZFP composition and the 
linker connecting it to SpCas9. 
Finally, we used genome-wide, unbiased identification of double-stranded breaks 
enabled by sequencing (GUIDE-seq)286 to provide an unbiased assessment of the 
propensity for SpCas9MT3-ZFPs to cleave at alternate off-target sites in the genome (Figure 
2.16). Using modified versions of the original protocol and bioinformatics pipeline, we 
assessed genome-wide double-stranded break induction by SpCas9 and SpCas9MT3-
ZFPTS2:TS3:TS4 (Online Methods). This analysis revealed dramatically enhanced precision 
of the SpCas9MT3-ZFPs compared with that of SpCas9 for all three target sites (Figure 
2.17a-d and Appendix 2). For SpCas9MT3-ZFPTS3 and SpCas9MT3-ZFPTS4, we did not 
detect nuclease-dependent oligonucleotide capture at any site other than the target site. For 
SpCas9MT3-ZFPTS2, which retained two active off-target sites that overlapped with SpCas9, 
cleavage activity at all of the alternate sequences was dramatically decreased compared 
with that of SpCas9. In addition, there was one new weak off-target site (OTG2-42) for 
SpCas9MT3-ZFPTS2. These data demonstrate that use of the SpCas9MT3-ZFP fusion 
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decreased cleavage at wild-type SpCas9 off-target sites without generating a new class of 
highly active ZFP-mediated off-target sites. 
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Figure 2. 14 Deep-sequencing analysis of SpCas9MT3-ZFP chimera precision 
a) Lesion rates for target sites and off-target sites with statistically significant activity (P <= 0.01) 
assayed by deep-sequencing of PCR products spanning each genomic locus for SpCas9 (blue), 
SpCas9MT3 (light blue), SpCas9WT-ZFP (red) and SpCas9MT3-ZFP (pink). NegCT indicates 
untransfected negative control. b) Specificity ratio of SpCas9MT3-ZFP relative to that of SpCas9WT 
for the target-site lesion rate relative to each off-target lesion rate (Specificity ratio = (Target site 
lesion rate)/(Off-target lesion rate)). c) Comparison of average lesion rates at TS2 and OT2-2 
determined by T7EI assay for SpCas9WT and SpCas9MT3-ZFPTS2 variants that altered the number of 
zinc fingers or changed them completely (TS2*). The binding site for ZFPTS2* is indicated in green. 
Removing finger 1 (F2-4) or finger 4 (F1-3) from the four-finger TS2 ZFP array (F1-4) at most 
modestly affected the target-site activity, but it dramatically improved precision (dashed box). Data 
are from three independent biological replicates performed on different days in HEK293T cells 
(Figure 2.14). Error bars indicate ±s.e.m. 
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Figure 2. 15 SpCas9MT3-pDBD activity can be tuned to further improve precision 
a) The sequence complementary to the guide is underlined with the two mismatched positions in 
bold.  The nGG PAM is red and the potential ZFPTS2 binding site highlighted in yellow.  Below the 
genomic sequence is predicted consensus recognition motif and sequence logo for ZFPTS2 based on 
a Random Forest model of ZFP recognition362. The predicted recognition motif only differs 
substantially at one position in the finger 4 binding site (C versus A). (b-c) T7EI activity profile of 
SpCas9MT3-ZFPTS2 at the TS2 genomic locus and OT2-2 as a function of the number of fingers. b) 
Both Cas9WT and SpCas9MT3-ZFPTS2 with four fingers (F1-4) result in efficient cleavage at the TS2 
target site (magenta arrowheads indicate cleaved products).  Removing a single finger from either 
end of the zinc finger array (F1-3 or F2-4) at most modestly reduces activity of the SpCas9MT3-ZFP 
chimera. Removing a both terminal fingers from the zinc finger array (F2-3) dramatically reduces 
activity of the SpCas9MT3-ZFP chimera.  Construction of an alternate ZFP (TS2*) that recognizes 
an overlapping target site can also promote target cleavage.  c) Both Cas9WT and SpCas9MT3-ZFPTS2 
with four fingers (F1-4) result in efficient cleavage at the OT2-2 off-target site (magenta 
arrowheads indicate cleaved products). Removing a single finger from either end of the zinc finger 
array (F1-3 or F2-4) dramatically reduces activity of the SpCas9MT3-ZFP chimera. As does the 
utilization of an alternate ZFP (TS2*) that recognizes a different target site. Data from three 
independent biological replicates (Rep1, Rep2, Rep3) performed on different days in HEK293T 
cells. 
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Figure 2. 16 Schematic overview of GUIDE-seq library preparation 
In addition to sgRNA and Cas9 expression constructs, cells are provided with end-protected 
double-stranded, short GUIDE-seq oligonucleotides (red lines with circles). Once Cas9 (magenta 
scissors) generates DSB(s) at the target site (left, green) or an off-target site (right, cyan), the 
GUIDE-seq oligo is incorporated at the cleavage sites. To identify genome-wide Cas9 active sites, 
genomic DNA of the treated cells are isolated, mechanically sheared, end repaired, and ligated to 
deep sequencing adaptors (yellow and purple). The adaptor-ligated DNA pieces are amplified and 
enriched within the library prior to deep sequencing.  
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Figure 2. 17 Genome-wide off-target analysis of SpCas9MT3-ZFPs by GUIDE-seq 
a) Number of off-target sites with nuclease activity detected for SpCas9WT (blue) and SpCas9MT3-
ZFP (red) with TS2, TS3 and TS4 guides. (b–d) Number of unique reads captured by GUIDE-seq 
for nuclease active sites in the genome (TS2 b), TS3 c) and TS4 d) target sites (bold) and off-target 
sites). Previously defined off-target sites are in black font257, 286, and potential new off-target sites 
that were identified in this analysis are in green font for SpCas9WT and orange font for SpCas9MT3-
ZFP. Some sites (e.g., OGT2-10 and OGT2-20) contained only reads from a single library for 
SpCas9MT3-ZFP and so are not binned as off-target sites in a). Detailed information on the sites and 
counts is presented in Appendix 2. e) Model of the three stages of target-site licensing that are 
necessary for SpCas9MT3-pDBD to cleave DNA. Because of the modification of SpCas9 (mutation, 
indicated by yellow stars), the efficient engagement of a sequence for PAM recognition or guide 
RNA complementarity requires the presence of a neighboring DNA sequence that can be bound by 
the attached pDBD. This requirement for pDBD binding adds a third stage of target-site licensing 
for efficient cleavage.  
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2.4 Discussion 
Our analysis of the activity of SpCas9-pDBD chimeras provides new insights into 
the mechanism of target-site licensing by SpCas9 and methods to exploit this mechanism 
to improve precision. Fusion of a pDBD to SpCas9 allows for efficient use of a broader 
repertoire of PAM sequences by SpCas9. However, even for SpCas9-pDBDs, there 
remains a dichotomy between functional and inactive PAMs. The broader targeting range 
of SpCas9-pDBDs probably reflects the bypass of a kinetic barrier to R-loop formation that 
follows PAM recognition, as proposed by Seidel and colleagues249. We believe that the 
pDBD tethering of SpCas9 leads to activity at a target site containing a suboptimal PAM 
by increasing the effective concentration of SpCas9 around the target site and hence 
stabilizing the SpCas9-PAM interaction363. For wild-type SpCas9, only high-affinity 
(NGG) PAM sites consistently have sufficient residence time to facilitate efficient 
progression to R-loop formation, but pDBD tethering increases the likelihood that 
SpCas9:sgRNA will be able to overcome this barrier at suboptimal PAMs. Our data also 
support an allosteric licensing mechanism, as described by Doudna and colleagues248, 
which is likely to restrict Cas9 nuclease activity for the majority of sequence combinations 
in the PAM element even with the increased local concentration afforded by pDBD 
tethering. The enhanced sensitivity to guide–target site heteroduplex stability observed for 
our SpCas9MT3-ZFPTS3 chimera (Figure 2.10d and Figure 2.13) further supports the 
interplay between PAM recognition and guide complementarity in the licensing of nuclease 
activity. 
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We found that mutations to the SpCas9 PAM-interacting domain introduced a third 
stage of licensing (pDBD site recognition) for efficient target-site cleavage in the 
SpCas9MT-pDBD system (Figure 2.16e). The weakened interaction between mutant Cas9 
and the PAM sequence necessitated an increased effective concentration for nuclease 
function that was achieved by the high-affinity interaction of the tethered pDBD with its 
target site. This combination dramatically improved precision as assessed by targeted deep-
sequencing and GUIDE-seq analysis. Compared with previous GUIDE-seq analysis of 
TS2, TS3 and TS4 for SpCas9, we detected five, three and three of the top five off-target 
sites that were previously described286. The discrepancy between the studies could be due 
to our lower sequencing depth, the use of an alternate cell line or different delivery 
methods. Nonetheless, on the basis of our analysis we can exclude the presence of a new 
class of highly active off-target sites generated by the fusion of the ZFP to Cas9. 
This system has important advantages over previously described Cas9 variant 
systems that improve precision190, 198, 261, 293, 298, 300. The SpCas9MT-pDBD system increased 
the targeting range of the nuclease by expanding the repertoire of highly active PAM 
sequences. This is in contrast to dimeric systems (e.g., dual nickases and FokI-dCas9 
nucleases) that have a more restricted targeting range because of the requirement for a pair 
of compatible target sequences. Moreover, our system should be compatible with either of 
these dimeric nuclease variants, providing a further potential increase in precision while 
also expanding the number of compatible target sites for these platforms. In addition, the 
affinity and the specificity of the pDBD component can be easily tuned to achieve the 
desired level of nuclease activity and precision for demanding gene therapy applications. 
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We programmed our SpCas9-ZFPs targeting TS2, TS3 or TS4 with four-finger ZFPs, as 
we believed that these would provide the optimal balance of specificity and affinity. In the 
case of SpCas9MT3-ZFPTS3, this proved prudent (Figure 2.11). However, for SpCas9MT3-
ZFPTS2, we achieved improved precision with a three-finger ZFP, which demonstrates the 
flexibility provided by modular pDBDs. (More details on ZFP design for Cas9-ZFPs are 
given in section 2.4.1. Readers can refer to our website (http://mccb.umassmed.edu/Cas9-
pDBD_search.html) for assistance with the identification of target sites and compatible 
ZFP sequences.) In addition to pDBD tuning, further optimization of the linker length and 
its composition can provide improvements in precision (and potentially activity) by further 
restricting the relative orientation and spacing of the SpCas9 and pDBD. Finally, it should 
be possible to generate Cas9-pDBD fusions for other Cas9 orthologs that have superior 
characteristics for gene therapy applications (for example, more compact Cas9 
nucleases242, 244 for viral delivery). Ultimately, for gene therapy applications where 
precision, activity and target-site location are of paramount importance, the expanded 
targeting range and precision achieved by the Cas9-pDBD framework provide a potent 
platform for the optimization of nuclease-based reagents that cleave a single target site in 
the human genome. 
2.4.1 Discussion on Designing and Construction of Cas9-pDBDs 
(1) Cas9-ZFP fusions 
In principle Zinc Finger Arrays (ZFAs) containing from three to six fingers can be 
designed for the construction of Cas9-ZFPs, which will bind 9bp to 18bp target sites 
respectively (3 bp per finger). Based on the results of our studies with the TS2, TS3 and 
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TS4 Cas9-ZFPs, we would recommend the construction of four-finger ZFAs when possible 
for the initial testing of Cas9-ZFPs at a particular target site. For Cas9-ZFPs containing a 
58 aa linker the target site can be 5 to 14 bp downstream of the last base pair of the PAM 
triplet and can be on either the Watson or the Crick strand. If longer ZFAs are desired (5 
or 6 fingers), we recommend using one or more TGSQKP linkers to break the array into 2 
or 3 finger module sets107. Other modified linkers can be utilized to skip a base between 
pairs of zinc finger modules364, 365 to achieve more favorable recognition by neighboring 
arrays if desired.  
For the commercial design of zinc fingers, Sangamo Biosciences’ proprietary zinc 
finger module archive has a design density likely less than every 10 bp366, combined with 
the flexibility of the spacing and orientation, multiple ZFAs can be designed and tested 
around almost any Cas9 target site. These ZFAs can be purchased from Sigma Aldrich. 
In addition, a number of open-source systems have been described for selecting or 
assembling ZFAs. Highly specific ZFAs can be selected from randomized finger libraries 
using phage or bacterial selections 28-37, 367, but this process is labor intensive and may be 
accessible to only few laboratories. By contrast, modular assembly35, 36, 368-372 wherein pre-
characterized single zinc finger modules that recognize 3-base-pair (bp) subsites are joined 
into arrays, rapidly yields ZFAs that bind desired target sites, and has proven to be an 
effective method for the creation of active Cas9-ZFPs in this manuscript. For modular 
assembly, a number of zinc finger archives have been described focusing on single-finger 
(1F)37, 38, 369, 371 and two-finger (2F) modules35, 36, 368, 370, 373. Using phage-based selections, 
Barbas lab identified 1F-modules that target 49 of the 64 triplets29-32, 369. The Kim 
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laboratory has reported 1F-modules recognizing 38 of the 64 triplets371. We have also 
published a curated archive of 1F-modules that bind 27 of 64 triplets38. Recently, using 
bacterial-one-hybrid based selections Noyes lab defined zinc finger modules that can 
recognize each of the 64 DNA triplets allowing targeting virtually any DNA sequence37. 
In addition, two-finger archives have been published that take into account finger-finger 
interface and therefore can yield ZFAs with higher specificity but the targeting range of 
these 2F archives is more limited35, 36, 368, 370. The 1F and 2F archives that our laboratory 
has described can be used to design a ZFP roughly every 10 bp, whereas some of the other 
finger archives can achieve even higher design densities.  
With the number of finger archives now available, it is possible to design a ZFA 
targeting almost every DNA sequence. Moreover, there are a number of tools available to 
help users to identify the best target site and design the ZFA.  We have designed a web-
based tool for the identification of Cas9-ZFP target sites for which ZFAs can be designed 
from our zinc finger archive.  This site (http://mccb.umassmed.edu/Cas9-
pDBD_search.html) provides a simple scoring function for the evaluation of ZFAs with 
higher activity based on the number of arginine-guanine contacts that are present. Tools 
from other laboratories are available for the construction of ZFAs. The “Zinc Finger Tools” 
published by Barbas lab can identify target sites for single ZFAs and design ZFAs using 
their archive of 49 1F-modules374.  
(http://www.scripps.edu/barbas/zfdesign/zfdesignhome.php). The Joung laboratory has 
developed a suite of tools “ZiFiT” that allows the design of ZFAs for a particular target 
sequence284 (http://zifit.partners.org/ZiFiT/). In addition, a zinc finger tool developed by 
   95 
Noyes laboratory can be used to design zinc finger arrays one finger at a time for a desired 
target sites37 (http://zf.princeton.edu/b1h/dna.html). This tool provides multiple zinc 
finger(s) for every DNA triplet but does not identify the best zinc finger site in a given 
target sequence.  
(2) Cas9-TALE fusions 
When designing TALE-arrays for Cas9-TALE fusion, we recommend a minimum 
of a 10 bp target site (excluding the 5’ T) approximately 10-14 bp downstream and on the 
Watson strand relative to the NGG PAM site. The principal requirement for finding a target 
site is a 5’ T but other rules of target recognition can be important for site selection121. 
Multiple programs are available that allow design of single TAL-arrays including TALE-
NT375 (https://tale-nt.cac.cornell.edu/) and SAPTA TAL Targeter Tool376. 
(http://bao.rice.edu/Research/BioinformaticTools/TAL_targeter.html) 
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CHAPTER III: Inducible Cas9-DNA-binding-domain fusions for 
precise genome editing 
SpCas9-programmable DNA-binding domain (SpCas9-pDBD) chimeras introduce 
an extra stage of target site licensing that substantially improves Cas9 specificity. In this 
study, we integrate drug-dependent dimerization domains into the SpCas9-pDBD 
framework to provide temporal control over nuclease activity while retaining the high 
specificity and extended targeting range of the parent covalent system. In addition, we 
show that the SpCas9-pDBD system has higher precision at challenging target sites than 
other previously described precision variants of SpCas9. These features make the SpCas9-
pDBD nuclease system an attractive nuclease platform for therapeutic genome editing 
applications where precision is of paramount importance. 
3.1 Introduction 
CRISPR-Cas9 nucleases (and variants thereof) are being developed for a variety of 
gene therapy applications5, 7, but their off-target activity can create undesired collateral 
damage within the genome of treated cells377, 378.  We have previously described a PAM-
interacting domain (PID)-attenuated SpCas9-DNA-binding domain chimera (SpCas9-
pDBD) that reduces the off-target activity of Cas9 and expands the range of PAMs that can 
be effectively utilized within a genomic region of interest306. This nuclease platform has 
superior precision to many other types of SpCas9 variants engineered for improved 
precision377-379.  
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The in vivo delivery of nuclease-based gene therapy reagents presents challenges 
for many cell types or organ systems7.  When delivered using viral vectors, Cas9 expression 
can potentially persist for an extended time period, which can reduce nuclease precision289. 
One potential solution to this problem is to utilize nuclease systems whose activity can be 
regulated through the administration of a small molecule or light stimulus.  A number of 
different regulatable nuclease systems have been described308, 309, 311, 312, 380-383, and many 
display improved precision compared to constitutively expressed nucleases in small 
surveys of previously defined off-target sites308, 312.  However, to our knowledge no 
unbiased, genome-wide analysis of precision has been reported on one of these regulatable 
nuclease platforms. Herein we report the development of drug-inducible SpCas9-pDBDs 
and the genome-wide analysis of their precision.  These data demonstrate that SpCas9-
pDBD systems are more precise than other existing nuclease platforms, and thus provide 
an appealing technology platform for therapeutic genome editing applications. 
3.2 Materials and Methods 
3.2.1 Plasmid constructs 
Our dimeric SpCas9-pDBD experiments employed the following plasmids: All 
sgRNAs are expressed via a U6 promoter from a pLKO1-puro-based vector, as previously 
described306. All SpCas9 and SpCas9-DBD constructs are expressed via a CMV IE94 
promoter from a pCS2-Dest gateway plasmid306. The ZFP sequences (Zif268, TS2 ZFP, 
TS3 ZFP) and TALE sequences (TS3 TALE) used to target the SpCas9-ZFP, SpCas9-DD-
ZFP and Split-SpCas9-ZFP constructs were previously described306. Representative 
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SpCas9-DD-ZFP, Split-SpCas9-ZFP, SpCas9-DD-TALE and Split-SpCas9-TALE 
plasmid constructs used for the activity, precision and off-target analysis will be deposited 
with Addgene. The mutations associated with the eSpCas9_v1.1301 and SpCas9-HF1302 
sequences were introduced into our pCS2-Dest SpCas9WT plasmid by cassette 
mutagenesis, where eSpCas9_v1.1 was amplified from the deposited Addgene plasmid 
(#71814). Plasmid reporter assays of nuclease activity detected the restoration of GFP 
activity through SSA-mediated repair of an inactive GFP construct based on the M427 
plasmid developed by the Porteus laboratory354.  SpCas9 target sites were cloned into 
plasmid M427 via ligation independent methods following SbfI digestion. 
3.2.2 Cell culture assay 
Human Embryonic Kidney (HEK293T) obtained from our collaborator M. Green 
(UMass Medical School, Worcester, Massachusetts, USA) cells were cultured in high 
glucose DMEM with 10% FBS and 1% Penicillin/Streptomycin (Gibco) in a 37°C 
incubator with 5% CO2. These cells were authenticated by University of Arizona Genetics 
Core and tested for mycoplasma contamination at regular intervals. For transient 
transfection to assay nuclease activity, we used early to mid-passage cells (passage number 
5-25). Approximately 1.6X105 cells were transfected using Polyfect transfection reagent 
(Qiagen) in 24-well format according to the manufacturer’s suggested protocol. Each 
transfection contained 50ng sgRNA expressing plasmid and 25 ng mCherry plasmid.  In 
addition the following nuclease expression plasmid amounts were included in the 
transfections: 50 ng for monomeric nuclease systems (Cas9WT, Cas9MT3 or Cas9MT3-ZFP, 
SpCas9-HF1 or eSpCas9 v1.1), 100 ng of Cas9-DD expression plasmid and 50 ng pDBD-
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DD expression plasmid for DD dimeric systems; 100 ng of each Split-Cas9 component for 
Split-Cas9 systems. A pBlueScript II plasmid was added to bring the total DNA mass of 
plasmid to 300ng per transfection. For the SSA-reporter assay, 150ng M427 SSA-reporter 
plasmid was also included in the co-transfection mix and 100 ng of cherry plasmid was 
used. 
3.2.3 Flow cytometry reporter assay 
The flow cytometry experiments were done as we described previously306. Briefly, 
48 hours post-transfection cells were harvested and resuspended in 1XPBS for flow 
cytometry (Becton Dickonson FACScan). For FACS analysis, 10000 events were counted 
from each sample. To minimize the effect of differences in the efficiency of transfection 
among samples, cells were initially gated for mCherry-expression, and the percentage of 
EGFP expressing cells (nuclease positive events) were quantified within mCherry positive 
cells. All of the experimental replicates were performed in triplicate on different days with 
data reported as mean values with error bars indicating the standard error of the mean.    
3.2.4 Targeted deep-sequencing-based off-target analysis  
Regions flanking target and off-target sites were PCR amplified using locus-
specific primers bearing tails complementary to the Truseq adapters as described 
previously306 (Appendix 1). 25-50ng input DNA was PCR amplified with Q5 High-
Fidelity DNA Polymerase (New England Biolabs) with the addition of Q5 High GC 
Enhancer: (98°C, 15s; 59°C 25s; 72°C 20s) x30 cycles. 0.1 µl of each PCR reaction was 
amplified with barcoded primers to reconstitute the TruSeq adaptors using the Q5 High-
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Fidelity DNA Polymerase (New England Biolabs) with the addition of Q5 High GC 
Enhancer: (98°C, 15s; 59°C, 25s; 72°C, 20s) x9 cycles. Equal amounts of the products 
were pooled and gel purified. The purified library was deep sequenced using a paired-end 
150bp Illumina MiSeq run. 
MiSeq data analysis was performed using a suite of Unix-based software tools. 
First, the quality of paired-end sequencing reads (R1 and R2 fastq files) was assessed using 
FastQC. Raw paired-end reads were combined using paired end read merger (PEAR)384 to 
generate single merged high-quality full-length reads. Reads were then filtered by quality 
(using Filter FASTQ385) to remove those with a mean PHRED quality score under 30 and 
a minimum per base score under 24. Each group of reads was then aligned to a 
corresponding reference sequence using BWA (version 0.7.5) and SAMtools (version 
0.1.19). To determine indel frequency, size and distribution, all edited reads from each 
experimental replicate were combined and aligned, as described above. Indel types and 
frequencies were then cataloged in a text output format at each base using bam-readcount 
(https://github.com/genome/bam-readcount). For each treatment group, the average 
background indel frequencies (based on indel type, position and frequency) of the triplicate 
negative control group were subtracted to obtain the nuclease-dependent indel frequencies. 
3.2.5 GUIDE-seq off-target analysis 
We performed GUIDE-seq286 with some modifications as described previously306. 
Briefly, HEK293T cells were transfected using Lipofectamine 3000 transfection reagent 
(Invitrogen) according to the manufacturer’s suggested protocol with 50 ng of Cas9WT, 
Cas9MT3 or Cas9MT3-ZFP expression plasmid for monomeric systems, 200 ng of Cas9 
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expression plasmid and 100 ng pDBD expression plasmid for the ‘DD’ system, or 150 ng 
of each expression plasmid for the Split-Cas9 components. Each transfection also included 
100 ng sgRNA expressing plasmid, 50 ng of a GFP expression plasmid and 10 pmol of 
annealed GUIDE-seq oligonucleotide. 48 h after transfection, genomic DNA was extracted 
with a DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s suggested 
protocol. Library preparations were done with original adaptors according to protocols 
described by Joung and colleagues286, with each library barcoded within the P5 and P7 
adaptors for pooled sequencing. The barcoded, purified libraries were deep-sequenced as 
a pool using two paired-end 150-bp Illumina MiSeq runs. 
Deep sequencing data from the GUIDE-seq experiment was analyzed using the 
GUIDEseq v1.1.17 Bioconductor Package386  The upstream and downstream windows for 
peak aggregation we set to 50 bp. Off-target site identification parameters were set as 
follows: min.reads = 1, max.mismatch = 6, PAM.pattern = "(NAG|NGG|NGA)$”, 
allowed.mismatch.PAM = 2. The potential off-target sites identified for each nuclease are 
listed in Appendix 2.  The Specificity Ratio is calculated as the sum of the unique GUIDE-
seq reads at the target site divided by all of the unique reads at all of the off-target sites. 
3.3 Results 
Rapamycin-induced heterodimerization of FKRP and FRB domains is one of the 
most commonly employed technologies for associating two proteins383.  It has been used 
successfully in a variety of regulatable Split-Cas9 architectures for genome editing and 
gene regulation308, 309, 381, 387.  We examined the ability of the FKRP-FRB system to regulate 
the nuclease activity of a SpCas9-zinc finger protein (SpCas9-ZFP) in two different 
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formats (Figure 3.1a): a configuration where rapamycin-dependent FKRP and FRB 
dimerization domains (DD) replace the covalent linker between wild-type or PID-
attenuated306 SpCas9 and the zinc finger protein (SpCas9-DD-ZFP), or a configuration 
where a previously described rapamycin-inducible Split-Cas9 architecture308 (wild-type or 
PID-attenuated306) is fused covalently to the ZFP (Split-SpCas9-ZFP). A hallmark of the 
covalent SpCas9-ZFP system is its ability to utilize non-canonical PAM sequences306.  
Consequently, to confirm that these different dimeric nuclease configurations retain an 
extended targeting range, they were evaluated at a series of target sequences with a sub-
optimal NAG PAM using a GFP reporter assay354. In these target sequences the distance 
between the protospacer and the ZFP binding site was varied, as was their relative 
orientation.  We found that the SpCas9-DD-ZFP nuclease displayed distance-dependent 
activity in the presence of rapamycin, whereas the Split-SpCas9-ZFP nuclease displayed a 
more uniform activity profile (Figure 3.1b). The distance-dependent activity of the 
SpCas9-DD-ZFP system likely originates from steric restrictions associated with the 
interaction of the FKBP and FRB domains at separation distances of 8 bp or less. 
Next, we evaluated the activity of the dimeric SpCas9-ZFP nucleases at a genomic 
target site.  To demonstrate the functionality of the associated ZFP, we chose a target site 
within the PMPCA locus contained a suboptimal NAG PAM with a Zif268 binding site 14 
bp downstream of the PAM sequence. Pilot experiments revealed good nuclease activity 
in the presence of rapamycin when a nuclear localization sequence (NLS) was present 
within both dimeric components (Figure 3.2). However we also observed modest nuclease 
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activity in the absence of rapamycin for these constructs. Similar background activity has 
been observed with other inducible Cas9 architectures308.  
These results prompted an analysis of the impact of localization sequence 
composition within these constructs on their nuclease activity. For the SpCas9-DD-ZFP 
dimer, we achieved promising induction of nuclease activity when FKBP is fused to 
SpCas9 in the absence of either a nuclear export sequence (NES) or NLS, and when FRB 
is fused C-terminally to the ZFP with both NESs and NLSs appended (Figure 3.2a). For 
the Split-SpCas9-ZFP dimer, a similar strategy of withholding a localization sequence from 
one Cas9 fragment and including both NLSs and an NES within the other Cas9 fragment 
maximized the degree of nuclease activity and inducibility (Figure 3.2b). As described by 
Zetsche and colleagues for Split-SpCas9310, we found that the incorporation of a single 
NES on one nuclease component and the NLS on the other nuclease component with the 
dimeric SpCas9-ZFP systems decreased the background nuclease activity in the absence 
of rapamycin. However, this combination of localization sequences also restricted the 
maximum level of inducible nuclease activity that could be achieved.  Thus, both SpCas9-
ZFP dimerization systems achieved robust, drug-dependent nuclease activity at a genomic 
target site with a suboptimal PAM, which confirms their extended targeting range. In 
addition, we found that using a PID-attenuated SpCas9 variant (R1333S; SpCas9MT2)306 
in the Cas9-DD-ZFP framework achieved robust activity at the NAG PAM target site with 
lower background in the absence of rapamycin (Figure 3.2a), demonstrating that the PID-
attenuated SpCas9s are compatible with this dimerization system. 
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Figure 3. 1 Development of drug-inducible dimeric SpCas9-pDBD frameworks 
(a) Schematic of two different dimeric SpCas9-pDBD:sgRNA systems.  In Cas9MT-DD-ZFP (top) 
the rapamycin-induced dimerization of FKBP (red) and FRB (blue) domains associates the 
Cas9MT:sgRNA complex with the ZFP (orange) that recognizes a binding site 3’ to the PAM. In 
Split-Cas9MT-ZFP (bottom) the rapamycin induced dimerization of FKBP and FRB associates the 
N- (1-573) and C-terminal (574-1368) fragments of the Split-Cas9308:sgRNA complex where the 
ZFP is covalently fused to the C-terminal fragment. The yellow star indicates attenuation of PAM 
recognition through mutagenesis306 (b) Top, schematic of the examined pDBD binding-site 
orientation and spacing parameters. The position and 5’-to-3’ orientation of the pDBD binding site 
relative to the PAM element of the SpCas9 binding site are represented by orange arrows (Watson 
(W) and Crick (C)). Bottom, activity profiles of SpCas9WT (blue, on an NGG or NAG PAM), 
SpCas9-Zif268 (green, NAG PAM), SpCas9-DD-Zif268 (orange, NAG PAM) and Split-SpCas9-
Zif268 (brown, NAG PAM) in the GFP reporter assay on a common sgRNA target site. The pDBD-
site spacing is 5, 8, 11 or 14 bp from the PAM on either strand. The presence or absence of 
rapamycin in each experiment is indicated below the x-axis (c, d) Lesion rates determined by deep 
sequencing for SpCas9WT, SpCas9MT3, SpCas9MT3-ZFP, Split-SpCas9WT, SpCas9MT3-DD-ZFP and 
Split-SpCas9MT3-ZFP at the VEGFA TS2 (c) and TS3 (d) target sites, respectively.  The activity of 
the dimeric constructs was assayed +/- rapamycin (NA: not available). Sequences of TS2 and TS3 
regions are shown above the bar chart, where the 12-bp ZFP binding site is highlighted and arrows 
indicate the orientation of ZFP binding site. Fold induction in presence of rapamycin is shown. 
Data are from three independent biological replicates performed on different days in HEK293T 
cells. Error bars indicate ±s.e.m. 
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Figure 3. 2 Activity profiles dimeric SpCas9-Zif268 nuclease compositions 
The sequence of PMPCA target region is shown at the top, where the 9-bp Zif268 binding site 14 
bases from the PAM is highlighted with an arrow indicating recognition of the Crick strand. Lesion 
rates determined by deep sequencing for SpCas9WT, SpCas9MT2, SpCas9WT-Zif268, SpCas9MT2-
Zif268, Split-SpCas9WT, and different compositions of the SpCas9-DD-Zif268 and Split-SpCas9-
Zif268 dimers. (a) Impact of the organization of the FRB and FKBP domains and the types of 
localization sequences on the activity of SpCas9-DD-Zif268. The SpCas9WT and SpCas9MT2 
(R1333S) mutant306 respectively display little to no activity on this target site in the absence of a 
fusion to Zif268. Robust nuclease activity is observed when Zif268 is covalently fused to either of 
these constructs. For the SpCas9-DD-Zif268 architecture, the impact of three different parameters 
on nuclease activity in the absence and presence of rapamycin was examined: Cas9 nuclease variant 
(Cas9 type), the fusion partner for the FKRP and FRB dimerization domains (DD; Cas9-DD and 
ZFP-DD), and the type and number of localization sequences (LS) on each component (Cas9-LS 
and ZFP-LS).  A favorable combination (marked with an asterisk) of overall activity and drug-
dependent behavior was achieved with Cas9WT when the Cas9 domain lacked an NLS and Zif268 
fused to a combination of NLS and NES elements. Favorable activity profiles were also observed 
when SpCas9MT2 was substituted for SpCas9WT when an NLS was present on both components 
(Cas9 type = MT2). For the ZFP-DD fusion the position of the DD relative to Zif268 is indicated 
(C-FRB = FRB on the C-terminus of Zif268) where FRB* indicates the PLF mutant of FRB that 
destabilizes this domain388. (b) Impact of the organization of the types and number of localization 
sequences on the activity of Split-SpCas9WT-Zif268. The Split-SpCas9WT (NLS on N-terminal 
component & NES on C-terminal component) described by Zetsche and colleagues308 that is the 
basis for this dimeric architecture displays minimal activity on this target site. However, by fusing 
Zif268 to the C-terminal component FKBP-C-Cas9WT, robust activity can be achieved in the 
presence of rapamycin. As observed for the SpCas9-DD-Zif268 architecture, a promising 
combination of fold induction and overall activity in the presence of rapamycin was achieved when 
one fragment (N-Cas9-FRB) lacks a localization sequence and the other fragment (FKBP-C-
Cas9WT-Zif268) contains a combination of NLS and NES elements (marked with an asterisk). Data 
are from three independent biological replicates performed on different days in HEK293T cells. 
Error bars indicate ±s.e.m.  
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In preparation for the analysis of the genome-wide specificity of these dimeric 
SpCas9-ZFP systems, we evaluated their activity at two target sites within the VEGFA 
locus (target site 2 & target site 3; TS2 & TS3) previously used for assessing precision of 
different SpCas9 variants257, 286, 293, 302, 306. For these NGG PAM target sites, our dimeric 
constructs utilized a PID-attenuated SpCas9 variant (R1335K; SpCas9MT3) that requires 
recruitment by a pDBD to the genomic locus for robust activity306. The resulting extra stage 
of target site licensing increases the precision of the chimeric nuclease. In the context of 
the attenuated dimeric SpCas9MT3-ZFP systems, we assessed the impact of the incorporated 
localization sequences on their drug-dependent nuclease activity (Figures 3.3 & 3.4). As 
with the wild-type SpCas9-ZFP dimers at the PMPCA locus, dimeric SpCas9MT3-ZFP 
nuclease activity at the TS2 and TS3 target sites was sensitive to the type and number of 
localization sequences that were fused to each component. For particular combinations of 
localization sequences, both dimeric SpCas9MT3-ZFP systems displayed a greater degree 
of rapamycin-inducible nuclease activity than the Split-SpCas9 system described by 
Zetsche and colleagues308 (Figure 3.1c-d). All of these inducible nuclease systems display 
somewhat reduced activity relative to monomeric SpCas9, which can be attributed in part 
to the ~16 hour delay prior to adding rapamycin following transient transfection. The 
dimeric SpCas9MT3 system also functioned at the TS3 target site when a TALE DBD 
programmed to bind a neighboring sequence replaced the ZFP (Figure 3.5). However, the 
maximal nuclease activity of the TALE-fused dimeric systems was lower than the ZFP-
fused systems. Overall the nuclease activity and fold induction of both dimeric SpCas9MT3-
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ZFP systems compare favorably with the previously described inducible Split-SpCas9 
architecture308.  
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Figure 3. 3 Activity profiles of Split-SpCas9MT3-ZFP nuclease compositions 
The sequences of the TS2 and TS3 regions are shown above each bar chart of nuclease activity, 
where the 12-bp ZFP binding site is highlighted with an arrow indicating the bound strand (Watson 
= top pointing right; Crick = bottom pointing left). (a) Impact of the types of localization sequences 
incorporated within each fragment of Split-SpCas9MT3-ZFPTS2 on nuclease activity at the VEGFA 
TS2 target site. SpCas9WT displays robust activity on the target site. The SpCas9MT3 (R1335K) 
mutant306 displays little activity on this target site, however covalent fusion of the ZFP to the C-
terminal fragment restores nuclease activity. Split-SpCas9WT (NLS on N-terminal component & 
NES on C-terminal component described by Zetsche and colleagues308), which is the framework 
for this dimeric architecture, displays inducible activity on this target site with modest background 
activity in the absence of rapamycin. For the Split-SpCas9MT3-ZFPTS2 architecture, the most 
favorable combination of overall activity and fold induction was achieved when the N-terminal 
Cas9 fragment (N-Cas9-FRB) lacks a localization sequence and the C-terminal Cas9 fragment 
(FKBP-C-Cas9MT3-ZFPTS2) contained a 2xNLS. (b) Impact of the types of localization sequences 
incorporated within each fragment of Split-SpCas9MT3-ZFPTS3 on nuclease activity at the VEGFA 
TS3 target site. For the SpCas9MT3-DD-ZFPTS3 the most favorable combination of high activity and 
fold induction was achieved when the N-terminal Cas9 fragment (N-Cas9-FRB) lacks a localization 
sequence and the C-terminal Cas9 fragment (FKBP-C-Cas9MT3-ZFPTS3) contains a 2xNLS. Lesion 
rates were determined by deep sequencing. The constructs utilized for GUIDE-seq analysis are 
indicated by ‘#’ and for targeted amplicon deep sequencing of off-target sites to assess nuclease 
activity are indicated by an asterisk. Data are from three independent biological replicates 
performed on different days in HEK293T cells. Error bars indicate ±s.e.m.  
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Figure 3. 4 Activity profiles of SpCas9MT3-DD-ZFP nuclease compositions 
The sequences of the TS2 and TS3 regions are shown above each bar chart of nuclease activity, 
where the 12-bp ZFP binding site is highlighted with an arrow indicating the bound strand (Watson 
= top pointing right; Crick = bottom pointing left). (a) Impact of nuclease composition on the 
activity of SpCas9MT3-DD-ZFPTS2 at the VEGFA TS2 target site. SpCas9WT displays robust activity 
on the target site. The SpCas9MT3 (R1335K) mutant306 displays little activity on this target site, 
however covalent fusion of the ZFP restores nuclease activity. For the SpCas9MT3-DD-ZFPTS2 
architecture, the impact of two different parameters on rapamycin-inducible nuclease activity were 
evaluated: the type and number of localization sequences (LS) on each component (Cas9-LS and 
ZFP-LS), and the FRB type and fusion position relative to the ZFP. (FRB* indicates the PLF mutant 
of FRB that destabilizes this domain388.) Fold-activation of drug-dependent nuclease activity was 
maximized when the SpCas9MT3-FKBP domain lacked an NLS. The most favorable combination 
of overall activity was achieved with SpCas9MT3-FKBP when FRB is fused to the N-terminus of 
the ZFP with a combination of NLS and NES elements. (b) Impact of the position of fusion and 
the type of the FRB domain on the ZFP and the type of localization sequences on each component 
on the activity of SpCas9MT3-DD-ZFPTS3 at the VEGFA TS3 target site. For the SpCas9MT3-DD-
ZFPTS3 the activity was more sensitive to the organization of the ZFP-DD component. As at the 
TS2 target site, the most favorable combination of overall activity was achieved with Cas9MT3 when 
FRB is fused to the N-terminus of the ZFP with a combination of NLS and NES elements. Lesion 
rates were determined by deep sequencing. The constructs utilized for GUIDE-seq analysis are 
indicated by ‘#’ and for targeted amplicon deep sequencing of off-target sites to assess nuclease 
activity are indicated by an asterisk. Data are from three independent biological replicates 
performed on different days in HEK293T cells. Error bars indicate ±s.e.m. 
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Figure 3. 5 Activity profiles of dimeric SpCas9MT3-TALETS3 nuclease compositions 
The sequence of the TS3 region is shown above the bar chart of nuclease activity, where the 17-bp 
TALE binding site306 is highlighted with an arrow indicating the bound strand. SpCas9WT displays 
robust activity on the target site. The SpCas9MT3 (R1335K) mutant306 displays little activity on this 
target site, however covalent fusion of the TALE restores nuclease activity. A number of different 
SpCas9MT3-DD-TALETS3 (a) and the Split-SpCas9MT3-TALETS3 (b) systems display inducible 
nuclease activity as a function of the appended localization sequences. Lesion rates were 
determined by deep sequencing. The constructs utilized for GUIDE-seq analysis are indicated by 
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‘#’ and for targeted amplicon deep sequencing of off-target sites to assess nuclease activity are 
indicated by an asterisk. Data are from three independent biological replicates performed on 
different days in HEK293T cells. Error bars indicate ±s.e.m.  
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One of the valuable attributes of the SpCas9MT3-pDBD system is its enhanced 
precision relative to wild-type SpCas9306. To assess if this characteristic is retained in the 
dimeric SpCas9MT3-pDBD systems, we utilized GUIDE-seq to perform an unbiased 
evaluation of their off-target activities286. To provide a benchmark for comparison, we also 
evaluated the off-target activity of the canonical Split-SpCas9 system, which has improved 
precision relative to wild-type SpCas9308. All of these nuclease variants were programmed 
to target the VEGFA TS2 or TS3 sites, as these guide sequences provide a rigorous test of 
precision due to the number of similar sequences found within the human genome257, 286.  
Across our GUIDE-seq datasets, the number of unique GUIDE-seq oligonucleotide 
incorporations at each target site was comparable for all of the nuclease constructs except 
SpCas9WT at the TS3 target site (Appendix 2), which implies that the cellular nuclease 
activity for the majority of evaluated constructs was similar. For the TS2 sgRNA, there 
was a reduction in the number of GUIDE-seq peaks within the genome for our SpCas9MT3-
ZFP dimeric nucleases relative to both of the previously described Split-SpCas9WT 
systems308 (Figure 3.6a, left).  In addition, the Specificity Ratio (the number of the unique 
GUIDE-seq reads at the TS2 target site relative to the sum of reads at the off-target peaks) 
was improved for the SpCas9MT3-ZFP dimeric nucleases relative to the canonical Split-
SpCas9WT systems (Figure 3.6a, right). A reduction in the number of GUIDE-seq peaks 
and an improvement in Specificity Ratio was also observed for the dimeric SpCas9MT3-
ZFP nucleases programmed with the TS3 sgRNA (Figure 3.6b). The difference in 
genome-wide nuclease activity profiles was also evident from the number of unique reads 
associated with individual identified off-target GUIDE-seq peaks (Appendix 2). The off-
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target peaks for SpCas9WT or the canonical Split-SpCas9WT nucleases displayed a broad 
distribution of read counts (where a greater number of GUIDE-seq reads implies greater 
nuclease activity286). In contrast, most off-target peaks for the dimeric SpCas9MT3-pDBD 
nucleases displayed a low read count (Figure 3.7), which would suggest that many of these 
peaks are likely to be either weakly active sites or false positive peaks. In addition, strong 
new off-target sites are not observed for the dimeric SpCas9MT3-pDBD nucleases, which 
imply that the fused ZFP is not creating a new class of off-target sequences. Similarly, the 
SpCas9MT3-TALE nucleases programmed with the TS3 sgRNA displayed improved 
Specificity Ratios for both the dimeric and covalent systems relative to the other nuclease 
systems (Figure 3.8). Overall these GUIDE-seq datasets reveal a dramatic improvement 
in precision for the various dimeric SpCas9MT3-pDBD nucleases both with regards to the 
total number of potentially active off-target sites and the activity levels at the small number 
of remaining off-target sites.  
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Figure 3. 6 Specificity profiles of SpCas9MT3-ZFP nuclease variants 
(a, b) GUIDE-seq286 genome-wide off-target analysis of nuclease activity for SpCas9WT, Split-
SpCas9WT-dual-NLS308, Split-SpCas9WT-NLS/NES308, SpCas9MT3-ZFP, SpCas9MT3-DD-ZFP and 
Split-SpCas9MT3-ZFP programmed with the VEGFA TS2 (a) or TS3 (b) sgRNAs. The charts 
indicate (Left) the number of off-target peaks detected in the GUIDE-seq data and (Right) the fold 
improvement in Specificity Ratio (SR) [number of unique reads at the target site divided by the 
sum of the unique GUIDE-seq reads associated with the off-target peaks] for each nuclease 
compared with SpCas9WT (Appendix 2). (c) Lesion rates for target sites and a subset of off-target 
sites identified by GUIDE-seq analysis assayed by deep-sequencing of PCR products spanning 
each genomic locus for Split-SpCas9WT-NLS/NES308, SpCas9MT3-DD-ZFP and Split-SpCas9MT3-
ZFP programmed with the VEGFA TS2 or TS3 sgRNAs. Sequences of each of the target or putative 
off-target sites are shown to the left of the bar chart with the non-cognate positions shown in bold 
(protospacer) or cyan (PAM). Site IDs from Fu et al.257 are included for comparison.  Data are from 
three independent biological replicates performed on different days in HEK293T cells. Error bars 
indicate ±s.e.m. 
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Figure 3. 7 GUIDE-seq analysis of the SpCas9MT3-pDBD nuclease variants 
Each graph displays the distribution of GUIDE-seq off-target peaks that fall into different bins 
based on the number of associated unique reads within each peak for nucleases programmed to 
target the VEGFA TS2 (a) and TS3 (b) sites. The target site is excluded from this graph.  Both the 
SpCas9WT and two Split-Cas9 architectures described by Zetsche and colleagues10 (Split-
SpCas9WT-NLS [NLS on both components] & Split-SpCas9WT [NLS on N-terminal component & 
NES on C-terminal component]) have a number of off-target peaks that contain high read counts 
when programmed with the TS2 sgRNA, which is consistent with high nuclease activity at these 
sites. For the covalent and dimeric SpCas9MT3-ZFP nucleases programmed with the TS2 sgRNA 
the small number of identified off-target peaks primarily have a low number of reads.  Since the 
number of GUIDE-seq reads is correlated with nuclease activity20, this suggests that the off-target 
sites for the SpCas9MT3-ZFP nucleases have low activity or are perhaps false positives.  Although 
there are not as many GUIDE-seq peaks associated with nucleases programmed with the TS3 
sgRNA, the general trend for these nucleases is similar with the majority of off-target peaks 
associated with the SpCas9MT3-ZFP based nucleases having fewer than 10 reads (Appendix 2).  
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Figure 3. 8 GUIDE-seq analysis of the SpCas9MT3-TALETS3 variants. 
(a) Number of GUIDE-seq peaks that are associated with each nuclease. This chart contains the 
nucleases listed in Figure 3.6b as well as the covalent SpCas9MT3-TALETS3 nuclease, and the 
SpCas9MT3-DD-TALETS3 and Split-SpCas9MT3-TALETS3 dimeric nucleases. The SpCas9MT3-
TALE-based nucleases all display a reduction in the number of peaks, although when SpCas9MT3-
DD-TALETS3 is compared to the Split-Cas9WT constructs the reduction is modest. The Split-
SpCas9MT3-TALETS3 had the smallest number of off-target sites (1), but it also had the smallest 
number of reads at the target site – implying a lower cellular level of nuclease activity, which makes 
direct comparisons with the other constructs less direct. (b) Specificity Ratio (SR) for each 
nuclease, [number of unique reads at the target site divided by the sum of the unique GUIDE-seq 
reads associated with the off-target peaks]. This chart contains the nucleases listed in Figure 3.6b 
as well as the covalent SpCas9MT3-TALETS3 nuclease, and SpCas9MT3-DD-TALETS3 and Split-
SpCas9MT3-TALETS3 dimeric nucleases. The SpCas9MT3-TALE-based nucleases all display 
improved SRs relative to the SpCasWT-based constructs, where they are similar to the SpCas9MT3-
ZFP-based nucleases. The one outlier (Split-SpCas9MT3-TALETS3) had the lowest nuclease activity 
at the target site, which may reduce its activity at off-target sites (Appendix 2). 
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To confirm the improved precision of dimeric SpCas9MT3-pDBD nucleases, we 
performed deep sequencing of PCR amplicons spanning a representative set of off-target 
sites within the genomes of nuclease treated cells. In this analysis we utilized dimeric 
SpCas9MT3-ZFP systems with asymmetric localization sequences that have the highest on-
target activity (Figures 3.3 & 3.4). These dimeric SpCas9MT3-ZFP systems display a 
marked reduction in nuclease activity at off-target sites associated with the TS2 and TS3 
sgRNAs in comparison with the NES-containing Split-Cas9WT system (Figure 3.6c). 
Similar improvements in off-target activity were observed for the dimeric SpCas9MT3-
TALE nuclease programmed with the TS3 sgRNA (Figure 3.9).  
These data demonstrate that the outstanding precision and greater PAM targeting 
range of the covalent Cas9-pDBD systems can be extended to inducible dimeric systems 
derived from this framework. The results mirror the improvements in specificity that were 
observed with the covalent SpCas9MT3-ZFP system when compared to wild-type SpCas9 
at the TS2 target site, where only a single prominent off-target site (OT2-2) displayed 
substantial activity306. We previously showed that remaining off-target activity within the 
covalent SpCas9MT3-ZFP can be further attenuated by tuning the binding affinity of the 
associated ZFP306. We anticipate that this will also be the case for these dimeric systems. 
Although our dimeric systems were constructed using the FKRP/FRB domains to generate 
a rapamycin inducible system, they should also be amenable to the incorporation of other 
types of switchable domains (e.g. drug-dependent309, 381, 389, light-dependent309, 390) for the 
temporal regulation of nuclease activity. 
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Figure 3. 9 Specificity analysis of SpCas9MT3-TALETS3 nuclease variants 
Lesion rates for nucleases programmed to target VEGFA TS3 site.  All of the non-standard nuclease 
variants (Split-SpCas9WT [NLS on N-terminal component & NES on C-terminal component], 
SpCas9MT3-TALETS3, SpCas9MT3-DD-TALETS3 and Split-SpCas9MT3-TALETS3) have lower activity 
at the TS3 target site than SpCas9WT. All of the SpCas9MT3-TALE-based nucleases have lower 
activity at the off-target sites, where the difference in activity at OT3-2 are particularly dramatic. 
Site IDs from Fu et al.257 are included for comparison. Data are from three independent biological 
replicates performed on different days in HEK293T cells. Error bars indicate ±s.e.m. 
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Recently, two non-specific DNA contact attenuated SpCas9 systems were 
described that have improved nuclease precision (SpCas9-HF1302 and eSpCas9_v1.1301). 
We performed a side-by-side comparison of these Cas9 variants and our covalent 
SpCas9MT3-pDBD system to assess their relative levels of precision. Based on the deep-
sequencing analysis of previously defined off-target sites, the precision of the covalent 
SpCas9MT3-pDBD system compares favorably against SpCas9-HF1302 and 
eSpCas9_v1.1301 variants when loaded with challenging sgRNAs (TS2 and TS3; Figure 
3.10). In addition, the covalent SpCas9MT3-pDBD system can tolerate the presence of an 
extra G incorporated into the 5’ end of the guide sequence (G+20nt; Figure 3.11), which 
is necessary for guide expression from U6 and T7 promoters and is frequently incorporated 
as an extra based in the guide when the genomic target site does not begin with a G. 
However, the addition of an extra G at the 5’ end of the guide (G+20nt) diminishes the 
activities of both SpCas9-HF1 and eSpCas9_v1.1 similar to the attenuation previously 
described for SpCas9-HF1 when a G mismatch is present at the last position of the guide 
sequence (G+19nt302). 
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Figure 3. 10 Specificity comparison of SpCas9 variants 
Covalent SpCas9MT3-ZFP nucleases have improved precision relative to other high fidelity Cas9 
variants. Lesion rates for nucleases programmed with the VEGFA TS2 or TS3 sgRNA at the target 
site and a subset of off-target sites identified by GUIDE-seq analysis for SpCas9WT. Lesion rates 
were assayed by deep-sequencing of PCR products spanning each genomic locus for cells treated 
with SpCas9WT, SpCas9MT3, SpCas9MT3-ZFP, SpCas9-HF1 or eSpCas9_v1.1 and the appropriate 
sgRNA. Although SpCas9-HF1302 and eSpCas9_v1.1301 have greatly improved precision relative 
to SpCas9WT, there are still a few off-target sites that have near wild-type activity. SpCas9MT3-ZFP 
nucleases achieve a much more dramatic reduction in activity at these off-target sites. Site IDs from 
Fu et al.257 are included for comparison. Data are from three independent biological replicates 
performed on different days in HEK293T cells. Error bars indicate ±s.e.m.  
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Figure 3. 11 The effects of an extra 5' G at the guide sequence on nuclease activity 
Comparison of nuclease activity at the VEGFA TS2 or TS3 target sites for a variety of nuclease 
constructs.  Both of these target sites contain a G at the 5’ end of the protospacer, so a fully 
complementary guide (G+19) can be produced from a U6 promoter, which requires a G at the 
transcription start site for efficient initiation. SpCas9WT, SpCas9-HF1, eSpCas9_v1.1 and 
SpCas9MT3-ZFP display robust activity at the TS2 and TS3 target sites when programed with the 
G+19 guides. However, when an extra G is added onto the guide sequence (G+20) there is a 
dramatic reduction in activity for SpCas9-HF1 and eSpCas9_v1.1 at both target sites. The activities 
of SpCas9WT and SpCas9MT3-ZFP are unaffected. For reference, the attenuated SpCas9 PAM 
recognition mutants (MT1=R1333K, MT2=R1333S, MT3=R1335K and MT4=R1335S,) are 
included without a ZFP fusion. These have only limited activity in the absence of a ZFP fusion. 
Data are from three independent biological replicates performed on different days in HEK293T 
cells. Error bars indicate ±s.e.m.  
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3.4 Discussion 
In this study, we developed two working prototypes of drug inducible Cas9-pDBD 
chimeras to achieve highly specific genome editing with temporal control. Drug inducible 
Cas9-pDBD chimeras retain the features—enhanced targeting range and improved 
specificity—of the original Cas9-pDBD306. We also show that the SpCas9MT3-pDBD 
system has higher precision at challenging target sites than other previously described 
specific SpCas9 variants, SpCas9-HF1302 and eSpCas9_v1.1301. Unlike the SpCas9-HF1 
and eSpCas9_v1.1 systems, the SpCas9MT3-pDBD platforms require the design of DNA-
binding domains for the target site of interest. This extra effort makes the SpCas9MT3-
pDBD systems most amenable to therapeutic applications, where the improved nuclease 
precision and targeting range are worth the added investment needed to construct these 
systems. Recent advances in the characterization of zinc fingers recognizing all possible 
triplets and the selection of ZFPs with outstanding specificity from these libraries37, 64 
should facilitate the construction of ZFPs for a broad variety of sequences. Finally, we 
anticipate that the highly precise genome editing systems constructed on the SpCas9-pDBD 
framework will be adaptable to other Cas9 isoforms (e.g. NmCas9242 or SaCas9244) and 
perhaps Cpf1-based systems174. 
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CHAPTER IV: Orthogonal Cas9-Cas9 chimeras provide a versatile 
platform for genome editing 
The development of robust, versatile and accurate toolsets are critical for the 
development of therapeutic genome editing applications. In this study, we establish RNA-
programmable Cas9-Cas9 chimeras, in single- and dual-nuclease formats, as versatile 
genome engineering systems. In both of these formats, Cas9-Cas9 fusions display an 
expanded targeting repertoire and achieve highly specific genome editing. Dual-nuclease 
Cas9-Cas9 chimeras have distinct advantages over monomeric Cas9s including higher 
target site activity and the generation of predictable precise deletion products between their 
target sites. At a therapeutically relevant site within the BCL11a erythroid enhancer, Cas9-
Cas9 nucleases produced precise deletions that comprised up to 97% of all sequence 
alterations. Thus Cas9-Cas9 chimeras represent an important new tool that could be 
particularly valuable for therapeutic genome editing applications where a precise cleavage 
position and defined end products are desirable.   
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4.1 Introduction 
The Class 2 CRISPR-Cas bacterial adaptive immune system has been used for a 
wide variety of applications since being repurposed for programmable genome editing and 
gene regulation172, 391. The development of these tools for therapeutic genome editing 
applications is well underway with numerous investigations examining ex vivo and in vivo 
therapeutic approaches5, 392. The Type II effector protein Cas9 from S. pyogenes (SpCas9) 
is one of the most widely used of these nucleases due to its robust activity and broad 
targeting range170, 173. Target site recognition involves Cas9 binding its PAM recognition 
element and the complementarity of the complexed guide RNA170, 205, 248, 393. Once fully 
engaged, SpCas9 typically generates a blunt double-strand break (DSBs) at the target 
site170. In some instances the accuracy of the wild type SpCas9 (SpCas9WT) nuclease is 
imperfect, leading to cleavage of “off-target” sites within the genome256, 257, 286. The 
resulting collateral damage to the genome is suboptimal for many therapeutic applications.  
We and others have used protein and RNA engineering strategies to improve the 
specificity of SpCas9 for therapeutic genome editing applications377, 378. We previously 
reported that a chimera between PAM-interaction attenuated SpCas9 (SpCas9MT) and a 
programmable DNA-binding domain (pDBD; ZFP or TALE) enhances the targeting range 
and specificity of SpCas9306. In the SpCas9MT-pDBD chimeras the pDBD provides an 
additional stage of target site licensing prior to cleavage. The first stage is mediated by 
pDBD recognition of a sequence downstream of the PAM. The increased effective 
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concentration of SpCas9MT upon pDBD binding facilitates recognition of the PAM element 
and initiation of R-loop formation248, 306. If sufficient complementarity exists between the 
sgRNA and the target site, cleavage of the DNA strands occurs. When programmed to 
target challenging repetitive sites in human genome, SpCas9MT-pDBD chimeras achieve 
higher specificity than other high-fidelity SpCas9 variants (Figure 3.10). However, 
building functional pDBDs requires some level of expertise in pDBD assembly, which 
creates a barrier to this platform’s adoption. 
In this study, we assessed the feasibility of substituting the pDBD within the 
Cas9MT-pDBD platform with an orthogonal Cas9 from either N. meningiditis (NmCas9)242, 
314 or S. aureus (SaCas9)244 to develop an entirely RNA-programmable nuclease platform 
spanning two linked Cas9 domains. We constructed these Cas9-Cas9 chimeras in both 
single- and dual-nuclease formats. In the single-nuclease format, the attenuated SpCas9MT 
domain is fused to a nuclease-dead NmCas9 or SaCas9, whose orthogonal guide is 
programmed to target a neighboring DNA sequence. Here the nuclease-dead Cas9 
(dNmCas9 or dSaCas9) should act like a pDBD to deliver SpCas9MT to the target site, 
thereby permitting target site recognition through the increased effective concentration of 
the SpCas9MT nuclease (Figure 4.1a). Similar to SpCas9MT-pDBDs306, SpCas9MT-
dNm/SaCas9 chimeras achieve a high-level of specificity as assessed via GUIDE-seq286 
and targeted amplicon sequencing. In the dual-nuclease format, both nucleases within the 
orthogonal Cas9-Cas9 fusions are active. We hypothesized that synchronous cleavage of 
the genome at two neighboring positions will primarily produce segmental deletions with 
defined junctions (referred as precise deletions), as is observed to varying extents when 
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independent nucleases are targeted to neighboring sites within a genome173, 189, 193. When 
programmed to target composite sites within the human genome, SpCas9WT-Nm/SaCas9WT 
nuclease fusions produce a larger fraction of precise deletions, as high as 97% of all lesions, 
than a pair of independent Cas9 monomers used simultaneously. Similar to SpCas9-pDBD 
chimeras306, Cas9-Cas9 fusions in both the single- and dual-nuclease format expand the 
targeting range of SpCas9 by allowing the recognition of suboptimal PAMs.  
These dual nucleases should particularly be useful for the disruption of 
therapeutically relevant regulatory elements within a genome. In sickle cell disease, one 
proposed therapeutic approach is to induce the expression of the fetal γ-globin gene by 
deleting the GATA1 binding motif within the erythroid-lineage specific regulatory element 
(enhancer +58kb) of the BCL11A gene96-99, 394.  Here, we show that Cas9-Cas9 fusions 
programmed to target sites spanning the GATA1 element can delete this regulatory element 
with greater efficiency and accuracy than separate Cas9/sgRNA complexes.  
  
4.2 Materials and Methods 
4.2.1 Plasmid Constructs 
Our SpCas9-Sa/NmCas9 experiments employed the following plasmids: All 
sgRNAs are individually expressed under a U6 promoter from a pBluescript II SK(+)-
based vector. All single- or dual-Cas9 nuclease constructs are expressed via a CMV IE94 
promoter from a pCS2-Dest gateway plasmid306. NmCas9 and SaCas9 open reading frames 
for nuclease construction were obtained from Addgene ( #48670 & #61591). The nuclease-
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dead versions of these constructs (dNmCas9: D16A, D587A, H588A and N611A; 
dSaCas9: D10A and N580A) are generated via site-directed mutagenesis. These plasmids 
will be deposited to Addgene for community distribution. We used the single-strand 
annealing-based plasmid reporter assay developed by Porteus laboratory354 to monitor 
nuclease activity. Nuclease target sequences are cloned into the M427 plasmid in between 
EcoRI and SbfI sites. 
4.2.2 Cell culture and transfection 
We received the Human Embryonic Kidney (HEK293T) cells from our collaborator 
M. Green (UMass Medical School, Worcester, Massachusetts, USA). The cell line was 
authenticated by University of Arizona Genetics Core and tested for mycoplasma 
contamination at regular intervals. HEK293T were cultured in high glucose DMEM with 
10% FBS and 1% Penicillin/Streptomycin (Gibco) in a 37°C incubator with 5% CO2. We 
used cells at a passage number from 5 until 25 for transient transfection to assay nuclease 
activity. In 24-well format, about 1.6x105 cells were transfected by Polyfect transfection 
reagent (Qiagen) according to the manufacturer’s suggested protocol. For both single and 
dual nucleases we used 50 ng of each sgRNA-expressing plasmid and 50 ng mCherry-
expressing plasmid, 50 ng of single nuclease (SpCas9 or NmCas9 or SaCas9) or 100 ng 
Cas9-Cas9 fusion expressing plasmid. In addition, pBluescript II SK(+) was also added to 
the co-transfection mix to bring the total DNA mass to 300 ng per transfection. For the 
SSA-reporter assay, an additional 150 ng M427 reporter plasmid was added.  
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4.2.3 GFP Reporter Assay 
Flow cytometry experiments were performed as described previously306. 48 h after 
transfection, cells were harvested and resuspended in 1xPBS for flow cytometry (Becton 
Dickonson FACScan). 10000 events were counted from each sample for FACS analysis. 
To adjust the transfection efficiency differences in between samples, cells were initially 
gated for mCherry-expression, and the percentage of EGFP expressing cells (nuclease 
positive events) were quantified within mCherry positive cells. Experiments were 
performed in three replicates on different days. The data are reported as mean values with 
error bars indicating the standard error of the mean. 
4.2.4 Immunofluorescence 
HEK293T cells are transfected in 6-well format via Polyfect transfection reagent 
(Qiagen) using the manufacturer’s suggested protocol with 300 ng Cas9-Cas9 fusion 
expression plasmid and 150 ng of each sgRNA expression plasmid on a cover slip. 48 h 
following transfection, transfection media was removed, cells were washed with 1x PBS 
and fixed with 4% formaldehyde in 1x PBS for 15 min at room temperature. Following 
blocking (blocking solution: 2% BSA, 0.3% Triton X-100 within 1x PBS), samples were 
stained with mouse anti-hemagglutinin (Sigma, H9658, 1:500), and Alexa 488 donkey anti-
mouse IgG (H+L; Invitrogen, A-21202, 1:2000), sequentially. VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratories, H-1200) was used to stain the nuclei and to 
mount the samples on slide. Images were taken with Zeiss AxioPlan 2 IE Motorized 
Microscope System. 
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4.2.5 Target and off-targetsite lesion type and frequency analysis by deep 
sequencing 
Library construction for deep sequencing is modified from our previous report306. 
Briefly, 72 h after transfection, cells are harvested and genomic DNA extracted with 
GenElute Mammalian Genomic DNA Miniprep Kit (Sigma). Genomic loci spanning the 
target and off-target sites were PCR amplified with locus-specific primers carrying tails 
complementary to the Truseq adapters (Appendix 1). 50 ng input genomic DNA was PCR 
amplified with Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98°C, 15s; 
67°C 25s; 72°C 20s) x30 cycles. For the construction of the UMI-based library, 50 ng input 
genomic DNA was first linearly pre-amplified with 10 nM final concentration 5p-
BCL11A_enh58_UMI primer using the Q5 High-Fidelity DNA Polymerase (New England 
Biolabs): (98°C, 60s; 67°C, 25s; 72°C, 20s) x10 cycles. To the same reaction mix, 500 nM 
final concentration 5p-DS_constant and 3p-BCL11A_enh58_DS primers were added for 
another round of amplification (98°C, 60s; 67°C, 25s; 72°C, 20s) for 30 cycles. Next, 0.1 
µl of each PCR reaction was amplified with barcoded primers to reconstitute the TruSeq 
adaptors using the Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98°C, 15s; 
67°C, 25s; 72°C, 20s) x10 cycles. Equal amounts of the products were pooled and gel 
purified. The purified library was deep sequenced using a paired-end 150bp Illumina 
MiSeq run. 
MiSeq data analysis was done with the help of Unix-based software tools. First, we 
employed FastQC395 to determine the quality of paired-end sequencing reads (R1 and R2 
fastq files). Next, we used paired end read merger (PEAR)384 to pool raw paired-end reads 
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and generate single merged high-quality full-length reads. Reads were then filtered 
according to quality via FASTQ385 for a mean PHRED quality score above 30 and a 
minimum per base score above 24. After that, we used BWA (version 0.7.5) and SAMtools 
(version 0.1.19) for aligning each group of filtered reads to a corresponding reference 
sequence. To determine lesion type, frequency, size and distribution, all edited reads from 
each experimental replicate were combined and aligned, as described above. Alignments 
were categorized into seven classes: unedited, SpCas9 indels, Nm/SaCas9 indels, precise 
deletions, imprecise deletions, SpCas9 + Nm/SaCas9 indels, and inversions. Lesion types 
and frequencies were then cataloged in a text output format at each base using bam-
readcount. For each treatment group, the average background lesion frequencies (based on 
lesion type, position and frequency) of the triplicate negative control group were subtracted 
to obtain the nuclease-dependent lesion frequencies. Next, using R, a system for statistical 
computation and graphics357, we assessed whether the Cas9-Cas9 fusions resulted in 
different lesion rates from two independent Cas9s. Percent of lesion rates were transformed 
using logit function followed by one-way analysis of variance (ANOVA) with the 
Randomized Complete Block Design (Figures 4.3, 4.5, 4.6, and 4.9) or Completely 
Randomized Design (Figure 4.12). BH-adjusted p-values were calculated to counteract the 
problem of multiple comparisons of the data shown in Figure 4.12 (Ref. 358). 
For UMI analysis, we first used BWA (version 0.7.5) and SAMtools (version 
0.1.19) for aligning each group of filtered reads to a corresponding reference sequence. 
Next, we used a custom Python and PySAM script to process mapped reads into counts of 
UMI-labeled reads for each target. Alignments were categorized into seven classes: 
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unedited, SpCas9 indels, Nm/SaCas9 indels, precise deletions, imprecise deletions, SpCas9 
+ Nm/SaCas9 indels, and inversions. Next, we identified UMI duplicates and the minimal 
set of amplicons that can account for the full set of reads with unique UMIs. Then, the 
reads with unique UMI were counted. The same pipeline was used separately for each 
sample, and the resulting UMIs number tables were concatenated and loaded into 
GraphPad Prism 7 for data visualization. 
4.2.6 GUIDE-seq 
GUIDE-seq286 was performed with the adjustments to the original protocol as 
described previously306. Briefly, HEK293T cells were transfected using Polyfect 
transfection reagent (Qiagen) according to the manufacturer’s suggested protocol with 50 
ng of single nuclease (SpCas9WT, NmCas9WT, SaCas9WT) or 100 ng Cas9-Cas9 fusion 
expression plasmid, 50 ng of each sgRNA expressing plasmid, 50 ng of a mCherry 
expression plasmid and 5 pmol of annealed GUIDE-seq oligonucleotide. 72 h after 
transfection, genomic DNA was extracted with GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma) according to the manufacturer’s suggested protocol. We prepared 
the GUIDE-seq library with the original adaptors according to protocols described by 
Joung and colleagues286. Each library was indexed within the P5 and P7 adaptors for 
multiplex sequencing. The libraries were deep-sequenced as a pool using two paired-end 
150-bp Illumina MiSeq runs. 
Deep sequencing data from the GUIDE-seq experiment was analyzed using the 
Bioconductor Package GUIDEseq (v1.4.1) 386. The window size for peak aggregation was 
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set to 50 bp. Off-target site identification parameters were set for SpCas9 as follows: 
min.reads = 2, min.reads.per.lib = 1, distance.threshold = 70, min.peak.score.1strandOnly 
= 2, upstream = 20, downstream = 20, max.mismatch = 6, PAM.pattern = "NNN$”, 
allowed.mismatch.PAM = 2. For NmCas9, same parameters were used except the 
following: PAM.size = 8, PAM = "NNNNGHTT", PAM.pattern = "NNNNGNNN$", 
allowed.mismatch.PAM = 3, max.mismatch = 9. For SaCas9, same parameters were used 
as for SpCas9 except the following: PAM.size = 6, PAM = "NNGRRT", PAM.pattern = 
"NNGNNN$", allowed.mismatch.PAM = 3, max.mismatch = 6. The potential off-target 
sites identified for each nuclease are listed in Appendix 2.  The Specificity Ratio is 
calculated as the sum of the unique GUIDE-seq reads at the target site divided by all of the 
unique reads at all of the computationally identified off-target sites. 
4.3 Results 
4.3.1 Single nuclease Cas9MT-dCas9 fusions facilitate highly accurate editing 
To identify binding site parameters necessary for functional Cas9-Cas9 fusion 
activity, we used a plasmid reporter assay354 to detect DSB formation. In this assay, two 
protospacers with optimal cognate PAM elements (for SpCas9170, 304 and NmCas9242, 322 or 
SpCas9 and SaCas9244, 305) are arrayed in tandem in four configurations with various 
intervening spacings (Figure 4.1b and Figure 4.2b). In this assay, SpCas9WT displays 
robust nuclease activity while the R1335K mutant (SpCas9MT3)306 has substantially 
reduced activity. Fusion of nuclease-dead NmCas9 or SaCas9 to SpCas9MT3 (SpCas9MT3-
dNmCas9 or SpCas9MT3-dSaCas9) restores nuclease activity in configurations where the 
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SpCas9 protospacer is upstream of the orthogonal Cas9 target site (Figure 4.1b). Notably, 
the C-terminal fusions of dNm/SaCas9 are more successful at restoring the loss of activity 
of SpCas9MT3 than N-terminal fusions with the single linker configuration that we tested 
(Figure 4.2b). In our pilot experiments, Cas9-dCas9 fusions displayed a low level of 
activity at genomic sites. We reasoned that this could be due to poor nuclear localization 
of the fusion protein. Immunofluorescent imaging of the Cas9-Cas9 fusions indicated that 
the position and number of nuclear localization signals (NLSs) impact nuclear import 
efficiency of the Cas9-Cas9 fusions (Figure 4.2c). NLSs within the linker between the two 
Cas9 domains appeared to have little function.  Addition of NLSs at N and C termini was 
necessary for efficient nuclear localization of the Cas9-Cas9 fusions. We used this 
architecture for the remainder of this study. 
One of the salient features of the SpCas9MT-pDBD chimera is that this platform has 
improved specificity relative to SpCas9WT (Ref. 306). To evaluate the specificity of Cas9-
Cas9 fusions, we programmed SpCas9MT3-dNmCas9 and SpCas9MT3-dSaCas9 fusions to 
recognize a SpCas9 site (VEGFA-TS3)257, 286, which has numerous highly active off-target 
sites (Figure 4.1c). At the VEGFA-TS3 site, both SpCas9MT3-dNmCas9 and SpCas9MT3-
dSaCas9 fusions display similar levels of on-target activity (Figure 4.1d). We used 
GUIDE-seq286 to assess the genome-wide specificity of these nucleases. In comparison to 
SpCas9WT, both SpCas9MT3-dNmCas9 and SpCas9MT3-dSaCas9 fusions have a 
substantially reduced number of GUIDE-seq peaks (Figure 4.1e and Appendix 2). In 
addition to the reduction in the numbers of GUIDE-seq peaks, the Specificity Ratios 
(number of unique capture events at the target site divided by sum of unique capture events 
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at all off-target sites) for the SpCas9MT3-dNmCas9 and SpCas9MT3-dSaCas9 fusions are 
higher than for SpCas9WT (Figure 4.1f). To validate the off-target editing rates, we used 
targeted amplicon deep sequencing for a representative set of off-target sites within the 
genomes of the treated cells. Despite being comparably active to SpCas9WT at the target 
site, SpCas9MT3-dNmCas9 and SpCas9MT3-dSaCas9 fusions present dramatically better 
discrimination against near-cognate off-target sites (Figure 4.1g). Overall, GUIDE-seq and 
targeted amplicon deep sequencing datasets indicate that SpCas9MT-dNm/SaCas9 fusions 
substantially improve the specificity of SpCas9WT similar to the levels of achieved by 
SpCas9-pDBDs306.  
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Figure 4. 1 Development of a functional Cas9-Cas9 nuclease framework 
(a) Schematic of SpCas9MT-dNm/SaCas9 fusions. PAM-interaction attenuated SpCas9306 
(yellow star) is C-terminally fused to a nuclease dead Cas9 from N. meningiditis or S. 
aureus. Each Cas9 is loaded with its cognate sgRNA. (b) Top, schematic of parameters 
tested for target site organization. Four composite target site configurations are tested 
(D1:D4). Red arrow line and the rectangle represents SpCas9 protospacer in 5’ to 3’ 
orientation and PAM respectively. Blue arrow line and the rectangle represents Nm/SaCas9 
protospacer in 5’ to 3’ orientation and PAM respectively. Two dashed lines indicate the 
closest nucleotide in between the binding site of two orthogonal Cas9, and x represents the 
number of nucleotides in between. Bottom, activity profiles of SpCas9 (blue), SpCas9MT3 
(R1335K; gray), SpCas9MT3-dNmCas9 (pink), and SpCas9MT3-dSaCas9 (purple) in GFP 
reporter assay. (c) Sequences of dual Cas9 genomic target sites at VEGFA locus. SpCas9 
protospacer is bold underlined and its PAM is in red, SaCas9 protospacer is double 
underlined and its PAM is green, NmCas9 protospacer is wavy underlined and its PAM is 
in blue. (d) Lesion rates of the nuclease platforms are determined by deep sequencing. (e, 
f) Genome-wide off-target analysis of the nuclease platforms determined via GUIDE-
seq286 (Appendix 2). (e) The number of off-target peaks detected for the given nuclease. (f) 
Fold improvement of specificity ratio of the Cas9-dCas9 framework relative to SpCas9WT. 
(g) Deep sequencing determined lesion rates of the nucleases at small set of off-target sites 
discovered within the GUIDE-seq data. GUIDE-seq result is from single experiment, 
whereas GFP reporter assay and deep sequencing data are from three independent 
biological replicates performed on different days in HEK293T cells. Error bars indicate 
±s.e.m.  
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Figure 4. 2 Identification of the functional parameters for Cas9-Ca9 fusion activity 
(a) Sequence information of the target sites tested for SpCas9-SaCas9 and SpCas9-
NmCas9 fusions. SpCas9 protospacer is bold underlined and its PAM is in red, SaCas9 
protospacer is double underlined and its PAM is green, NmCas9 protospacer is wavy 
underlined and its PAM is in blue. (b) Activity profiles of SpCas9 (blue), SpCas9MT3 
(R1335K; gray), dNmCas9-SpCas9MT3 (pink), and dSaCas9-SpCas9MT3 (purple) in GFP 
reporter assay. The data are from three independent biological replicates performed on 
different days in HEK293T cells. Error bars indicate ±s.e.m. (c) Cellular localization 
profile of Cas9-Cas9 fusion proteins in cell. On left is the schematic of various 
compositions of the Cas9-Cas9 fusion protein. On right, immunofluorescence imaging of 
nucleus (blue) and Cas9-Cas9 proteins (green). 
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4.3.2 Cas9-Cas9 dual nucleases primarily generate precise segmental deletions 
Unlike SpCas9-pDBDs, the Cas9-Cas9 fusions can also be used as dual nucleases. 
We hypothesized that when a pair of Cas9 nucleases dock together on a target site, they 
will generate two DSBs synchronously. Since rejoining of the broken ends without 
resection via canonical NHEJ is the predominant DSB repair response in mammalian 
cells10, the primary editing outcome of Cas9-Cas9 dual nucleases should be the precise 
deletion of the intervening segment between the cleavage sites. Previous studies have 
demonstrated that wild-type Cas9 nucleases that are targeted to a pair of neighboring 
genomic sequences can produce precise deletions but with variable efficiencies173, 189, 193. 
Such variability in editing outcomes is possibly due to asynchronous cleavage due to 
differences in the efficiency of recognition or cleavage by the nuclease at two different 
sequences. Cas9-Cas9 dual nucleases should improve the level of synchrony by delivering 
both nucleases simultaneously to a pair of target sequences.  
To test this hypothesis, we programmed SpCas9WT-NmCas9WT dual nucleases to 
target the VEGFA locus in HEK293T cells. PCR amplification of the VEGFA locus from 
nuclease-treated cells indicates that dual-Cas9 nucleases, either independently or as 
fusions, generate precise segmental deletions, as anticipated (Figure 4.3a). In principle, 
two DSBs at a nearby locus in the genome can produce at least six possible repair 
outcomes: random indels at the first nuclease cut site (SpCas9 indel), random indels at the 
second nuclease cut site (NmCas9 indel), random indels at both nuclease cut sites 
(Sp&NmCas9 indel), precise deletions, imprecise deletions, and inversions. To monitor the 
presence and distribution of each set of repair events quantitatively, we applied targeted 
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amplicon deep sequencing of the genomic DNAs from cells treated with the different 
nuclease platforms. Analysis of the VEGFA amplicon sequencing data indicate two 
superior features of Cas9-Cas9 dual nuclease fusions (SpCas9WT-NmCas9WT, SpCas9MT-
NmCas9WT) over two independent Cas9s (SpCas9WT + NmCas9WT): Cas9-Cas9 fusions 
display higher levels of genome modification and the fraction of these events that are 
precise deletions than two independent Cas9 nucleases (Figure 4.3b). We observed similar 
editing outcomes for SpCas9 and SaCas9 dual nucleases (Figure 4.4).  
To test the generality of this phenomenon, we initially screened 41 genomic sites 
for the activity profiles of single and dual nucleases, and for the types of lesions that are 
produced within the genome. Overall, SpCas9 has a higher median nuclease activity than 
SaCas9 and NmCas9. The lesion rates of the dual independent nucleases are similar to the 
levels of achieved by SpCas9 alone, but the composition of the lesions changes due to the 
production of precise deletions (Figure 4.5a-b). In comparison to dual independent 
nucleases, Cas9-Cas9 dual nucleases not only have higher overall activity, but also produce 
precise segmental deletions more efficiently (Figure 4.5.c).  
Next, we selected a representative set of 12 sites from these 41 sites that span 
different activity profiles for the individual nucleases to assess in greater depth the nuclease 
activities of single and dual nucleases for wild-type and PAM-interaction-deficient306 
forms. SpCas9WT-Sa/NmCas9WT dual-nuclease fusions have higher overall activity than 
SpCas9 and two independent Cas9s (Figure 4.3c). This enhancement is likely due to 
cooperativity between the fused nucleases, where strong binding of one of the Cas9s 
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increases the effective concentration and consequently the activity of the other nuclease. 
The total activity levels of SpCas9MT-Sa/NmCas9WT fusions are associated with the activity 
levels of the orthogonal Cas9:sgRNA complexes (Figure 4.6). SpCas9WT-Sa/NmCas9WT 
dual-nuclease fusions double the production of precise deletions relative to two 
independent Cas9s (Figure 4.3d). More importantly, precise deletions are the predominant 
products of Cas9-Cas9 dual nucleases, encompassing on average >90% of all lesion types 
(Figure 4.3e and Figure 4.6).  These data suggest that generation of two synchronous 
nearby breaks by Cas9-Cas9 dual nucleases are preferentially repaired via canonical NHEJ.  
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Figure 4. 3 Cas9-Cas9 dual nucleases generate uniform deletion products 
(a) Top, sequence of SpCas9-NmCas9 target site: SpCas9 protospacer is bold underlined 
and its PAM is in red, NmCas9 protospacer is wavy underlined and its PAM is in blue. 
Purple arrows indicate the positions of the double-strand break formation. Bottom left, 
genomic region containing the target site is PCR amplified; higher band is the wild-type 
sequence or sequences with small indels, lower band is the segmental deletion product 
generated by dual nucleases. Bottom right, chromatogram from Sanger sequencing of the 
lower band extracted from the gel (black arrow). The main product is the perfect junction 
of two double-strand break sites yielding a precise deletion (black rectangle). (b) Lesion 
rates and types are determined by the deep sequencing. Single nucleases generate small 
indels at their corresponding cleavage sites, whereas dual nucleases (independent or fusion) 
may generate six types of lesion products. The majority of the lesions produced by dual 
nuclease fusions is a precise deletion. SpCas9MT-dNmCas9 fusions behave like a 
monomeric SpCas9. (c, d, e) Activity profiles of SpCas9WT (blue), Nm/SaCas9WT (pink), 
SpCas9WT + Nm/SaCas9WT (orange), and SpCas9WT- Nm/SaCas9WT (green) nucleases at 
12 genomic sites (6 D1 and 6 D2 configuration) are determined by deep sequencing. (c) 
Total lesion rates for the given nucleases. Typically, SpCas9 is more active than 
Nm/SaCas9. Total lesion rates of the Cas9-Cas9 dual nucleases are higher than the 
monomeric Cas9s used in combination. (d) Cas9-Cas9 fusions generate higher rates of 
precise deletions in the target genome than two independent Cas9 monomers. (e) Cas9-
Cas9 dual nucleases primarily generate exact deletion products whereas lesion types of the 
two independent monomeric Cas9s are site-dependent. Each Box plot is drawn by 
GraphPad Prism, where the box represent 25th and 75th percentile and the middle line is the 
median. Whiskers and outliers are defined by Tukey method. Statistical significance is 
determined by one-way analysis of variance (ANOVA), “**” and “****” denote P <0.01 
and <0.0001 respectively. Deep sequencing data are from three independent biological 
replicates performed on different days in HEK293T cells. Error bars indicate ±s.e.m. 
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Figure 4. 4 Analysis of lesion type and frequency profile of SpCas9-SaCas9 fusions 
(a) Sequence information of the VEGFA-TS2 target sites for SpCas9-SaCas9 and SpCas9-
NmCas9 fusions. SpCas9 protospacer is bold underlined and its PAM is in red, SaCas9 
protospacer is double underlined and its PAM is green. (b) Lesion rates and types are 
determined by the deep sequencing. Single nucleases generate small indels at their cognate 
cleavage sites, whereas dual nucleases (independent or fusion) may generate six types of 
lesion products. (c) Sequence information of the VEGFA-TS3 target sites for SpCas9-
SaCas9 and SpCas9-NmCas9 fusions. SpCas9 protospacer is bold underlined and its PAM 
is in red, SaCas9 protospacer is double underlined and its PAM is green. (d) Lesion rates 
and types are determined by the deep sequencing. Single nucleases generate small indels 
at their cognate cleavage sites, whereas dual nucleases (independent or fusion) may 
generate six types of lesion products. Red rectangle indicate the SaCas9 sgRNA that is 
used for specificity analysis of SpCas9MT3-dSaCas9 combination. Deep sequencing data 
are from three independent biological replicates performed on different days in HEK293T 
cells. Error bars indicate ±s.e.m. 
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Figure 4. 5 Activity profiles of singe and dual nucleases at 41 genomic sites 
SpCas9WT (blue), Nm/SaCas9WT (pink), SpCas9WT + Nm/SaCas9WT (orange), and 
SpCas9WT- Nm/SaCas9WT (green) nucleases activities are determined by deep sequencing. 
(a) Total lesion rates for the given nucleases. Typically, SpCas9 is more active than 
Nm/SaCas9. Total lesion rates of the Cas9-Cas9 dual nucleases are higher than the 
monomeric Cas9s used in combination. (b) Cas9-Cas9 fusions generate higher rates of 
precise deletions in the target genome than two independent Cas9 monomers. (c) Cas9-
Cas9 dual nucleases primarily generate exact deletion products whereas lesion types of the 
two independent monomeric Cas9s are site-dependent. Each Box plot is drawn by 
GraphPad Prism, where the box represent 25th and 75th percentile and the middle line is the 
median. Whiskers and outliers are defined by Tukey method. The scatter dot plot is drawn 
by GraphPad Prism, where middle line indicates the median and top and bottom lines 
borders the interquartile ranges. Statistical significance is determined by one-way analysis 
of variance (ANOVA), “**” and “****” denote P <0.01 and <0.0001 respectively. Deep 
sequencing data are from single replicate in HEK293T cells.  
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Figure 4. 6 Activity profiles of singe and dual nucleases at 12 genomic sites 
Activity profiles of SpCas9WT (blue), Nm/SaCas9WT (pink), SpCas9MT3-dNm/SaCas9 
(brown), SpCas9WT + Nm/SaCas9WT (orange), SpCas9WT- Nm/SaCas9WT (green), and 
SpCas9MT3-Nm/SaCas9WT (purple) nucleases at 12 genomic sites (6 D1 and 6 D2 
configuration) are determined by deep sequencing. (a) Total lesion rates for the given 
nucleases at 12 genomic sites. (b) Total lesion rates for the given nucleases at 6 genomic 
sites with D1 configuration. (c). Total lesion rates for the given nucleases at 6 genomic 
sites with D2 configuration. (d) SpCas9WT-Nm/SaCas9WT fusions generate higher rates of 
precise deletions in the target genome than two independent Cas9 monomers. (e) Cas9-
Cas9 dual nucleases primarily generate exact deletion products whereas lesion types of the 
two independent monomeric Cas9s are site-dependent. Each Box plot is drawn by 
GraphPad Prism, where the box represents 25th and 75th percentile and the middle line is 
the median. Whiskers and outliers are defined by Tukey method. Statistical significance is 
determined by one-way analysis of variance (ANOVA), “**” and “****” denote, P <0.01 
and P <0.0001 respectively. Deep sequencing data are from three independent biological 
replicates performed on different days in HEK293T cells. 
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4.3.3 Defining the targeting range of the Cas9-Cas9 fusions 
Another salient feature of SpCas9-pDBD fusions is their increased targeting range 
achieved through their functionality at suboptimal PAM sequences306. To examine the 
targeting range of Cas9-Cas9 fusions, we designed several SpCas9 guides that target 
protospacers with suboptimal PAMs in tandem with an SaCas9 target site with an optimal 
N2GRRT PAM sequence
244 (Figure 4.7a). Wild-type SpCas9 has very low or no activity 
on these sites, as expected (Figure 4.7b). However, in single- and dual-nuclease formats, 
SpCas9-SaCas9 fusions display nuclease activity at the SpCas9 sites with NAG, NTG, 
NCG, NGA, NGT, and NGC suboptimal PAMs. These data reflect the ability of the 
SpCas9-SaCas9 fusions to utilize the presence of a single guanine in the SpCas9 PAM 
element as a functional cleavage site (Figure 4.7b). Considering the flexibility in the target 
site spacing for Cas9-Cas9 fusions (Figure 4.1b), the target site density of the Cas9-Cas9 
fusions is likely the sum of the targeting repertoire of the SaCas9 and NmCas9 nucleases. 
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Figure 4. 7 Cas9-Cas9 fusions expand the PAM usage of SpCas9 
(a) Target site information; SpCas9 protospacer is bold underlined and a suboptimal PAM 
element is in red, SaCas9 protospacer is double underlined and the cognate PAM element 
is green. (b) Lesion rates and types at the tandem target sites are determined by the deep 
sequencing with bulk analysis. SaCas9 generates robust editing whereas SpCas9 displays 
low or no activity. In Cas9-Cas9 fusion format, SpCas9 cuts effectively at these 
protospacers as observed from the SpCas9-dSaCas9 fusions or the fused wild-type 
nucleases. Deep sequencing data are from three independent biological replicates 
performed on different days in HEK293T cells. Error bars indicate ±s.e.m. 
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4.3.4 Cas9-Cas9 dual nucleases accurately delete functional elements in genome 
Increased nuclease activity, enhanced targeting range, and the generation of 
uniform editing products favor the Cas9-Cas9 dual nucleases for the disruption of a gene 
or a regulatory element within genome. To apply this platform at a therapeutically relevant 
genomic locus, we tested the ability of Cas9-Cas9 dual nucleases to delete the GATA1 
binding motif within the BCL11A erythroid-lineage specific enhancer (+58kb) element97, 
98. Disruption of this regulatory element in the genomes of CD34+ hematopoietic stem and 
progenitor cells (HSPCs) silences BCL11A expression in the erythroid lineage, and thereby 
increases production of fetal γ-globin protein in differentiated red blood cells99. Ex vivo 
genome editing of this locus in HSPCs in conjunction with autologous bone marrow 
transplantation is a potential therapeutic approach for the treatment for sickle cell disease96, 
394.  
To efficiently delete the GATA1 binding motif, we programmed Cas9-Cas9 fusions 
to target twelve different sites spanning this regulatory element in HEK293T cells (Figure 
4.8). Similar to our analysis at other genomic loci, Cas9-Cas9 fusions effectively generate 
precise segmental deletions at most but not all of the examined sites (Figure 4.9). Notably, 
in SpCas9WT-Sa/NmCas9WT dual-nuclease fusion format, all three Cas9s (Sp/Nm/SaCas9s) 
effectively cut protospacers with suboptimal PAM sequences: SpCas9304 at NAG PAMs 
(GATA1-TS7, TS8, TS9, TS10, and TS11) and GATA1-TS5 and TS9), NmCas9242, 322 at 
N4GCTT (GATA1-TS4), N4GTTT (GATA1-TS5), and N4GACT (GATA1-TS6) PAMs, 
SaCas9244, 305 at N2GGGC (GATA1-TS10) and N2GAGG (GATA1-TS12) PAMs. Among 
the twelve sites, we focused on four with the most promising activity, GATA1-TS7, 
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GATA1-TS9, GATA1-TS10, and GATA1-TS11, for further characterization and 
specificity analysis (Figure 4.10a). 
 
Figure 4. 8 Cas9-Cas9 fusion target sequences in the BCL11A enhancer +58kb 
Target site information of Cas9-Cas9 fusions for deletion of GATA1 binding element 
(highlighted in gray) in BCL11A enhancer +58kb. SpCas9 protospacer is bold underlined 
and PAM element is in red, SaCas9 protospacer is double underlined and the PAM element 
is green, and NmCas9 protospacer is wavy underlined and the PAM element is blue. 
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Figure 4. 9 Activity profiles of nucleases at BCL11A enhancer +58kb GATA1 element  
(a) Lesion rates and types are determined by the deep sequencing. Single nucleases 
generate small indels at their corresponding cleavage sites, whereas dual nucleases 
(independent or fusionWT or fusionMT) may generate six types of lesion products. (b) Ratio 
distributions of precise deletions relative to other types of lesions. (c, d, e) Overview of the 
nuclease activities at 12 GATA1 target sites: (c) Total lesion rates, (d) precise deletion 
rates, and (e) fraction of precise deletion among all lesions. Each Box plot is drawn by 
GraphPad Prism, where the box represent 25th and 75th percentile and the middle line is the 
median. Whiskers and outliers are defined by Tukey method. Statistical significance is 
determined by one-way analysis of variance (ANOVA), “*”, “***” and “****” denote P 
<0.05, P <0.001 and P <0.0001 respectively. Deep sequencing data are from three 
independent biological replicates performed on different days in HEK293T cells. Error 
bars indicate ±s.e.m. 
 
One potential caveat on the precise quantification of the lesion levels is the PCR 
amplification bias of a precise deletion product due to its shorter length396. To address this 
possibility, we developed an assay based on unique-molecular identifiers (UMI)397 and 
linear amplification mediated (LAM) PCR332 (Figure 4.11a-c). In this approach, the 
genomic DNA is pre-amplified linearly with a single primer that is locus-specific, and that 
contains UMI and non-cognate adaptor sequences. Next, the UMI-containing single 
stranded DNA is selectively amplified and barcoded for deep sequencing. We used the 
UMI-correction method to measure the lesion profiles of four GATA1 target sites within 
the BCL11A enhancer +58kb locus. For single nucleases, there is no significant difference 
in the total lesion levels between bulk and UMI-corrected analyses. For dual nucleases, 
there is slight overestimation of the precise deletion levels in bulk sequencing data relative 
to the UMI-corrected analysis (Figure 4.11d-e). Since the SpCas9 target sites have 
suboptimal NAG PAMs, the activity levels of monomeric SpCas9 are modest. Cas9-Cas9 
dual nucleases display increased activity at all of these target sites relative to the dual 
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independent nucleases. Notably, Cas9-Cas9 fusions containing the attenuated R1333S 
SpCas9 mutant (SpCas9MT2) (Ref. 306) also retain high activity at all four target sites with 
NAG PAMs, concordant with our previous findings (Figure 4.10c). Similar to previous 
observations at other sites, even after UMI-correction, up to 97% of all lesions generated 
by Cas9-Cas9 dual nucleases are precise deletions (Figure 4.10c-d). These data suggest 
that Cas9-Cas9 dual nucleases are a promising platform for the generation of uniform 
editing products at therapeutically important sites. 
. 
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Figure 4. 10 Cas9-Cas9 fusions effectively delete BCL11A enhancer +58kb GATA1 element  
(a) Sequence information of the four target sites chosen for more detailed assessment of 
the application of Cas9-Cas9 fusions to the deletion of the GATA1 binding element 
(highlighted in gray) at BCL11A enhancer +58kb. (b, c) Lesion rates and types at four target 
sites spanning the GATA1 element are determined by the deep sequencing after UMI-
correction. (c) Ratio distributions of precise deletions relative to other types of lesions. 
Deep sequencing data are from three independent biological replicates performed on 
different days in HEK293T cells. Error bars indicate ±s.e.m. 
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Figure 4. 11 Accurate quantification of the segmental deletions  
Accurate quantification of the segmental deletions via unique molecular identifiers (UMI) 
and linear amplification mediated (LAM) PCR. (a) Schematic of the library construction 
process for deep sequencing. Left, standard library prep where the region of interest (gray 
box) is first amplified with locus specific oligos (black arrows) bearing constant sequences 
(magenta and red) for TruSeq adaptor recognition. Next, the amplicon is further amplified 
from the constant sequences with oligos bearing indexes (purple and orange squares) and 
overhangs for P7 (light green) and P5 (blue). Right, library construction with for UMI-
correction, where the genomic DNA is pre-amplified with oligos bearing UMI (N…N) and 
5’ constant sequence (magenta) via LAM PCR. Next, the single stand DNA is amplified 
with 5’ constant sequence and 3’ locus specific primer (black arrow) bearing 3’ constant 
sequence (red). Then, the amplicon is further amplified from the constant sequences with 
oligos bearing indexes (purple and orange squares) and overhangs for P7 (light green) and 
P5 (blue). (b) An example agarose gel electrophoresis picture showing the outcome of PCR 
1b of the UMI-correction library. The primer ratio indicates the value of 5’ constant primer 
concentration (y µM) divided by 5’ BCL11A_enh58_UMI primer concentration (x µM). 
In the absence of the 5’ constant primer, the amplification product is not visible. (c) A 
representative histogram plotting the distribution of particular UMI abundance of 
TS11_SpCas9WT-SaCas9WT_Replicate-3 sample in the deep sequencing library. (d) For 
single nucleases the analysis of total lesions indicate that indels do not generate 
amplification bias. (e) For dual nucleases, the rate of precise deletions are a bit over-
estimated via bulk analysis. Deep sequencing data are from three independent biological 
replicates performed on different days in HEK293T cells. Error bars indicate ±s.e.m. 
 
To evaluate the targeting specificity of these nucleases at the four GATA1 target 
sites, we performed GUIDE-seq genome-wide specificity analysis286. We screened for 
active off-target sites for each individual wild-type Cas9 and the wild type Cas9-Cas9 dual 
nucleases. We observed robust GUIDE-seq oligo incorporation at the target sites for all of 
the wild-type Cas9-Cas9 dual nucleases (Figure 4.12a). A small number of potential off-
target sites were identified for the TS7 and TS9 based on the GUIDE-seq analysis. A larger 
number of off-target sites were associated with the SaCas9 guide for the TS11 target site. 
The number of off-target sites identified by GUIDE-seq and the unique counts that are 
associated with each site are similar between the Cas9-Cas9 fusions and the individual 
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Cas9 nucleases (Appendix 2), suggesting that there is not a dramatic difference in the off-
target activity between the individual nucleases and the Cas9-Cas9 fusions. The three off-
target sites identified for NmCas9 have nine-nucleotide mismatches to the guide sequence, 
and are so divergent that they potentially represent false positive sequences.  
To assess the editing rate at potential off-target sites, we performed amplicon deep 
sequencing at these regions within the genome.  We evaluated ten potential off-target sites 
for each nuclease, which were identified by either the GUIDE-seq analysis286 or 
computationally predicted via Cas-OFFinder198 when insufficient high-quality sites were 
identified by GUIDE-seq. We evaluated the off-target activities of two different versions 
of the Cas9-Cas9 dual-nuclease fusions, SpCas9WT-Sa/NmCas9WT or SpCas9MT2-
Sa/NmCas9WT, in comparison with the independent SpCas9WT and Sa/NmCas9WT 
nucleases delivered simultaneously. The deep sequencing analysis indicates that the Cas9-
Cas9 dual nuclease fusions display similar levels of off-target activity when compared to 
independent dual-Cas9 nucleases. At two of the SpCas9 off-target sites (OT9-4 and OT9-
8), the use of the attenuated SpCas9MT2-SaCas9WT nuclease dramatically reduces the off-
target activity compared to the independent wild-type SpCas9 or the SpCas9WT-SaCas9WT 
nuclease (Figure 4.12b). These data demonstrate that Cas9-Cas9 dual nucleases achieve 
robust editing at the target site without generating a new class of off-target sites. The 
generation of uniform, accurate editing products within the BCL11A enhancer +58kb locus 
highlights the utility of Cas9-Cas9 dual nucleases as a promising genome editing platform 
for the deletion of therapeutically relevant regulatory elements96, 394. 
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Figure 4. 12 Cas9-Cas9 fusions achieve robust and specific genome editing 
(a) Summary of the GUIDE-seq genome-wide off-target analysis of SpCas9WT, 
Sa/NmCas9WT, and SpCas9WT-Sa/NmCas9WT at four GATA1 target sites (Appendix 2). (b) 
Deep sequencing determined lesion rates for these nucleases at small set of off-target sites 
discovered by the GUIDE-seq data or predicted by CasOFFinder. The names of SpCas9, 
NmCas9 and SaCas9 off-target sites are colored in dark red, blue, and green. The GUIDE-
seq result is from single experiment, deep sequencing data are from three independent 
biological replicates performed on different days in HEK293T cells. Error bars indicate 
±s.e.m. Statistical significance is determined by one-way analysis of variance (ANOVA), 
“*”, “**”, “***”, and “NS” denote BH-adjusted P-values of <0.05, <0.01, <0.001, and “not 
significant” respectively.  
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4.4 Discussion 
In this study, we have expanded the CRISPR/Cas9 toolset by developing 
orthogonal Cas9-Cas9 chimeras in single- and dual-nuclease formats. Unlike the original 
Cas9-pDBD platform, which required some expertise in protein engineering, the entirely 
RNA-programmable Cas9-Cas9 fusions should be completely accessible to the broader 
scientific community. In both single- and dual-nuclease formats, Cas9-Cas9 fusions act 
similarly to SpCas9-pDBDs with regards to enhanced targeting range and improved 
specificity306. The presence of a single guanine within the PAM is sufficient for SpCas9 to 
cleave its targets in the context of Cas9-Cas9 fusions. In principle, similar suboptimal PAM 
usage should be applicable for SaCas9 and NmCas9 when the SpCas9 targets an optimal 
NGG PAM element. For homology-directed repair applications, the ability to target sites 
with suboptimal PAM elements may allow Cas9-Cas9 fusions to generate a DSB closer to 
the site of the desired sequence conversion398. This feature can also be useful for allele-
specific targeting by Cas9-Cas9 nucleases by placing the PAM recognition at a 
polymorphic site. In the dual-nuclease format, SpCas9WT-Sa/NmCas9WT fusions display 
superior nuclease activity and primarily produce uniform, predictable lesions within the 
targeted genome. These fusions are also compatible with PAM-interaction-attenuated 
SpCas9 to provide an additional level of target site specificity. Overall, RNA-
programmable Cas9-Cas9 fusions offer superior features to independent nucleases: 
expanded targeting range, improved specificity, and efficient generation of uniform editing 
products.  
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Our analysis of the DNA repair products produced by Cas9-Cas9 fusions provides 
insights into methods to increase the efficiency of DSB-mediated genome sequence 
alterations by programmable nucleases. Canonical NHEJ (cNHEJ) is typically the default 
choice for DSB repair in most stages of the cell cycle10. Precise ligation by cNHEJ of the 
ends of a DSB generated by a single nuclease restores the target site sequence, and in the 
context of an active nuclease leads to another round of cleavage. The predominant 
production of precise deletions after the generation of two synchronous blunt DSBs at a 
composite target site supports the cellular preference for cNHEJ for DSB repair. 
Consistently, SpCas9MT-Sa/NmCas9WT dual nuclease fusions display higher total lesion 
rates than SpCas9MT-dSa/NmCas9 single nuclease fusions, where the latter only rely on 
less frequent non-canonical NHEJ mediated DSB repair to produce a stable end product 
(Figure 4.3b and Figure 4.4). This is particularly striking for dual nucleases at target sites 
where one of the Cas9 monomers is weakly active, such as at some of the Nm/SaCas9 
target sites (TS5, TS7 & TS12; Figure 4.9) or at SpCas9 protospacers with suboptimal 
PAMs (Figure 4.7). DNA cleavage at these sites by the independent nuclease is inefficient, 
and since cNHEJ repair restores the native DNA sequence, they are marked by low lesion 
rates. Cas9 nucleases employed in combination reveal the activity of the weak nuclease in 
the form of precise deletions between the cleavage sites. This increase in lesion rates could 
also be due in part to the relaxation of the local chromatin architecture as observed for 
proximal CRISPR targeting399.  
One of the hurdles for therapeutic genome editing applications is the uncertainty of 
the functional activity of the lesions that are produced by individual nucleases when relying 
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on imprecise DNA repair. At a therapeutically relevant site, Cas9-Cas9 dual nuclease 
fusions produce defined precise deletions comprising up to 97% of the modified genomes, 
which should produce specific alleles that have activities that can be defined in model 
systems prior to advancement in therapeutic applications. Cas9-Cas9 fusion mediated 
production of precise deletions should be applicable to the development of therapeutic 
genome editing strategies for a number of genetic disorders. As the immediate extension 
of the results described in this study, efficient excision of the core regulatory elements 
within the BCL11A erythroid enhancer in CD34+ HSPCs via Cas9-Cas9 
ribonucleoproteins is likely to achieve higher rates of inactivation than the production of 
local indels by a single nuclease97-99. This increased efficiency should reduce the number 
of modified cells that need to be administered to a patient for the treatment of β-
hemoglobinopathies, such as sickle cell disease96.  
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CHAPTER V: Discussion and future outlook 
5.1 Summary of the chimeric Cas9 platforms 
The most commonly employed CRISPR-Cas9 system uses the Cas9 effector from 
S. pyogenes due to its efficacy and relatively broad targeting range; the PAM requirement 
of “GG” occurs every 8 base pairs in a random genome. However, the wild type SpCas9 
has been reported to generate double strand breaks at unintended sites in human genome378. 
Chapter 2 describes the development of a chimeric SpCas9-pDBD (programmable DNA-
binding domain, ZFP or TALE) platform to expand the targeting range and improve the 
specificity of SpCas9. Upon fusion to a pDBD that is targeting a downstream DNA 
sequence, SpCas9 is able to cleave target sites with suboptimal PAM elements: NAG, 
NGA, and NGC. Attenuation mutations of the PAM interaction residues of SpCas9 
(SpCas9MT) make the nuclease activity dependent on the fused pDBD targeting a 
downstream sequence. This additional stage of target site recognition provides substantial 
improvement to the nuclease specificity. Furthermore, the SpCas9-pDBD framework can 
be tuned to achieve extreme genome editing specificity. 
Continuous expression of programmable nucleases increases the likelihood of off-
target nuclease activity289. Additional level of targeting specificity can be achieved by 
adding a mechanism for temporal control over the nuclease activity. Chapter 1 provides an 
overview of some of the platforms that offer temporal control in nuclease activity. Chapter 
3 describes the development of two SpCas9-pDBD variants that are inducible by a small 
molecule. The first variant involves the splitting the covalent linkage between SpCas9 and 
the pDBD through the addition of FKBP:FRB heterodimerization domains. The second 
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variant is developed from previously described Split-Cas9 architecture308 with a PAM-
interaction attenuation mutation and fusion to a pDBD. Both of these variants achieve 
rapamycin inducible genome editing with similar levels of specificity to the SpCas9-DBD 
platform. 
Although SpCas9-pDBD platforms offer accurate genome editing, the challenges 
inherent in the construction of pDBDs—particularly ZFPs—limit their usage by the 
broader scientific community. Chapter 4 describes the conversion of the chimeric Cas9 
platforms into an entirely RNA-programmable system. Substitution of the pDBD with a 
nuclease dead Cas9 orthologue—from N. meningiditis242 or S. aureus244—simplifies the 
construction of chimeric Cas9 platforms with three-stages of target site recognition. Cas9-
Cas9 fusions can be utilized as a single or a dual nuclease. Both nucleases achieve accurate 
genome editing with the expansion of PAM usage of SpCas9 to a single guanine. 
Furthermore, dual nuclease Cas9-Cas9 fusions predominantly produce a defined editing 
product (precise deletion) as opposed to random indels at the target site. This feature is 
particularly useful to disrupt therapeutically relevant genes and regulatory elements.   
5.2 The future of the chimeric Cas9 platforms 
Similar to other programmable nucleases, the chimeric Cas9 platforms described in 
this thesis can be used in various basic genome engineering applications in cell lines and 
model organisms. There can also be cases where the usage of a chimeric Cas9 platform 
becomes even more advantageous over standard Cas9 nucleases. For example, in gene 
correction applications, keeping the DSB close to the conversion site increases the HDR 
rate398. Being able to target sites with suboptimal PAM elements may allow chimeric Cas9s 
   171 
to generate a DSB closer to the site of the desired sequence conversion. Suboptimal PAM 
licensing can also be useful to for allele-specific targeting of these nucleases by placing the 
PAM recognition at a polymorphic site. In dividing cells, generation of a DSB in one of 
alleles can trigger HDR templated from the other non-cut allele in similar mechanism to 
the gene drive phenomenon400 described below. In autosomal dominant diseases with 
heterozygous genotype, nuclease targeting of the disease causing allele should be 
converted to the other allele. In addition to PAM expansion, the improved specificity of 
these platforms makes them appealing for therapeutic genome editing application for 
genetic disorders. Such applications can be either ex vivo where the nuclease can be 
delivered as mRNA or ribonucleoprotein complex or in vivo where the nuclease can be 
delivered within viral or non-viral carriers. Particularly, AAV-mediated delivery of 
nucleases may be the most therapeutically relevant but challenging due the limited cargo 
capacity. Therefore, the development of Cas9-pDBD platforms employing smaller Cas9 
orthologues242, 244, 245 should provide a solution. For example, an NmCas9 fused with 4 
finger ZFP is around 3.7kb. Including the additional regulatory sequences, the expression 
cassette should be within the packaging limit (~4.7 kb) of single AAV401.  For viral 
deliveries, the constitutive expression of nucleases may increase the likelihood of off-target 
cleavage no matter how specific the nuclease platform is. Therefore, incorporation of a 
temporal control at the expression or the activity stages of any nucleases would be useful.  
Cas9-Cas9 fusions can provide additional utility in therapeutic genome editing 
applications. The data in Chapter 4 suggest that dual nuclease fusions can effectively and 
accurately delete the GATA1 binding motif within the erythroid-lineage specific enhancer 
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element of BCL11A gene97, 98. The immediate extension of this application is its 
recapitulation in CD34+ hematopoietic stem and progenitor cells as a potential ex vivo 
therapeutic approach for sickle cell disease95, 96. Since the GATA1 deletion is a canonical 
NHEJ mediated event, the rate of editing in long term progenitor cells should be 
comparable to the bulk population99. The Cas9-Cas9 fusions can be delivered into CD34+ 
HSPCs as electroporation of an mRNA or an RNP. The latter may be associated with 
additional challenges such as the difficulty in its bacterial expression as a single 
polypeptide. Yet, by employing a split intein system402, 403, the two Cas9 component can 
first be expressed and purified independently, and then ligated to form the fusion protein. 
Another application area of the Cas9-Cas9 dual nucleases is functional genomics 
screening. Because Cas9-Cas9 dual nuclease fusions typically have higher activity and 
produce more uniform lesions than single Cas9s, a Cas9-Cas9 fusion based loss-of-
function screening platform should produce cleaner outcomes. In addition to single and 
dual nucleases, Cas9-Cas9 should be able used as a single nickase, a dual nickase or a 
nuclease nickase combination. Such fusions will generate synchronous nicks and (or) 
double strand breaks at the target site to form various end products which may trigger 
different cellular repair machineries9-11. The HDR potentials of such cleavage products are 
worth investigation. Overall, the chimeric Cas9 platforms described in this thesis offer 
highly specific, versatile genome editing applications.  
5.3 The future of genome engineering 
Novel applications of programmable nucleases are happening at a breathtaking 
pace. In addition to what has been projected in Chapter 1, there are other avenues of 
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genome editing applications that will impact the future of medicine and the ecosystem. One 
such application is their use as gene drives, a term to describe inheritance bias of a 
particular gene against the odds of natural genetics404, 405. In order to initiate a gene drive, 
a Cas9 and sgRNA expression cassette with homology arms against the flanking sequences 
of the sgRNA target site is inserted into a genome. Germline expression of the Cas9 and 
sgRNA from the incorporated allele generates a DSB on the other allele, which is repaired 
via HDR templated from the Cas9 sgRNA inserted allele, which results in gene conversion. 
Once transferred into germline, mating of the gene drive carrying organism with a wild 
type mate predominantly gives rise to progeny carrying homozygous gene drive400. 
Although being controversial with regards to their safety and the environmental risks 
associated, gene drives have the potential to control vector based diseases (e.g. malaria and 
dengue fever), and invasive species405.    
Another interesting application of programmable nucleases is in 
xenotransplantation. The term corresponds to the transplantation of living organs (or 
tissues) from one species into another species to treat organ failure of the recipient. Due to 
the persistent shortage of organs from compatible human donors, xenotransplantation is 
one potential solution to this problem406. Pigs are considered as suitable organisms for the 
development of human transplantable organs. However, there are critical barriers 
associated with the xenotransplantation of pig organs into humans: immunological 
rejection, compatibility of the organs, and potential transmission of porcine viruses406. 
Programmable nuclease-directed genome engineering is being used to engineer porcine 
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cell lines and generate transgenic animals to investigate and improve their feasibility for 
xenotransplantation407, 408.   
Ever since the birth of the genome editing concept, the possibility of human 
germline editing has been debated. In earlier 2017, three research groups reported the use 
of CRISPR-Cas9 nucleases in human embryos for studying the gene function in early 
human embryogenesis409 or the correction of disease causing mutations in monogenic 
diseases410, 411. These proof-of-principle studies provide insight with regards to feasibility 
of the technique and potential challenges associated. Particularly, Ma et al. investigated the 
HDR efficacy and embryo mosaicism upon the co-injection of CRISPR-Cas9 nucleases 
and ssODN donor template either at the time of or after fertilization. The former approach 
reported to be more effective with regards to reducing mosaicism. Interestingly, the 
researchers argue that the HDR in human embryos is mainly templated from the non-
targeted allele rather than the exogenous donor supplied410. Although being 
controversial412, 413, if verified, inter-homologue templated HDR will have utility in 
therapeutic gene correction applications. Based on these studies, it is likely that more of 
therapeutic genome editing experiments in human embryos are underway. There are ethical 
concerns associated with human embryo genome editing which is discussed further in a 
later section 5.3.2. 
5.3.1 Limitations 
Despite the success of programmable nucleases, there are still hurdles that need to 
be overcome for therapeutic genome editing applications: (i) safety and toxicity, (ii) 
efficacy and control of editing outcome, (iii) and delivery.  
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 Nuclease-directed genome editing depends on creation of a site-specific double 
strand break in the genome and its repair via cellular machineries. The presence of DSBs 
at unintended genomic positions may result in confounding point mutations, chromosomal 
breaks and translocations. Therefore, the specificity of any nuclease platform must be 
thoroughly assessed prior to clinical application. The core work of this thesis is mainly 
focused on the specificity of CRISPR-Cas9 nucleases. As reviewed in Chapter 1, there are 
many methods to identify and reduce the off-target mutations produced by CRISPR-Cas9 
nucleases. At present, the prudent method for assessing off-target activities of Cas9 
nucleases involves a two-step verification: a genome-wide unbiased screening for 
identification of potential off-target sites in the cell type of interest, and their verification 
with targeted amplicon deep sequencing. The chimeric Cas9 platforms described in 
Chapters 2, 3 and 4 are of the most specific genome editing platforms available. Although 
their specificity needs to be verified in a therapeutically relevant system, the observed level 
of specificity of these nucleases should be sufficient for ex vivo therapeutic applications.  
Since the sensitivity level of the current deep sequencing methodologies is about 0.01%8, 
an advance in mutation detection levels is needed to fully assess the specificity of these 
nucleases for treating larger populations of cells for therapeutic use.  
Another remaining challenge is the efficient editing of the genomes of quiescent 
and post-mitotic cells. Previous research indicates that the activity of CRISPR-Cas 
nucleases is impacted by the chromatin accessibility of the target site414, 415. The effect of 
chromatin accessibility can be neglected for many dividing cells type due the changes in 
chromatin accessibility during the cell cycle. However, when targeting slow or non-
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dividing cells in a therapeutic setting, such as the long term progenitors within the bulk 
CD34+ HSPC population or differentiated neurons, the impact of chromatin accessibility 
on nuclease activity may be greater. In addition to the potential chromatin accessibility 
problems, driving HDR in these cells still stands as a barrier. 
Efficient delivery of the nucleases into target tissue and organs is as important as 
engineering functional nucleases. For ex vivo therapeutics, electroporation of the Cas9 
mRNA or RNP has proven to be effective213, 217. Additional optimization of parameters 
such as nuclear localization signal composition or additional RNA modifications may 
provide useful improvements. On the other hand, for in vivo therapeutics, nuclease delivery 
is still a problem. Adeno-associated viruses have being used in clinical gene therapy 
applications and offer advantageous features such as low rates of integration, cargo 
expression, and tropism to different tissues401. Yet, the relatively small cargo capacity of 
AAVs may limit their use for co-delivery of the components (including the HDR template) 
of genome editing. Nanoparticle-based non-viral delivery vectors239 or local delivery of the 
RNP416 can be promising but further assessment on their ability to transport the editing 
components to different tissues and organs is needed. 
Finally, another point related to the safety and the toxicity of these nucleases is 
immunogenicity. Either the viral delivery agents417 or the bacterial Cas9 protein itself may 
run into immune rejection by the host in an in vivo therapeutic setting. Instead of the 
continuous expression of the Cas9 protein and the sgRNA from viral expression cassette, 
the non-viral delivery (nanoparticles) of the Cas9 expressing mRNA and the sgRNA may 
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have advantageous. In such setting, the modifications to the Cas9 encoding mRNA and the 
sgRNA are needed to circumvent the host’s immune responses191, 239. 
5.3.2 Ethical concerns 
As the genome editing field advances, the debate over human genome editing 
applications is heating up. Two main aspects of human genome editing are particularly 
debated: medical use and personal enhancement (e.g. improved athletic ability). Recently, 
two surveys reported similar trends of public opinion on human genome editing418, 419. 
Although there is support for adult medical genome editing applications, there is opposition 
for adult enhancement genome editing applications. For human germline editing, there is 
weaker support—perhaps a neutral stand—for medical applications, yet strong rejection of 
enhancement applications418, 419. One of the surveys also points out that in vitro basic 
research on human embryo editing that does not culminate pregnancy is supported for 
continuation and public funding419. Manipulation of human embryos, even for medically 
relevant reasons is a delicate subject. There are two types of germline therapies in limited 
use: pre-implantation genetic diagnosis (PGD) and mitochondrial replacement therapy 
(MRT). The first report of PGD was almost three decades ago420. Following in vitro 
fertilization, PGD has been applied to screen and select embryos against monogenic 
disorders and cancer or for increased pregnancy changes and human leukocyte antigen 
matching savior siblings421. MRT is a relatively newer subject than PGD. If the mother has 
mitochondrial genetic disorder and the PGD is not a suitable option, MRT is appended to 
in vitro fertilization to use the mitochondrial DNA of a healthy donor422. In 2015, the 
United Kingdom became the first country where MRT is legal. Despite the ongoing debate, 
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embryo genome editing—once its safety is assured—is likely be allowed as a 
complementary therapeutic approach only to cases where pre-implantation genetic 
diagnosis and mitochondrial replacement therapies are not applicable and there is no 
conventional treatment option.  
5.3.3 Summary 
The future of genome editing is wide open; yet, there are challenges and concerns 
on the table. Up until this point, researchers have developed and tested the potential of 
programmable nucleases on eukaryotic genomes for various applications. There is growing 
interest in the biotechnology and pharmacology industry to direct these tools towards 
economically viable medical products and applications. Conversion of a working prototype 
into a complete reliable product requires effort, patience, and professionalism. Although 
the broad utility and wide potentials of genome editing is appealing to us (researchers), an 
untimed mistake at clinical level can lead to major setback if not a catastrophe for the field. 
Having regulations to control the pace of this conversion and is critical to build a reputation 
and gain public’s trust.  
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APPENDIX 
Appendix 1.1 Primer information for T7EI assays in Chapter II 
Target name 5p Oligo Sequence 3p Oligo Sequence 
LRTM2 CTAGAAAGGGTAAGTGCCCCCTTGT CCACAACTGTCACCTGTCCCTGG 
KANK3 CTGCACTCACCTCTGTGAGGCAGG GGAGTGGGGAGGAAGAGGGAACAG 
TGM2 GCGATGAATGTTGCTCATGTTCTGCTTC CTTCTGTGGACCCATCAGTGGTCTC 
PLXNB2 GACAGACATAGGATCTGGGAACTTGC GTAGCATCTTCCTCTGAGCAATACCG 
TS2 AGCCCAGAAGTTGGACGAAAAGT AGCCCCAGCTACCACCTCCT 
OT2-2 TCCTGTCACAATTCCCTGAACTC CTAAACTCTGACTGGGCCTCCA 
TS3 GTGTGCAGACGGCAGTCACTAGG CGTTCCCTCTTTGCTAGGAATATTGAAG 
OT3-2 TGTCATCGTTATCGCTCATTTCCTAC GCCGTCTGTTAGAGGGACAAGAACTA 
TS4 CTCAGTCTTCCCATCAGGCTCTCAG ACCCTAGTCATTGGAGGTGACATCG 
DNAJC6 CTTAAATATTCTGCCGCAGTTGG GAAAGCGGGTGAAAAGAAAGG 
PLXDC2 ATCCCGGTGGTTACTGTAGCTGT ATTGAAATTGCCCAGAAAACACA 
GPRC5B CGAGTCTTGTTTACACACGCAGA TTAAGGTTGAGAGTGGGCTGAAC 
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Appendix 1.2 Deep Sequencing primers used in Chapter II 
Target name 5p Oligo Sequence 
TS2 ctacacgacgctcttccgatctAGCCCAGAAGTTGGACGAAAAGT 
OT2-1 ctacacgacgctcttccgatctCTGTCCTCTCCACATCCTCTCTG 
OT2-2 ctacacgacgctcttccgatctAATATTCCTGGCCAAGTCGATTCC 
OT2-6 ctacacgacgctcttccgatctTTACTCTTGAGATTGGAACGGGAAA 
OT2-9 ctacacgacgctcttccgatctAAACAGCCAGAAGAGAACATCCAC 
OT2-15 ctacacgacgctcttccgatctAATTGGGCAAAGCAAAAACCAG 
OT2-17 ctacacgacgctcttccgatctTGCTGTCTAAACTTCCATTTCTCCA 
OT2-19 ctacacgacgctcttccgatctGAACCCCTAGCCCAAACTGAGATA 
OT2-23 ctacacgacgctcttccgatctGGCTCCTCGGTGCTCTGGTC 
OT2-24 ctacacgacgctcttccgatctCTCATCCTTGTATCAGCTGCCTTC 
TS2BZFP-OT1 ctacacgacgctcttccgatctACCACAGGAGTTCCGTCCTCTAAG 
TS2BZFP-OT2 ctacacgacgctcttccgatctCAGTCCCAATAACAGTGATTCCAT 
TS3 ctacacgacgctcttccgatctGTCTTCGAGAGTGAGGACGTGTG 
OT3-2 ctacacgacgctcttccgatctCTGCAGTGAGGAGGTGGTTCTT 
OT3-3 ctacacgacgctcttccgatctCTTTTCCTGTGGAACAACCAGAC 
OT3-4 ctacacgacgctcttccgatctCTGTGTACACTGGTGGGCAGGAG 
OT3-17 ctacacgacgctcttccgatctTTGCACAAATAGGCGCTTAATAAAT 
OT3-18 ctacacgacgctcttccgatctCATATCTGTCACCACACAGTTACCA 
OT3-19 ctacacgacgctcttccgatctATTGCGCGATCTTGAGTGAC 
OT3-20 ctacacgacgctcttccgatctGGAGAAGCAAGTACCTTCTTTACAA 
OT3-21 ctacacgacgctcttccgatctGCAGCCACACGACACTGAGG 
OT3-22 ctacacgacgctcttccgatctGTGTGCCTCGTTTGGCTTCT 
OT3-24 ctacacgacgctcttccgatctACAAATGGATGGGTGGGAGGTT 
OT3-29 ctacacgacgctcttccgatctCGTGGGGCTAAAGTTGTATATGTG 
OT3-30 ctacacgacgctcttccgatctGTAATGGGAGTAAGTGGACGTGTG 
OT3-39 ctacacgacgctcttccgatctCTTGGAGAAGGCAGCTCGTC 
VEGF3_New1 ctacacgacgctcttccgatctCCAGGGTCCCTTACTCCTTTTT 
VEGF3_New2 ctacacgacgctcttccgatctGCACTGGGGAAAGAGAAGAGAAG 
VEGF3_New3 ctacacgacgctcttccgatctTCCTCATAATTTATCAACAAACACAAA 
TS3ZFP-OT1 ctacacgacgctcttccgatctGCTTACTCCCAGTGTGGGGATG 
TS3ZFP-OT2 ctacacgacgctcttccgatctGACTGAGGGTGGAGGGGAAG 
TS3ZFP-OT3 ctacacgacgctcttccgatctGCTCCAGCACCTCAATTTCCTTC 
TS4 ctacacgacgctcttccgatctGCAGAAGCTGGAGGAGGAAGG 
OT4-1 ctacacgacgctcttccgatctAAGAATAGGGGCTTATGGCATGG 
OT4-2 ctacacgacgctcttccgatctTCCCCATCTTCCAGTTCCATAGC 
OT4-3 ctacacgacgctcttccgatctCCACTTGGAGAGTCAGAGGTCACA 
OT4-4 ctacacgacgctcttccgatctCATTCCTCCTGAGGGAAAATAAA 
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OT4-5 ctacacgacgctcttccgatctCAGCTCTGGCCTGGGAAAATA 
OT4-15 ctacacgacgctcttccgatctGTTGGGGTCATGTGTGGTCCT 
OT4-20 ctacacgacgctcttccgatctTTAGTGAGGAGCAGCTTTACAGG 
OT4-22 ctacacgacgctcttccgatctTACCAAACAGCCCAGTTTTCTCC 
OT4-26 ctacacgacgctcttccgatctACCGAGCTCAGGGTCTCTGC 
OT4-52 ctacacgacgctcttccgatctCAGAGGCTGAAGAGGAAGACCAG 
OT4-53 ctacacgacgctcttccgatctTGCAAATAGAGCCCTTTATTCAT 
TS4ZFP-OT1 ctacacgacgctcttccgatctCCAGCTTAGCGTTTGTTTTCCTG 
TS4ZFP-OT2 ctacacgacgctcttccgatctACTAGGGTGGGAGCCCAGAGAT 
Target name 3p Oligo Sequence 
TS2 agacgtgtgctcttccgatctAGCCCCAGCTACCACCTCCT 
OT2-1 agacgtgtgctcttccgatctATGGCCTATGGGTTGAAAACAGT 
OT2-2 agacgtgtgctcttccgatctCTGAAATGACCCCCAAGGGATAC 
OT2-6 agacgtgtgctcttccgatctCGTGAAACTCCACACTTATCTACGC 
OT2-9 agacgtgtgctcttccgatctTTGCTCTTTGTTGAGAGGGAAAGA 
OT2-15 agacgtgtgctcttccgatctCGGAGCTGTTTCTGCTGACTGT 
OT2-17 agacgtgtgctcttccgatctAACAGATGAGCCACAACCCTGTT 
OT2-19 agacgtgtgctcttccgatctTTTGTGCTGATCTGTGGGTATCCT 
OT2-23 agacgtgtgctcttccgatctGGAGTTAAGGGTGTCTCCGAGGT 
OT2-24 agacgtgtgctcttccgatctCTGCGCTCTTCTTTCCTCTTCAA 
TS2BZFP-OT1 agacgtgtgctcttccgatctGCCTCCAGGAGTGGGAGTGG 
TS2BZFP-OT2 agacgtgtgctcttccgatctAGGTAGCTGGGGGAGGCACT 
TS3 agacgtgtgctcttccgatctTCTATTGGAATCCTGGAGTGACC 
OT3-2 agacgtgtgctcttccgatctGGGAAGTCACCGACAACAACAAG 
OT3-3 agacgtgtgctcttccgatctCATGCATTCATGCACATATACCAC 
OT3-4 agacgtgtgctcttccgatctCCCATTTCTCCTTTGAGGTTCATC 
OT3-17 agacgtgtgctcttccgatctAGATAGCAGGTAAGGAGGGGTGTC 
OT3-18 agacgtgtgctcttccgatctGGAATCTAATGTATGGCATGGTG 
OT3-19 agacgtgtgctcttccgatctAGCAGCAGGAGCCTAGTACCAC 
OT3-20 agacgtgtgctcttccgatctCCCATGCTTTTCTTGTGATAGTGA 
OT3-21 agacgtgtgctcttccgatctGTCCACACACAGCGTCTTCC 
OT3-22 agacgtgtgctcttccgatctAATGGTGAAGACAAGCACCTCAT 
OT3-24 agacgtgtgctcttccgatctCATTGACCAATTCATTCACGCATC 
OT3-29 agacgtgtgctcttccgatctGAGGTTAAATCCCTCCTCCACAG 
OT3-30 agacgtgtgctcttccgatctTGGGTACAGCTGCAGACACAG 
OT3-39 agacgtgtgctcttccgatctAAAGGTGGAAAGCATGATGAGG 
VEGF3_New1 agacgtgtgctcttccgatctCAGGACAGAACACTTGGGTAAGTGAA 
VEGF3_New2 agacgtgtgctcttccgatctTTTGGTGATGCTTGTTCATGTTG 
VEGF3_New3 agacgtgtgctcttccgatctTTTATTTCCATGCATACAAACGTG 
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TS3ZFP-OT1 agacgtgtgctcttccgatctTAGATGCTGAAGTGGGCCTAGCA 
TS3ZFP-OT2 agacgtgtgctcttccgatctGCTCCAACACCTGACATTTTCCT 
TS3ZFP-OT3 agacgtgtgctcttccgatctCACTGGGGAGCTGTCGTACAGAA 
TS4 agacgtgtgctcttccgatctCATCGATGTCCTCCCCATTG 
OT4-1 agacgtgtgctcttccgatctTTTTTCTGAGGGCTGCTACCTG 
OT4-2 agacgtgtgctcttccgatctCAGCTTCCTGCAGTGAGAAAGGA 
OT4-3 agacgtgtgctcttccgatctCATTCATGGAGGGGCACAGAAG 
OT4-4 agacgtgtgctcttccgatctTGGTTTACATTTTATTAATGGCTTACA 
OT4-5 agacgtgtgctcttccgatctCACACCAGCAATGCTCTCGTC 
OT4-15 agacgtgtgctcttccgatctCTGCTTGACCAGGCCATTTGTA 
OT4-20 agacgtgtgctcttccgatctCCCATTTCTTCAAATCTCCTTGC 
OT4-22 agacgtgtgctcttccgatctTCACCTCCTTTATTGCAGATTGCT 
OT4-26 agacgtgtgctcttccgatctCAGAGACCTAGAAGCCAGCCAAT 
OT4-52 agacgtgtgctcttccgatctTTGGCCCCAGTCTCTCTTCTATG 
OT4-53 agacgtgtgctcttccgatctTGGCCTTTGTAGGAAAACACCA 
TS4ZFP-OT1 agacgtgtgctcttccgatctCTGGCTGAGGGCATAACTCAAG 
TS4ZFP-OT2 agacgtgtgctcttccgatctCATGTGCACACACACGTATTTCG 
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Appendix 1.3 Deep Sequencing primers used in Chapter III 
Target Site 5p Oligo Sequence 
PMPCA ctacacgacgctcttccgatctGAACTACTACACTCCCGACCG 
VEGFA_TS2 ctacacgacgctcttccgatctAGCCCAGAAGTTGGACGAAAAGT 
OTD_TS2_1 ctacacgacgctcttccgatctTGCAGCTGCCTCTGCCTCTA 
OTD_TS2_2 ctacacgacgctcttccgatctGATACCAGCATGGGCTACCCA 
OTD_TS2_3 ctacacgacgctcttccgatctACCCCTAGCCCAAACTGAGATATTAAC 
OTD_TS2_4 ctacacgacgctcttccgatctTTACTCTTGAGATTGGAACGGGAAATC 
OTD_TS2_5 ctacacgacgctcttccgatctCTGTCCTCTCCACATCCTCTCTG 
OTD_TS2_6 ctacacgacgctcttccgatctTGCTGTCTAAACTTCCATTTCTCCA 
OTD_TS2_7 ctacacgacgctcttccgatctGCAAAGCAAAAACCAGGGCCAG 
OTD_TS2_8 ctacacgacgctcttccgatctGAGTTCCCAACCTTTTTGACACTAG 
OTD_TS2_9 ctacacgacgctcttccgatctCAGAGCAGCATCTGCTATTTC 
OTD_TS2_10 ctacacgacgctcttccgatctCTCCTGAGCAAATGGCAAAC 
OTD_TS2_11 ctacacgacgctcttccgatctTCCAGGACCTGAGATTCCATT 
OTD_TS2_12 ctacacgacgctcttccgatctGGGACAGAAACAAGCCCTTT 
OTD_TS2_13 ctacacgacgctcttccgatctAAACAAATGAGAGAGCATACCTG 
OTD_TS2_14 ctacacgacgctcttccgatctGAGTGCAGTGGCACGATCT 
OTD_TS2_15 ctacacgacgctcttccgatctTCTCGTGGAAGTGAATGAGG 
OTD_TS2_16 ctacacgacgctcttccgatctAATCACTGTGCTCTCCCT 
VEGFA_TS3 ctacacgacgctcttccgatctGTCTTCGAGAGTGAGGACGTGTG 
OTD_TS3_1 ctacacgacgctcttccgatctTGCAGTGAGGAGGTGGTTCTTG 
OTD_TS3_2 ctacacgacgctcttccgatctTGTCACCACACAGTTACCACCTT 
OTD_TS3_3 ctacacgacgctcttccgatctACACTGGTGGGCAGGAGCA 
OTD_TS3_4 ctacacgacgctcttccgatctGTGTTCTCATGAGATCTGATGGT 
OTD_TS3_5 ctacacgacgctcttccgatctTCTCCACCATGCCTCTGGCAT 
OTD_TS3_6 ctacacgacgctcttccgatctCAGCCGGCTTTGTAGCTTTT 
OTD_TS3_7 ctacacgacgctcttccgatctACTGCAGGCAAGCTGTCAAG 
OTD_TS3_8 ctacacgacgctcttccgatctTGCCCCCAGGAGAGTGGCT 
OTD_TS3_9 ctacacgacgctcttccgatctGCCAAGATCACGCCATTTGCACT 
OTD_TS3_10 ctacacgacgctcttccgatctGCCAAGGGTATTCATAAATTCTTC 
OTD_TS3_11 ctacacgacgctcttccgatctGACCATATATAGAGACCATATATATAGAC 
OTD_TS3_12 ctacacgacgctcttccgatctTGACGAGGACCCTGGAG 
OTD_TS3_13 ctacacgacgctcttccgatctGGCAATTATTCTGTCAAGATTTTAAAGG 
OTD_TS3_15 ctacacgacgctcttccgatctACCGAGGAGGTGGGGGTGT 
OTD_TS3_16 ctacacgacgctcttccgatctATGGAATAGTTTATTCGTGTGTGT 
OTD_TS3_17 ctacacgacgctcttccgatctCATTCTGCTGTTGTGAGACTTAT 
OTD_TS3_18 ctacacgacgctcttccgatctGACCACATCCAGTGCCTGA 
OTD_TS3_19 ctacacgacgctcttccgatctGTCTCTTGGGAGTGGTTTTGAGCA 
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OTD_TS3_20 ctacacgacgctcttccgatctTTGGAATTTTGGGCTTTATATTTGA 
OTD_TS3_21 ctacacgacgctcttccgatctTCACGTGATCCTCCCCTTTCAGAC 
OTD_TS3_22 ctacacgacgctcttccgatctTCACTTGAGCTCACAGGTTTG 
OTD_TS3_24 ctacacgacgctcttccgatctGAGTAGGAAAGGTATGTCTTGTTCCT 
Target Site 3p Oligo Sequence 
PMPCA agacgtgtgctcttccgatctAGTGTACTGGGCCACAGATCTG 
VEGFA_TS2 agacgtgtgctcttccgatctAGCCCCAGCTACCACCTCCT 
OTD_TS2_1 agacgtgtgctcttccgatctACTATTGCACACCTGGGTCCT 
OTD_TS2_2 agacgtgtgctcttccgatctAATATTCCTGGCCAAGTCGATTCC 
OTD_TS2_3 agacgtgtgctcttccgatctGTGCTGATCTGTGGGTATCCTTTTTAG 
OTD_TS2_4 agacgtgtgctcttccgatctTGCAACTTAACTTACGTGAAACTCCACA 
OTD_TS2_5 agacgtgtgctcttccgatctATGGCCTATGGGTTGAAAACAGT 
OTD_TS2_6 agacgtgtgctcttccgatctAACAGATGAGCCACAACCCTGTT 
OTD_TS2_7 agacgtgtgctcttccgatctAGCTGTTTCTGCTGACTGTCGGT 
OTD_TS2_8 agacgtgtgctcttccgatctAAATGTAATGTGCTCGAATCATCCT 
OTD_TS2_9 agacgtgtgctcttccgatctGCACAATGATTGGTCATCTGTTA 
OTD_TS2_10 agacgtgtgctcttccgatctGTTCTGGGCTGGACACTGAG 
OTD_TS2_11 agacgtgtgctcttccgatctGACAAGCTGCCAGGAACAAA 
OTD_TS2_12 agacgtgtgctcttccgatctTGGCACCATAGGCATAATCTG 
OTD_TS2_13 agacgtgtgctcttccgatctGGGATGCTTGAAGATGGAAAG 
OTD_TS2_14 agacgtgtgctcttccgatctTAGCCTGGCATAGTGGTGGT 
OTD_TS2_15 agacgtgtgctcttccgatctCAGTCGACAGTGACACAATTC 
OTD_TS2_16 agacgtgtgctcttccgatctCGGATAAGATGGTCTTGGATTG 
VEGFA_TS3 agacgtgtgctcttccgatctTCTATTGGAATCCTGGAGTGACC 
OTD_TS3_1 agacgtgtgctcttccgatctGAAGTCACCGACAACAACAAGCC 
OTD_TS3_2 agacgtgtgctcttccgatctGGGAATCTAATGTATGGCATGG 
OTD_TS3_3 agacgtgtgctcttccgatctCATTTCTCCTTTGAGGTTCATC 
OTD_TS3_4 agacgtgtgctcttccgatctAGGCCTCGGGAAACTTACAATCATG 
OTD_TS3_5 agacgtgtgctcttccgatctCAGAGATGTGTGGCTGTGTCA 
OTD_TS3_6 agacgtgtgctcttccgatctGAACAAGCTGCTGGCTTTCC 
OTD_TS3_7 agacgtgtgctcttccgatctACACACCCACACACCCTCAC 
OTD_TS3_8 agacgtgtgctcttccgatctCTCATCAGTGCTGTGTTCGCCT 
OTD_TS3_9 agacgtgtgctcttccgatctGGAAGAAGATCAACTAAGCAGTTATAAGC 
OTD_TS3_10 agacgtgtgctcttccgatctGTATCTGTCTCTGTCTCTCTCTCC 
OTD_TS3_11 agacgtgtgctcttccgatctAGTGCCATGCTATTTACATTCTGTCT 
OTD_TS3_12 agacgtgtgctcttccgatctCTCGGGACAGGCAAGTT 
OTD_TS3_13 agacgtgtgctcttccgatctGGCAACTTCCAACTCTTTATTTCCGA 
OTD_TS3_15 agacgtgtgctcttccgatctCCTACCTGGTGGCCCTGTG 
OTD_TS3_16 agacgtgtgctcttccgatctGAAGGAAGTTCTCAGGACACACAAG 
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OTD_TS3_17 agacgtgtgctcttccgatctGTACATTGACTGAAATAAGGATGGT 
OTD_TS3_18 agacgtgtgctcttccgatctCTCGCATGGCACACTCAG 
OTD_TS3_19 agacgtgtgctcttccgatctGAAAGTTCACTCTGGCCCCAGTG 
OTD_TS3_20 agacgtgtgctcttccgatctAGTACCCAACAATGCCCATATC 
OTD_TS3_21 agacgtgtgctcttccgatctGCTGAGGCTGGAGCATTGTTTGAG 
OTD_TS3_22 agacgtgtgctcttccgatctCTCAAGCAATCCTCCCTCAA 
OTD_TS3_24 agacgtgtgctcttccgatctAGTCAAAAGGTCATTTGCAGGGTC 
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Appendix 1.4 Deep Sequencing primers used in Chapter IV 
Target Site Sequence 
5p_DS_OT_B7_1 ctacacgacgctcttccgatctTGTAAAATGCACACAAGGTTCG 
5p_DS_OT_B7_2 ctacacgacgctcttccgatctGACAGAGCTTTCAGGCCAACA 
5p_DS_OT_B7_3 ctacacgacgctcttccgatctTCAGCCAACCGTAAGACTCAGA 
5p_DS_OT_B7_4 ctacacgacgctcttccgatctACCAATTCAGGGATGGTGAGG 
5p_DS_OT_B7_5 ctacacgacgctcttccgatctATTCCATCATGCTGCCTCCTT 
5p_DS_OT_B7-10_1 ctacacgacgctcttccgatctTCCTTAGATTGTTTTCTTCCTCATGTT 
5p_DS_OT_B7-10_2 ctacacgacgctcttccgatctAAAGGAGGACCAGAGGTGGACT 
5p_DS_OT_B7-10_3 ctacacgacgctcttccgatctCCTCAAAAAGGAAGGAACTGGA 
5p_DS_OT_B7-10_4 ctacacgacgctcttccgatctAATATTTGCTGACGGCCTTCTC 
5p_DS_OT_B7-10_5 ctacacgacgctcttccgatctGCCTCCCAAAGTGTTGGATTT 
5p_DS_OT_B9_1 ctacacgacgctcttccgatctCCTGGCTAATACTTTGGGGAGT 
5p_DS_OT_B9_2 ctacacgacgctcttccgatctGTGGACTGCATCTCAGGAAAGA 
5p_DS_OT_B9_3 ctacacgacgctcttccgatctAGCTGATCAATCCCCAATGTCT 
5p_DS_OT_B9_4 ctacacgacgctcttccgatctGCACTGCTCTTTGGAAAACTACC 
5p_DS_OT_B9_5 ctacacgacgctcttccgatctTGGAACACAGGTCTTCCTACCC 
5p_DS_OT_B9_6 ctacacgacgctcttccgatctGAAGAGGTGGAAGGTGCTGCT 
5p_DS_OT_B9_7 ctacacgacgctcttccgatctGCTGATCAATCCCCAATGTCTC 
5p_DS_OT_B9_8 ctacacgacgctcttccgatctCGTGTGTGAAAGCCATGTTGA 
5p_DS_OT_B9_9 ctacacgacgctcttccgatctCAGGACCACAGTCCTCTGCTG 
5p_DS_OT_B9_10 ctacacgacgctcttccgatctTGGATTTTCCATTTGAAGCACA 
5p_DS_OT_B10_1 ctacacgacgctcttccgatctCATGTGTTCATTGACATACAGGACA 
5p_DS_OT_B10_2 ctacacgacgctcttccgatctTCAGGCTGCTTGACCTTTCTG 
5p_DS_OT_B10_3 ctacacgacgctcttccgatctGCCACATTTTCTGAAGCATCC 
5p_DS_OT_B10_4 ctacacgacgctcttccgatctGTGAGGGGAGATGGAATCGAG 
5p_DS_OT_B10_5 ctacacgacgctcttccgatctGGGTGGTTTTCTCATCCCACT 
5p_DS_OT_B11_1 ctacacgacgctcttccgatctCTCAGTGGCAGCAGATCCTGT 
5p_DS_OT_B11_2 ctacacgacgctcttccgatctTCTCCATTTTCTAAGCGCAACA 
5p_DS_OT_B11_3 ctacacgacgctcttccgatctAGCAGATATGGGACCTGAAAGG 
5p_DS_OT_B11_4 ctacacgacgctcttccgatctACTCATGCTTGTTTTGGGAGGA 
5p_DS_OT_B11_5 ctacacgacgctcttccgatctTTAGGTACCCCTGTGAATAAATCC 
5p_DS_OT_B11_6 ctacacgacgctcttccgatctCCATTTGTGTCCTTCTCTCTCA 
5p_DS_OT_B11_7 ctacacgacgctcttccgatctATGTGGCCAAGAGAGCACCT 
5p_DS_OT_B11_8 ctacacgacgctcttccgatctCAGTCTGGTCTCAGCTTTGGTC 
5p_DS_OT_B11_9 ctacacgacgctcttccgatctGCAGGGATGGAAAAGAGAAGAC 
5p_DS_OT_B11_10 ctacacgacgctcttccgatctAGCCAAGGAGAAATTGAGGTGA 
5p_DS_OT3-4 ctacacgacgctcttccgatctACACTGGTGGGCAGGAGCA 
5p_DS_OT3-18 ctacacgacgctcttccgatctTGTCACCACACAGTTACCACCTT 
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5p_DS_OT3-20 ctacacgacgctcttccgatctTCATGGAAGAATGCAAAGGAGA 
5p_DS_OT3-2 ctacacgacgctcttccgatctTGCAGTGAGGAGGTGGTTCTTG 
5p_DS_OT3-3 ctacacgacgctcttccgatctTTCCTGTGGAACAACCAGACAC 
5p_DS_OT3_Sp_new ctacacgacgctcttccgatctTTTGAAGTCCGTGCTTGAATGA 
5p_DS_OT3-21 ctacacgacgctcttccgatctGCCAGCACCCTTGACGTCTG 
5p_DS_OTD3-6 ctacacgacgctcttccgatctACAAGCTGCTGGCTTTCCTAAG 
5p_DS_OT3-1 ctacacgacgctcttccgatctACTGCAGGCAAGCTGTCAAG 
5p_DS_OT3-17 ctacacgacgctcttccgatctGGAAGTGCCTTGCACAAATAGG  
3p_DS_OT_B7_1 agacgtgtgctcttccgatctCGGACAGTGAGGAGGATAGGAC 
3p_DS_OT_B7_2 agacgtgtgctcttccgatctCATTTGGGCTTGATGCTTGAG 
3p_DS_OT_B7_3 agacgtgtgctcttccgatctTTTGCCAATCTGAAGGTCCAA 
3p_DS_OT_B7_4 agacgtgtgctcttccgatctGGTGCCTTTCACACTGTGGATAC 
3p_DS_OT_B7_5 agacgtgtgctcttccgatctACACTGAAGGAAGCCCTGCAC 
3p_DS_OT_B7-10_1 agacgtgtgctcttccgatctGGCCATCAGTCATCTGCAATTT 
3p_DS_OT_B7-10_2 agacgtgtgctcttccgatctACCATGGCTCTGATGATACCAA 
3p_DS_OT_B7-10_3 agacgtgtgctcttccgatctAGCATTAGACTCTGGGCTGAGG 
3p_DS_OT_B7-10_4 agacgtgtgctcttccgatctAAACGCCTTCTTTCTTCACCTG 
3p_DS_OT_B7-10_5 agacgtgtgctcttccgatctTGGCCATGTTTAGAATTGAAGAGA 
3p_DS_OT_B9_1 agacgtgtgctcttccgatctCCCCAGAGTCACTCAAACAACA 
3p_DS_OT_B9_2 agacgtgtgctcttccgatctACACTCCAGGAGGCAGTTAAGG 
3p_DS_OT_B9_3 agacgtgtgctcttccgatctGAGGATTTCATCATGCTGGTTG 
3p_DS_OT_B9_4 agacgtgtgctcttccgatctGCAGGGGAGTTTGGTGTACATT 
3p_DS_OT_B9_5 agacgtgtgctcttccgatctGTAAGGATCTTGCTCCCCACAG 
3p_DS_OT_B9_6 agacgtgtgctcttccgatctCAACAGGGGCATGGAGAACT 
3p_DS_OT_B9_7 agacgtgtgctcttccgatctGGATTTCATCATGCTGGTTGG 
3p_DS_OT_B9_8 agacgtgtgctcttccgatctGGCCATGGTCAAAACCCTTAT 
3p_DS_OT_B9_9 agacgtgtgctcttccgatctCTCCTGGCACTGCTGCTGCT 
3p_DS_OT_B9_10 agacgtgtgctcttccgatctCCAGGAAGAGTTTGGTTTTCC 
3p_DS_OT_B10_1 agacgtgtgctcttccgatctCCTTTCCACCTGTAAGCACAGA 
3p_DS_OT_B10_2 agacgtgtgctcttccgatctCAAGAAGGGTGGTAGGGATGG 
3p_DS_OT_B10_3 agacgtgtgctcttccgatctTTGTTCAATGAAAGAGAACCCACA 
3p_DS_OT_B10_4 agacgtgtgctcttccgatctTCCTGCATCTGAACCCACATT 
3p_DS_OT_B10_5 agacgtgtgctcttccgatctCTGCAGTGGACCAGTTGTGC 
3p_DS_OT_B11_1 agacgtgtgctcttccgatctAAATGACTGAAGCCCAAACTCC 
3p_DS_OT_B11_2 agacgtgtgctcttccgatctCCCAGCTGCTCTTTCTTTTCTC 
3p_DS_OT_B11_3 agacgtgtgctcttccgatctCAGGGTCATTGGTGAGTCAGAG 
3p_DS_OT_B11_4 agacgtgtgctcttccgatctTTTCCCAGCACACCATATAGGA 
3p_DS_OT_B11_5 agacgtgtgctcttccgatctAACCCAGTGGTAATTGAGCAAA 
3p_DS_OT_B11_6 agacgtgtgctcttccgatctCCCTGGCTATGTTTCTGTCGAT 
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3p_DS_OT_B11_7 agacgtgtgctcttccgatctCCCTTCCTTGCATTAATGGATTT 
3p_DS_OT_B11_8 agacgtgtgctcttccgatctGTTACTTCTGGGCCCATTTCTG 
3p_DS_OT_B11_9 agacgtgtgctcttccgatctTTAGACGGCTTCAAGGTCATGT 
3p_DS_OT_B11_10 agacgtgtgctcttccgatctGGGAGGGAAGAGTCTGAGGAG 
3p_DS_OT3-4 agacgtgtgctcttccgatctCATTTCTCCTTTGAGGTTCATC 
3p_DS_OT3-18 agacgtgtgctcttccgatctGGGAATCTAATGTATGGCATGG 
3p_DS_OT3-20 agacgtgtgctcttccgatctCCCCATGCTTTTCTTGTGATAG 
3p_DS_OT3-2 agacgtgtgctcttccgatctGAAGTCACCGACAACAACAAGCC 
3p_DS_OT3-3 agacgtgtgctcttccgatctACACAGAGACACCCCACACACT 
3p_DS_OT3_Sp_new agacgtgtgctcttccgatctCCCAACACCTACATCTACCCACA 
3p_DS_OT3-21 agacgtgtgctcttccgatctCGAATTCCGTCCACACACAG 
3p_DS_OTD3-6 agacgtgtgctcttccgatctGGTGAGGAGCAACGAGACGTTA 
3p_DS_OT3-1 agacgtgtgctcttccgatctACACACCCACACACCCTCAC 
3p_DS_OT3-17 agacgtgtgctcttccgatctGTTGGTTTGGAAGGCTGTCATT 
 
  
   212 
Appendix 2.1 GUIDE-seq data in Chapter 2 
SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
mismatch
es 
chromo
some 
Stra
nd Start 
Peak 
Score 
OTG2
-1 
CTGCCCCCCCACCC
CGCCACTGG 
CTG....C....
......A. 5 chrX + 
14993
2511 133 
OTG2
-2 
GCCCCCACCCACCC
CGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
552 114 
OTG2
-3 
GGGCCCCTCCACCC
CGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
476 108 
OTG2
-4 
ATTCCCCCCCACCC
CGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4589 88 
OTG2
-5 
CTACCCCTCCACCC
CGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
01 76 
OTG2
-6 
TGCCCCCCCCACCC
CACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
422 60 
OTG2
-7 
TACCCCCCACACCC
CGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
45 54 
TS2 
GACCCCCTCCACCC
CGCCTCCGG 
............
........ 0 chr6 - 
43738
555 47 
OTG2
-8 
GACCCCCCCCACCC
CGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
100 45 
OTG2
-9 
TGCCCCTCCCACCC
CGCCTCTGG 
TG....TC....
........ 4 chr17 - 
40044
750 45 
OTG2
-10 
ACACCCCCCCACCC
CGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9642 40 
OTG2
-11 
TGCCCCCCCCACCC
CGCCCCCGG 
TG.....C....
......C. 4 chrX + 
12904
0623 37 
OTG2
-12 
CCGCCCCTCCACCC
CGCCACTGG 
CCG.........
......A. 4 chr17 - 
55740
522 28 
OTG2
-13 
ATCCCCCTCCACCC
CACCCCTGG 
AT..........
...A..C. 4 chr11 + 
12308
917 27 
OTG2
-14 
GACCCCTCCCACCC
CGACTCCGG 
......TC....
....A... 3 chr9 + 
27338
857 25 
OTG2
-15 
GCTTCCCTCCACCC
CGCATCCGG 
.CTT........
.....A.. 4 chr11 + 
71948
787 25 
OTG2
-16 
CCTCCCCCACACCC
CGCATCCGG 
CCT....CA...
.....A.. 6 chr1 + 
15103
1868 24 
OTG2
-17 
TACCCCCCCCACCC
CGCCACAGG 
T......C....
......A. 3 chr11 + 
13948
353 22 
OTG2
-18 
CCCCCCCCCCCCCC
CGCCTCAGG 
CC.....C..C.
........ 4 chr13 - 
10054
6982 22 
OTG2
-19 
AGGCCCCCACACCC
CGCCTCAGG 
AGG....CA...
........ 5 chr4 + 
14962
40 21 
OTG2
-20 
CTCCCCCTCCACCC
CACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
820 21 
OTG2
-21 
CTCCCCCGCCACCC
CGCCCCAGG 
CT.....G....
......C. 4 chr17 - 
16954
845 18 
OTG2
-22 
AGCCCCCACCTCCC
CGCCTCGGG 
AG.....A..T.
........ 4 chr22 + 
43684
478 18 
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OTG2
-23 
GTACCCCACCACCC
CGCCCCAGG 
.TA....A....
......C. 4 chr8 + 
14482
2944 18 
OTG2
-24 
ACCCCCCCCCGCCC
CGCCCCCGG 
AC.....C..G.
......C. 5 chr11 + 
73458
481 17 
OTG2
-25 
CCACCCCCCCACCC
CGCCCCTGG 
CCA....C....
......C. 5 chr20 - 
10913
954 16 
OTG2
-26 
CTCCCCACCCACCC
CGCCTCAGG 
CT....AC....
........ 4 chr4 + 
38537
610 15 
OTG2
-27 
CCACCCCCCCACCC
CGCCCCAGG 
CCA....C....
......C. 5 chr2 + 
17057
3333 15 
OTG2
-28 
GTCCCCCTCCTCCC
CACCTCCGG 
.T........T.
...A.... 3 chrX + 
15283
7111 14 
OTG2
-29 
GACTCCCTCCGCCC
CGCTTCCAG 
...T......G.
.....T.. 3 chr5 + 
17958
8285 13 
OTG2
-30 
CTACCCCTCCACCC
CGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
343 12 
OTG2
-31 
CCCCCCCCCCACCC
CGCCCCCGG 
CC.....C....
......C. 4 chr2 - 
12924
4195 7 
OTG2
-32 
GCCCCCCACCACCC
CACCTCGGG 
.C.....A....
...A.... 3 chr19 + 
13122
171 6 
OTG2
-33 
CCCCCCCACCACCC
CGCCCCGGG 
CC.....A....
......C. 4 chr8 - 
18041
539 6 
OTG2
-34 
GACCCCCCCCACCC
CACCCCAGG 
.......C....
...A..C. 3 chr6 + 
26470
606 6 
OTG2
-35 
CCCCACCCCCACCC
CGCCTCAGG 
CC..A..C....
........ 4 chr10 - 
11629
4249 5 
OTG2
-36 
TACCCCCTCCACCC
CCCTCCAGG 
T...........
...C.TC. 4 chr17 + 
30391
257 4 
OTG2
-37 
GTCCCCTCCCACCC
CGCCTCCAG 
.T....TC....
........ 3 chr14 + 
90403
304 4 
OTG2
-38 
GACCCCTCACACCC
CGCCCCTGG 
......TCA...
......C. 4 chr7 - 
95319
670 4 
OTG2
-39 
CCCCCACCCCACCC
CGCCTCCAG 
CC...A.C....
........ 4 chr9 + 
13066
3069 4 
OTG2
-40 
GACCCTCCCCACCC
CACCCCTGG 
.....T.C....
...A..C. 4 chr1 + 
22609
3591 4 
OTG2
-41 
CATACCCCCCACCC
CGCCCCGGG 
C.TA...C....
......C. 5 chr4 - 
88419
10 3 
TS3 
GGTGAGTGAGTGTG
TGCGTGTGG 
............
........ 0 chr6 + 
43737
454 64 
OTG3
-1 
TGTGGGTGAGTGTG
TGCGTGAGG 
T...G.......
........ 2 chr5 + 
11543
4659 38 
OTG3
-2 
AGTGAGTGAGTGTG
TGTGTGGGG 
A...........
....T... 2 chr14 - 
65102
435 26 
OTG3
-3 
GGTGAGTGAGTGTG
TGTGTGAGG 
............
....T... 1 chr14 + 
10602
9015 18 
OTG3
-4 
AGAGAGTGAGTGTG
TGCATGAGG 
A.A.........
.....A.. 3 chr5 - 
89440
962 7 
OTG3
-5 
AGTGAGTGAGTGTG
AGTGCGGGG 
A...........
..A.T.C. 4 chr8 - 
67579
421 6 
OTG3
-6 
TGTGAGTGAGTGTG
TGTGTGTGA 
T...........
....T... 2 chr8 - 
22932
496 5 
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SpCas9MT3-ZFP 
Name Sequence 
Alignment to 
target 
# of 
mismatch
es 
chromo
some 
Stra
nd Start 
Peak 
Score 
OTG2
-3 
GGGCCCCTCCACCC
CGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
476 26 
OTG2
-5 
CTACCCCTCCACCC
CGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
01 7 
TS2 
GACCCCCTCCACCC
CGCCTCCGG 
............
........ 0 chr6 - 
43738
555 27 
OTG2
-10 
ACACCCCCCCACCC
CGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9642 2 
OTG2
-20 
CTCCCCCTCCACCC
CACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
820 2 
TS3 
GGTGAGTGAGTGTG
TGCGTGTGG 
............
........ 0 chr6 + 
43737
454 53 
OTG3
-2 
AGTGAGTGAGTGTG
TGTGTGGGG 
A...........
....T... 2 chr14 - 
65102
435 1 
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Appendix 2.2 GUIDE-seq data in Chapter 3 
SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 128 
OTD_TS
2_1 
CTGCCCCCCCACC
CCGCCACTGG 
CTG....C....
......A. 5 chrX + 
14993
2512 448 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 353 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 354 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 323 
OTD_TS
2_5 
GACCCCCCCCACC
CCGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
101 206 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 202 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 170 
OTD_TS
2_8 
TGCCCCCCCCACC
CCACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
423 146 
OTD_TS
2_9 
TGCCCCCTCCACC
CCACCTCTGA 
TG..........
...A.... 3 chr6 + 
11052
1018 17 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 14 
  
GCCCCCACCCACC
CCGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
553 174 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 43 
  
CCCCCCCCCCCCC
CCGCCTCAGG 
CC.....C..C.
........ 4 chr13 - 
10054
6983 149 
  
CTCCCCACCCACC
CCGCCTCAGG 
CT....AC....
........ 4 chr4 + 
38537
611 67 
  
CCCCCCCCCCACC
CCGCCCTCGG 
CC.....C....
......CT 5 chr11 + 
19798
641 8 
  
TACCCCCCCCACC
CCGCCACAGG 
T......C....
......A. 3 chr11 + 
13948
354 133 
  
TGCCCCCCCCACC
CCGCCCCCGG 
TG.....C....
......C. 4 chrX + 
12904
0624 120 
  
CCGCCCCTCCACC
CCGCCACTGG 
CCG.........
......A. 4 chr17 - 
55740
523 108 
  
TGCCCCTCCCACC
CCGCCTCTGG 
TG....TC....
........ 4 chr17 - 
40044
751 97 
  
GACCCCTCCCACC
CCGACTCCGG 
......TC....
....A... 3 chr9 + 
27338
858 92 
  
GTACCCCACCACC
CCGCCCCAGG 
.TA....A....
......C. 4 chr8 + 
14482
2945 84 
  
GCTTCCCTCCACC
CCGCATCCGG 
.CTT........
.....A.. 4 chr11 + 
71948
788 77 
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CCCCCCCCCCACC
CCGCCCCCGG 
CC.....C....
......C. 4 chr2 - 
12924
4196 67 
  
ATCCCCCTCCACC
CCACCCCTGG 
AT..........
...A..C. 4 chr11 + 
12308
918 65 
  
ACCCCCCCCCGCC
CCGCCCCCGG 
AC.....C..G.
......C. 5 chr11 + 
73458
481 58 
  
ACCCCCCCCCCCC
CCGCCCCCGG 
AC.....C..C.
......C. 5 chr2 + 
24857
577 47 
  
CAACCCCCCCACC
CCGCTTCAGG 
C.A....C....
.....T.. 4 chr3 + 
14039
8784 47 
  
CCACCCCCCCACC
CCGCCCCTGG 
CCA....C....
......C. 5 chr20 - 
10913
955 41 
  
CACTCCCCCCACC
CCGCCCCAGG 
C..T...C....
......C. 4 chr9 - 
12613
8175 41 
  
GGACCCTCCCACC
CCACCTCAAG 
.GA...TC....
...A.... 5 chr13 - 
10062
1456 40 
  
AGGCCCCCACACC
CCGCCTCAGG 
AGG....CA...
........ 5 chr4 + 
14962
41 39 
  
CCACCCCCCCACC
CCGCCCCAGG 
CCA....C....
......C. 5 chr2 + 
17057
3334 35 
  
GACCCCCCCCACC
CCACCCCAGG 
.......C....
...A..C. 3 chr6 + 
26470
607 33 
  
CTCCCCCGCCACC
CCGCCCCAGG 
CT.....G....
......C. 4 chr17 - 
16954
846 27 
  
CATACCCCCCACC
CCGCCCCGGG 
C.TA...C....
......C. 5 chr4 - 
88419
11 27 
  
GACCCCTCCCTCC
CCACCTCAGG 
......TC..T.
...A.... 4 chr1 - 
51442
186 26 
  
AAGACCCCCCACC
CCGCCCCAGG 
A.GA...C....
......C. 5 chr19 + 
45952
038 26 
  
CCCCCCCCCCCCC
CCGCCTCCGG 
CC.....C..C.
........ 4 chr22 + 
50884
786 26 
  
CCCCACCCCCACC
CCGCCTCAGG 
CC..A..C....
........ 4 chr10 - 
11629
4250 25 
  
CTACCCCCACTCC
CCGCCTCCGG 
CTA....CA.T.
........ 6 chr10 + 
10282
1501 24 
  
TCCACCCCCCACC
CCGCCCCGGG 
TC.A...C....
......C. 5 chr7 + 
10493
3939 24 
  
GACCCCTCACACC
CCGCCCCTGG 
......TCA...
......C. 4 chr7 - 
95319
671 22 
  
GTCCCTCCCCACC
CCGCCTTGGG 
.T...T.C....
.......T 4 chr22 + 
40102
384 21 
  
GCCCCCCACCACC
CCACCTCGGG 
.C.....A....
...A.... 3 chr19 + 
13122
172 20 
  
CGCCCTCCCCACC
CCGCCTCCGG 
CG...T.C....
........ 4 chr10 + 
13514
9931 19 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr20 - 
35991
127 19 
  
GACCCCACCCACC
CCGCCGCAGG 
......AC....
......G. 3 chr12 + 
13252
9350 17 
  
AGCCCCCCCCTCC
CCGCCCCAGG 
AG.....C..T.
......C. 5 chr14 + 
10460
1192 16 
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CTCCCCCCCCACC
CCGTCCCCGG 
CT.....C....
....T.C. 5 chr2 - 
12907
7573 16 
  
CACCCCCCCCCCC
CCGCCCCCGG 
C......C..C.
......C. 4 chr17 + 
79881
137 15 
  
GGACCCCCCCCCC
CCGCCCCCGG 
.GA....C..C.
......C. 5 chr3 - 
13187
297 15 
  
GCCCCCCCCCACC
CCGCAGCTGG 
.C.....C....
.....AG. 4 chr7 - 
11179
73 15 
  
GGACCCCGACGCC
CCGCCTCAGG 
.GA....GA.G.
........ 5 chr3 - 
31574
996 14 
  
CAGTCCCCCCACC
CCACCTCTGG 
C.GT...C....
...A.... 5 chr10 + 
72538
201 13 
  
CATCCCCCCCACC
CCACCCCGGG 
C.T....C....
...A..C. 5 chr11 - 
46141
849 13 
  
ACACCCCCCCACC
CCACCCCAGG 
ACA....C....
...A..C. 6 chr2 - 
22153
5826 12 
  
AGCCCCCACCTCC
CCGCCTCGGG 
AG.....A..T.
........ 4 chr22 + 
43684
479 12 
  
CTCACCCCCCACC
CCACCTCTGG 
CT.A...C....
...A.... 5 chr11 - 
26862
43 11 
  
ACCCCCCCCCCAC
CCGCCCCCGG 
AC.....C..CA
......C. 6 chr6 - 
27382
04 11 
  
GACCCTGTCCACC
CCACCTCAGG 
.....TG.....
...A.... 3 chr1 + 
87532
1 10 
  
GACCCGCCCCGCC
CCGCCTCTGG 
.....G.C..G.
........ 3 chr1 + 
11714
529 10 
  
GACCCTCCCCACC
CCACCCCTGG 
.....T.C....
...A..C. 4 chr1 + 
22609
3591 10 
  
AGGCCCCCCCGCC
CCGCCTCAGG 
AGG....C..G.
........ 5 chr11 - 
37466
1 10 
  
CCCCCCCACCACC
CCGCCCCGGG 
CC.....A....
......C. 4 chr8 - 
18041
540 10 
  
GGCCCTCTCCACT
CCACCTCAGG 
.G...T......
T..A.... 4 chr1 - 
17873
8721 9 
  
AACCTCCCCCACC
CCACCCCAGG 
A...T..C....
...A..C. 5 chr17 - 
46103
841 9 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr21 + 
47440
541 9 
  
GCCGCCCCCCACT
CCGCCTCCGG 
.C.G...C....
T....... 4 chr4 - 
14376
7367 9 
  
CCCCCCCCCCACC
CCGCCCCGAG 
CC.....C....
......C. 4 chr12 + 
22487
644 8 
  
CTCCCCCCCCTCC
CCGCCTCGGG 
CT.....C..T.
........ 4 chr5 + 
13902
8240 8 
  
CCGCCCCCCCACC
CCGCCGCCGG 
CCG....C....
......G. 5 chr5 + 
17087
8053 8 
  
CCCCCCTCCCACC
CCGCCTCTAG 
CC....TC....
........ 4 chr9 + 
37465
348 8 
  
CCCCCCCCCCGCC
CCGCCTCCAG 
CC.....C..G.
........ 4 chr10 + 
10272
9240 7 
  
CACCCCCTCCCCT
CCGCCTCAGG 
C.........C.
T....... 3 chr11 - 
61321
433 7 
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CATTCCCCCCACC
CCACCTCAGG 
C.TT...C....
...A.... 5 chr12 - 
26025
089 7 
  
CCCCCCCCCCCCC
CCGCCCCAGG 
CC.....C..C.
......C. 5 chr13 - 
52341
910 7 
  
GTCCCCTCCCACC
CCGCCTCCAG 
.T....TC....
........ 3 chr14 + 
90403
305 7 
  
GAGCTCCCCCACC
CCGCCCCGGG 
..G.T..C....
......C. 4 chr19 - 
14142
969 7 
  
AGCCCCCCCCACC
CCGCCCCTGG 
AG.....C....
......C. 4 chr19 - 
28341
692 7 
  
AACACCCCCCACC
CCACCCCGGG 
A..A...C....
...A..C. 5 chr19 - 
51915
513 7 
  
CCCCCCCCCCCCC
CCGCCCCCGG 
CC.....C..C.
......C. 5 chr4 + 
54259
934 7 
  
GTCCCCCTCCTCC
CCACCTCCGG 
.T........T.
...A.... 3 chrX + 
15283
7112 7 
  
AACCCCACCCACC
CCATCTCAGG 
A.....AC....
...AT... 5 chr1 - 
23719
5675 6 
  
CGGACCCCCCACC
CCGCCCCCAG 
CGGA...C....
......C. 6 chr8 + 
66934
423 6 
  
TACCCCCTCCACC
CCGCTCCAGG 
T...........
.....TC. 3 chr17 + 
28975
224 5 
  
AAGCCCCCCCACC
CCGCCCCCGA 
A.G....C....
......C. 4 chr19 - 
15311
180 5 
  
GGCCCCACCCACC
CCGCCGCAGG 
.G....AC....
......G. 4 chr19 - 
30335
983 5 
  
CCGCCCCCCCATC
CCGCCCCAGG 
CCG....C...T
......C. 6 chr20 - 
62575
811 5 
  
GCCTCCCCCCACC
CAGCCTCGGG 
.C.T...C....
..A..... 4 chr6 - 
36853
819 5 
  
GGCCCCCTCCTCC
TCGCCTCTGG 
.G........T.
.T...... 3 chr1 + 
98848
74 4 
  
GACCCCCTCCACC
CCACTCCTGG 
............
...A.TC. 3 chr1 + 
19506
1768 4 
  
GGTCCCCCCCACC
CCACCTCCAG 
.GT....C....
...A.... 4 chr11 - 
70991
72 4 
  
AACCCCACCCACC
CCGCCCTGGG 
A.....AC....
......CT 5 chr11 - 
17662
650 4 
  
GACCCCCCCCACC
CCGCCCCGAG 
.......C....
......C. 2 chr11 - 
10143
7790 4 
  
CCGCCCCTGCACC
CAGCCTCCGG 
CCG.....G...
..A..... 5 chr12 + 
13328
7132 4 
  
ACTCCCCTCCACC
CCGGCTCGGG 
ACT.........
....G... 4 chr17 - 
62167
048 4 
  
CTCTCCCCCCTCC
CCGCCCCCGG 
CT.T...C..T.
......C. 6 chr17 + 
80013
580 4 
  
TGCCCCCTCCACC
CCGACCCTGG 
TG..........
....A.C. 4 chr19 - 
49908
283 4 
  
CGGCCTCCCCACC
CCGCCCCCGG 
CGG..T.C....
......C. 6 chr7 - 
10013
7234 4 
  
AACCCCACCCACC
CCACCCCCGG 
A.....AC....
...A..C. 5 chr8 - 
10451
2392 4 
   219 
  
GGGCCCCCCTACC
CCGCCCCCGG 
.GG....C.T..
......C. 5 chr9 + 
13898
7551 4 
  
TCTCCACCCCACC
CCGCCCCTGG 
TCT..A.C....
......C. 6 chr1 - 
78245
430 3 
  
TGGCCCCTCCGCC
CCACCTCTGG 
TGG.......G.
...A.... 5 chr1 + 
12942
56 3 
  
TCCCCCCCCCACC
CCGCTTTGGG 
TC.....C....
.....T.T 5 chr11 - 
64012
937 3 
  
GCCCACCCCCCCC
CCCCCCCCAG 
.C..A..C..C.
...C..C. 6 chr11 - 
64604
177 3 
  
GCCACCCACCACC
CCACCTCAGG 
.C.A...A....
...A.... 4 chr12 + 
57604
316 3 
  
GAGCCACTGCACC
CAGCCAACAG 
..G..A..G...
..A...AA 6 chr13 + 
76825
276 3 
  
AGTAGCCCCCACC
CCGCCTCGGG 
AGTAG..C....
........ 6 chr16 - 
69166
705 3 
  
TTTCCCCCCCACC
CCAACTCAGG 
TTT....C....
...AA... 6 chr17 + 
71474
64 3 
  
AACCCACCCCACC
CCACCTCGGA 
A....A.C....
...A.... 4 chr19 - 
55362
87 3 
  
TTCTCCCTCCTCC
CCGCCTCGGG 
TT.T......T.
........ 4 chr19 - 
42806
795 3 
  
GACATCCCCCACC
CCGCCCCCAG 
...AT..C....
......C. 4 chr20 + 
45571
881 3 
  
CTTCCCCCCCGCC
CCGCCCCGGG 
CTT....C..G.
......C. 6 chr4 + 
43892
69 3 
  
GTCCCCCTCCAGC
CCGCCCCTGG 
.T.........G
......C. 3 chr5 - 
77269
272 3 
  
TGCACCCCCCACC
CCGCCCCTGG 
TG.A...C....
......C. 5 chr5 + 
13286
0359 3 
  
GCCCCGCCCCACC
CCACCCCCGG 
.C...G.C....
...A..C. 5 chr6 - 
13814
822 3 
  
AACCACCCCCACC
CCACCCCAGG 
A...A..C....
...A..C. 5 chr7 + 
50765
512 3 
  
AAGCCCCCCCACC
CCGCCCCGGG 
A.G....C....
......C. 4 chr9 - 
14026
3439 3 
  
CCCCCACCCCACC
CCGCCTCCAG 
CC...A.C....
........ 4 chr9 + 
13066
3070 3 
  
GTCCTCCACCACC
CCGCCTCTGG 
.T..T..A....
........ 3 chrX - 
11886
5477 3 
  
CTTTCCCTCCACC
CAGCCTCTGG 
CTTT........
..A..... 5 chr15 + 
85828
607 2 
  
AGGCCCTCCCACC
CCGCATCAGG 
AGG...TC....
.....A.. 6 chr16 + 
67289
431 2 
  
CCTGCCCCCCACC
CCGCCCCAGG 
CCTG...C....
......C. 6 chr19 + 
14943
14 2 
  
CCTCCCCTCCACC
CCGCTCCTGG 
CCT.........
.....TC. 5 chr2 - 
23334
5192 2 
  
CTCCCTCCCCACC
CCACCTCTGG 
CT...T.C....
...A.... 5 chr2 + 
11699
948 2 
  
GACACACCCCACC
CCACCTCAGG 
...A.A.C....
...A.... 4 chr2 + 
12744
759 2 
   220 
  
CACCCCCCCCACC
CCGTCTTGGG 
C......C....
....T..T 4 chr2 + 
23906
1941 2 
  
CTTCCCCCACACC
CCGCCCCAGG 
CTT....CA...
......C. 6 chr3 - 
31458
652 2 
  
TCCCCCCCCCACC
CCACCCCCGG 
TC.....C....
...A..C. 5 chr3 + 
45348
439 2 
  
ACCCCACCCCACC
CCACCCCAGG 
AC...A.C....
...A..C. 6 chr6 - 
14057
990 2 
  
GTACCCCTCCACC
CAGCCCCAGG 
.TA.........
..A...C. 4 chr8 + 
61544
623 2 
SpCas9MT3-ZFP 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 119 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 156 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 4 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 37 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 5 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 7 
OTD_TS
2_10 
GAGCCCCTGGGGG
CCGCCTCTGA 
..G.....GGGG
G....... 6 chr8 - 
37462
351 2 
OTD_TS
2_11 
CAGCCCCTCCTCC
AGGCCCCCAG 
C.G.......T.
.AG...C. 6 chr15 + 
78149
388 2 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 8 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 2 
  
AAGCCCCCCCACC
CCGCCCCCGA 
A.G....C....
......C. 4 chr19 - 
15311
180 7 
  
GATCCCGCCCTTC
CCACCTCTGG 
..T...GC..TT
...A.... 6 chr1 - 
28431
632 2 
  
CCCCCCCCCCCCC
CCGCCCCGGG 
CC.....C..C.
......C. 5 chr2 + 
22373
1481 2 
Split-SpCas9WT-NLS 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 151 
OTD_TS
2_1 
CTGCCCCCCCACC
CCGCCACTGG 
CTG....C....
......A. 5 chrX + 
14993
2512 281 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 264 
   221 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 249 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 271 
OTD_TS
2_5 
GACCCCCCCCACC
CCGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
101 176 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 168 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 155 
OTD_TS
2_8 
TGCCCCCCCCACC
CCACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
423 97 
OTD_TS
2_9 
TGCCCCCTCCACC
CCACCTCTGA 
TG..........
...A.... 3 chr6 + 
11052
1018 15 
OTD_TS
2_12 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr6 - 
63921
631 15 
OTD_TS
2_13 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr20 + 
13561
41 2 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 9 
  
GCCCCCACCCACC
CCGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
553 163 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 25 
  
CCCCCCCCCCCCC
CCGCCTCAGG 
CC.....C..C.
........ 4 chr13 - 
10054
6983 144 
  
CTCCCCACCCACC
CCGCCTCAGG 
CT....AC....
........ 4 chr4 + 
38537
611 37 
  
CCCCCCCCCCACC
CCGCCCTCGG 
CC.....C....
......CT 5 chr11 + 
19798
641 5 
  
TACCCCCCCCACC
CCGCCACAGG 
T......C....
......A. 3 chr11 + 
13948
354 73 
  
TGCCCCCCCCACC
CCGCCCCCGG 
TG.....C....
......C. 4 chrX + 
12904
0624 108 
  
CCGCCCCTCCACC
CCGCCACTGG 
CCG.........
......A. 4 chr17 - 
55740
523 76 
  
TGCCCCTCCCACC
CCGCCTCTGG 
TG....TC....
........ 4 chr17 - 
40044
751 90 
  
GACCCCTCCCACC
CCGACTCCGG 
......TC....
....A... 3 chr9 + 
27338
858 89 
  
GTACCCCACCACC
CCGCCCCAGG 
.TA....A....
......C. 4 chr8 + 
14482
2945 66 
  
GCTTCCCTCCACC
CCGCATCCGG 
.CTT........
.....A.. 4 chr11 + 
71948
788 73 
  
CCCCCCCCCCACC
CCGCCCCCGG 
CC.....C....
......C. 4 chr2 - 
12924
4196 46 
  
ATCCCCCTCCACC
CCACCCCTGG 
AT..........
...A..C. 4 chr11 + 
12308
918 77 
  
ACCCCCCCCCGCC
CCGCCCCCGG 
AC.....C..G.
......C. 5 chr11 + 
73458
481 69 
  
ACCCCCCCCCCCC
CCGCCCCCGG 
AC.....C..C.
......C. 5 chr2 + 
24857
577 17 
   222 
  
CAACCCCCCCACC
CCGCTTCAGG 
C.A....C....
.....T.. 4 chr3 + 
14039
8784 57 
  
CCACCCCCCCACC
CCGCCCCTGG 
CCA....C....
......C. 5 chr20 - 
10913
955 20 
  
CACTCCCCCCACC
CCGCCCCAGG 
C..T...C....
......C. 4 chr9 - 
12613
8175 116 
  
GGACCCTCCCACC
CCACCTCAAG 
.GA...TC....
...A.... 5 chr13 - 
10062
1456 8 
  
AGGCCCCCACACC
CCGCCTCAGG 
AGG....CA...
........ 5 chr4 + 
14962
41 54 
  
CCACCCCCCCACC
CCGCCCCAGG 
CCA....C....
......C. 5 chr2 + 
17057
3334 23 
  
GACCCCCCCCACC
CCACCCCAGG 
.......C....
...A..C. 3 chr6 + 
26470
607 21 
  
CTCCCCCGCCACC
CCGCCCCAGG 
CT.....G....
......C. 4 chr17 - 
16954
846 19 
  
CATACCCCCCACC
CCGCCCCGGG 
C.TA...C....
......C. 5 chr4 - 
88419
11 42 
  
GACCCCTCCCTCC
CCACCTCAGG 
......TC..T.
...A.... 4 chr1 - 
51442
186 14 
  
AAGACCCCCCACC
CCGCCCCAGG 
A.GA...C....
......C. 5 chr19 + 
45952
038 20 
  
CCCCCCCCCCCCC
CCGCCTCCGG 
CC.....C..C.
........ 4 chr22 + 
50884
786 30 
  
CCCCACCCCCACC
CCGCCTCAGG 
CC..A..C....
........ 4 chr10 - 
11629
4250 13 
  
CTACCCCCACTCC
CCGCCTCCGG 
CTA....CA.T.
........ 6 chr10 + 
10282
1501 22 
  
TCCACCCCCCACC
CCGCCCCGGG 
TC.A...C....
......C. 5 chr7 + 
10493
3939 20 
  
GACCCCTCACACC
CCGCCCCTGG 
......TCA...
......C. 4 chr7 - 
95319
671 20 
  
GTCCCTCCCCACC
CCGCCTTGGG 
.T...T.C....
.......T 4 chr22 + 
40102
384 10 
  
GCCCCCCACCACC
CCACCTCGGG 
.C.....A....
...A.... 3 chr19 + 
13122
172 14 
  
CGCCCTCCCCACC
CCGCCTCCGG 
CG...T.C....
........ 4 chr10 + 
13514
9931 29 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr20 - 
35991
127 16 
  
GACCCCACCCACC
CCGCCGCAGG 
......AC....
......G. 3 chr12 + 
13252
9350 5 
  
AGCCCCCCCCTCC
CCGCCCCAGG 
AG.....C..T.
......C. 5 chr14 + 
10460
1192 12 
  
CTCCCCCCCCACC
CCGTCCCCGG 
CT.....C....
....T.C. 5 chr2 - 
12907
7573 4 
  
GGACCCCCCCCCC
CCGCCCCCGG 
.GA....C..C.
......C. 5 chr3 - 
13187
297 12 
  
GCCCCCCCCCACC
CCGCAGCTGG 
.C.....C....
.....AG. 4 chr7 - 
11179
73 4 
  
GGACCCCGACGCC
CCGCCTCAGG 
.GA....GA.G.
........ 5 chr3 - 
31574
996 24 
   223 
  
CAGTCCCCCCACC
CCACCTCTGG 
C.GT...C....
...A.... 5 chr10 + 
72538
201 35 
  
CATCCCCCCCACC
CCACCCCGGG 
C.T....C....
...A..C. 5 chr11 - 
46141
849 12 
  
ACACCCCCCCACC
CCACCCCAGG 
ACA....C....
...A..C. 6 chr2 - 
22153
5826 6 
  
AGCCCCCACCTCC
CCGCCTCGGG 
AG.....A..T.
........ 4 chr22 + 
43684
479 18 
  
CTCACCCCCCACC
CCACCTCTGG 
CT.A...C....
...A.... 5 chr11 - 
26862
43 5 
  
ACCCCCCCCCCAC
CCGCCCCCGG 
AC.....C..CA
......C. 6 chr6 - 
27382
04 5 
  
GACCCTGTCCACC
CCACCTCAGG 
.....TG.....
...A.... 3 chr1 + 
87532
1 10 
  
GACCCGCCCCGCC
CCGCCTCTGG 
.....G.C..G.
........ 3 chr1 + 
11714
529 7 
  
GACCCTCCCCACC
CCACCCCTGG 
.....T.C....
...A..C. 4 chr1 + 
22609
3591 3 
  
AGGCCCCCCCGCC
CCGCCTCAGG 
AGG....C..G.
........ 5 chr11 - 
37466
1 24 
  
CCCCCCCACCACC
CCGCCCCGGG 
CC.....A....
......C. 4 chr8 - 
18041
540 13 
  
AACCTCCCCCACC
CCACCCCAGG 
A...T..C....
...A..C. 5 chr17 - 
46103
841 8 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr21 + 
47440
541 8 
  
GCCGCCCCCCACT
CCGCCTCCGG 
.C.G...C....
T....... 4 chr4 - 
14376
7367 6 
  
CCCCCCCCCCACC
CCGCCCCGAG 
CC.....C....
......C. 4 chr12 + 
22487
644 6 
  
CTCCCCCCCCTCC
CCGCCTCGGG 
CT.....C..T.
........ 4 chr5 + 
13902
8240 5 
  
CCGCCCCCCCACC
CCGCCGCCGG 
CCG....C....
......G. 5 chr5 + 
17087
8053 7 
  
CCCCCCTCCCACC
CCGCCTCTAG 
CC....TC....
........ 4 chr9 + 
37465
348 10 
  
CCCCCCCCCCGCC
CCGCCTCCAG 
CC.....C..G.
........ 4 chr10 + 
10272
9240 8 
  
CACCCCCTCCCCT
CCGCCTCAGG 
C.........C.
T....... 3 chr11 - 
61321
433 5 
  
CATTCCCCCCACC
CCACCTCAGG 
C.TT...C....
...A.... 5 chr12 - 
26025
089 5 
  
CCCCCCCCCCCCC
CCGCCCCAGG 
CC.....C..C.
......C. 5 chr13 - 
52341
910 2 
  
GTCCCCTCCCACC
CCGCCTCCAG 
.T....TC....
........ 3 chr14 + 
90403
305 14 
  
GAGCTCCCCCACC
CCGCCCCGGG 
..G.T..C....
......C. 4 chr19 - 
14142
969 2 
  
AACACCCCCCACC
CCACCCCGGG 
A..A...C....
...A..C. 5 chr19 - 
51915
513 2 
  
CCCCCCCCCCCCC
CCGCCCCCGG 
CC.....C..C.
......C. 5 chr4 + 
54259
934 8 
   224 
  
GTCCCCCTCCTCC
CCACCTCCGG 
.T........T.
...A.... 3 chrX + 
15283
7112 3 
  
AACCCCACCCACC
CCATCTCAGG 
A.....AC....
...AT... 5 chr1 - 
23719
5675 9 
  
CGGACCCCCCACC
CCGCCCCCAG 
CGGA...C....
......C. 6 chr8 + 
66934
423 5 
  
GGCCCCACCCACC
CCGCCGCAGG 
.G....AC....
......G. 4 chr19 - 
30335
983 5 
  
CCGCCCCCCCATC
CCGCCCCAGG 
CCG....C...T
......C. 6 chr20 - 
62575
811 4 
  
GCCTCCCCCCACC
CAGCCTCGGG 
.C.T...C....
..A..... 4 chr6 - 
36853
819 3 
  
AACCCCACCCACC
CCGCCCTGGG 
A.....AC....
......CT 5 chr11 - 
17662
650 2 
  
GACCCCCCCCACC
CCGCCCCGAG 
.......C....
......C. 2 chr11 - 
10143
7790 4 
  
ACTCCCCTCCACC
CCGGCTCGGG 
ACT.........
....G... 4 chr17 - 
62167
048 8 
  
CGGCCTCCCCACC
CCGCCCCCGG 
CGG..T.C....
......C. 6 chr7 - 
10013
7234 7 
  
AACCCCACCCACC
CCACCCCCGG 
A.....AC....
...A..C. 5 chr8 - 
10451
2392 9 
  
GGGCCCCCCTACC
CCGCCCCCGG 
.GG....C.T..
......C. 5 chr9 + 
13898
7551 10 
  
TCTCCACCCCACC
CCGCCCCTGG 
TCT..A.C....
......C. 6 chr1 - 
78245
430 11 
  
TTCTCCCTCCTCC
CCGCCTCGGG 
TT.T......T.
........ 4 chr19 - 
42806
795 3 
  
GACATCCCCCACC
CCGCCCCCAG 
...AT..C....
......C. 4 chr20 + 
45571
881 8 
  
CTTCCCCCCCGCC
CCGCCCCGGG 
CTT....C..G.
......C. 6 chr4 + 
43892
69 6 
  
GTCCCCCTCCAGC
CCGCCCCTGG 
.T.........G
......C. 3 chr5 - 
77269
272 3 
  
TGCACCCCCCACC
CCGCCCCTGG 
TG.A...C....
......C. 5 chr5 + 
13286
0359 5 
  
AACCACCCCCACC
CCACCCCAGG 
A...A..C....
...A..C. 5 chr7 + 
50765
512 3 
  
AAGCCCCCCCACC
CCGCCCCGGG 
A.G....C....
......C. 4 chr9 - 
14026
3439 5 
  
GTCCTCCACCACC
CCGCCTCTGG 
.T..T..A....
........ 3 chrX - 
11886
5477 7 
  
CTCCCTCCCCACC
CCACCTCTGG 
CT...T.C....
...A.... 5 chr2 + 
11699
948 2 
  
GACACACCCCACC
CCACCTCAGG 
...A.A.C....
...A.... 4 chr2 + 
12744
759 2 
  
CTTCCCCCACACC
CCGCCCCAGG 
CTT....CA...
......C. 6 chr3 - 
31458
652 7 
  
CCACCCCTCCACC
CTGCTTCGGG 
CCA.........
..T..T.. 5 chr1 + 
15667
5969 3 
  
TTCCCACTCCATC
CCCCTTCTGG 
TT...A.....T
...C.T.. 6 chr1 + 
23232
7590 4 
   225 
  
GAACTCATACACC
ACACCTCTGG 
..A.T.A.A...
.A.A.... 6 chr10 + 
10350
6362 2 
  
AGTCCCCCCCACC
CCACCACAGG 
AGT....C....
...A..A. 6 chr10 + 
12604
2244 2 
  
GGCTCCCTCCGCC
CCGCCCCGGG 
.G.T......G.
......C. 4 chr11 - 
65479
763 2 
  
AACCCCTTCTTCC
CAACCTCAGA 
A.....T..TT.
..AA.... 6 chr13 - 
47079
419 2 
  
TCCCCACCCCGCC
CCGCCTCTGG 
TC...A.C..G.
........ 5 chr15 - 
78857
719 13 
  
TATCCTCCCCACC
CCGCCCCGGG 
T.T..T.C....
......C. 5 chr16 - 
57974
232 3 
  
CGCCCACCCCACC
CCACCTCAGG 
CG...A.C....
...A.... 5 chr17 + 
58404
852 3 
  
CCCCACCCCCACC
CCATCTCTGG 
CC..A..C....
...AT... 6 chr19 - 
18131
307 2 
  
AGTCCCATCCACC
CCGCCTAAGG 
AGT...A.....
.......A 5 chr19 - 
18633
477 2 
  
GCTCCCCCCCACC
CCGCCCCCAG 
.CT....C....
......C. 4 chr19 + 
42785
69 2 
  
GGCCGCCTCCGCC
CCAGCTGCAG 
.G..G.....G.
...AG..G 6 chr19 + 
81309
30 3 
  
CCCCCCCCTCACC
CCGCCCCTGG 
CC.....CT...
......C. 5 chr19 + 
45324
565 3 
  
GACCTCCGCCTCC
CAGGTTCAAG 
....T..G..T.
..A.GT.. 6 chr21 - 
27175
337 2 
  
GACCCCCTTCACC
CCACCTATGG 
........T...
...A...A 3 chr22 + 
23260
188 2 
  
GACTCCCTCCGCC
CCGCTTCCAG 
...T......G.
.....T.. 3 chr5 + 
17958
8285 4 
  
CTGCCCCCCCACC
CCAACTCAGG 
CTG....C....
...AA... 6 chr7 + 
66023
157 3 
  
GTCCCTACCCACC
CCGCCCCTGG 
.T...TAC....
......C. 5 chr7 + 
14296
0402 5 
  
CCCCCCCCCCCCC
CCGCCCCAGG 
CC.....C..C.
......C. 5 chr9 + 
12888
6485 3 
Split-SpCas9MT3-ZFPTS2 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 126 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 148 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 12 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 87 
OTD_TS
2_5 
GACCCCCCCCACC
CCGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
101 3 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 10 
   226 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 8 
OTD_TS
2_8 
TGCCCCCCCCACC
CCACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
423 12 
OTD_TS
2_9 
TGCCCCCTCCACC
CCACCTCTGA 
TG..........
...A.... 3 chr6 + 
11052
1018 4 
OTD_TS
2_12 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr6 - 
63921
631 20 
OTD_TS
2_13 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr20 + 
13561
41 3 
OTD_TS
2_14 
AACCCCCGCCTCC
CGGGTTCAAG 
A......G..T.
..G.GT.. 6 chr1 + 
11725
7633 3 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 10 
  
GCCCCCACCCACC
CCGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
553 3 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 7 
  
GACCCTGTCCACC
CCACCTCAGG 
.....TG.....
...A.... 3 chr1 + 
87532
1 4 
  
GCCCACGTCCACC
CTGACCCCGA 
.C..A.G.....
..T.A.C. 6 chr11 + 
16639
57 2 
  
GACCCTCTCTATC
CCCTCTCAGA 
.....T...T.T
...CT... 5 chr19 - 
46053
661 2 
  
GGCGCCCCCGCCC
CCGCCCCCGG 
.G.G...C.GC.
......C. 6 chr5 - 
52405
377 2 
SpCas9MT3-DD-ZFPTS2 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 121 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 54 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 11 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 85 
OTD_TS
2_5 
GACCCCCCCCACC
CCGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
101 3 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 8 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 6 
OTD_TS
2_8 
TGCCCCCCCCACC
CCACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
423 7 
OTD_TS
2_9 
TGCCCCCTCCACC
CCACCTCTGA 
TG..........
...A.... 3 chr6 + 
11052
1018 13 
OTD_TS
2_12 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr6 - 
63921
631 4 
OTD_TS
2_15 
CCCCCCCCCCCCC
CCGCCATAGA 
CC.....C..C.
......AT 6 chr6 - 
16356
9986 2 
   227 
OTD_TS
2_16 
CCCCCCCACCACA
CCCCCTGGAG 
CC.....A....
A..C...G 6 chr15 + 
91964
829 2 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 10 
  
GCCCCCACCCACC
CCGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
553 8 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 4 
  
CCCCCCCCCCCCC
CCGCCTCAGG 
CC.....C..C.
........ 4 chr13 - 
10054
6983 2 
  
CTCCCCACCCACC
CCGCCTCAGG 
CT....AC....
........ 4 chr4 + 
38537
611 2 
  
CCCCCCCCCCACC
CCGCCCTCGG 
CC.....C....
......CT 5 chr11 + 
19798
641 2 
Split-SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS2 
GACCCCCTCCACC
CCGCCTCCGG 
............
........ 0 chr6 - 
43738
556 83 
OTD_TS
2_1 
CTGCCCCCCCACC
CCGCCACTGG 
CTG....C....
......A. 5 chrX + 
14993
2512 118 
OTD_TS
2_2 
GGGCCCCTCCACC
CCGCCTCTGG 
.GG.........
........ 2 chr11 - 
31817
477 138 
OTD_TS
2_3 
ATTCCCCCCCACC
CCGCCTCAGG 
ATT....C....
........ 4 chr2 + 
24221
4590 143 
OTD_TS
2_4 
CTACCCCTCCACC
CCGCCTCCGG 
CTA.........
........ 3 chr5 + 
67151
02 147 
OTD_TS
2_5 
GACCCCCCCCACC
CCGCCCCCGG 
.......C....
......C. 2 chr15 - 
33286
101 88 
OTD_TS
2_6 
ACACCCCCCCACC
CCGCCTCAGG 
ACA....C....
........ 4 chr9 - 
10359
9643 119 
OTD_TS
2_7 
TACCCCCCACACC
CCGCCTCTGG 
T......CA...
........ 3 chr17 - 
43587
46 41 
OTD_TS
2_8 
TGCCCCCCCCACC
CCACCTCTGG 
TG.....C....
...A.... 4 chr16 - 
56963
423 40 
OTD_TS
2_9 
TGCCCCCTCCACC
CCACCTCTGA 
TG..........
...A.... 3 chr6 + 
11052
1018 2 
OTD_TS
2_12 
AACCCCTTCTTCC
CAGCCTCGGA 
A.....T..TT.
..A..... 5 chr6 - 
63921
631 12 
  
CTACCCCTCCACC
CCGACTCGGA 
CTA.........
....A... 4 chr18 + 
55101
344 3 
  
GCCCCCACCCACC
CCGCCTCTGG 
.C....AC....
........ 3 chr18 - 
21359
553 47 
  
CTCCCCCTCCACC
CCACCTCCAG 
CT..........
...A.... 3 chr6 - 
31462
821 4 
  
CCCCCCCCCCCCC
CCGCCTCAGG 
CC.....C..C.
........ 4 chr13 - 
10054
6983 60 
  
CTCCCCACCCACC
CCGCCTCAGG 
CT....AC....
........ 4 chr4 + 
38537
611 16 
  
CCCCCCCCCCACC
CCGCCCTCGG 
CC.....C....
......CT 5 chr11 + 
19798
641 7 
   228 
  
TACCCCCCCCACC
CCGCCACAGG 
T......C....
......A. 3 chr11 + 
13948
354 35 
  
TGCCCCCCCCACC
CCGCCCCCGG 
TG.....C....
......C. 4 chrX + 
12904
0624 41 
  
CCGCCCCTCCACC
CCGCCACTGG 
CCG.........
......A. 4 chr17 - 
55740
523 22 
  
TGCCCCTCCCACC
CCGCCTCTGG 
TG....TC....
........ 4 chr17 - 
40044
751 26 
  
GACCCCTCCCACC
CCGACTCCGG 
......TC....
....A... 3 chr9 + 
27338
858 43 
  
GTACCCCACCACC
CCGCCCCAGG 
.TA....A....
......C. 4 chr8 + 
14482
2945 16 
  
GCTTCCCTCCACC
CCGCATCCGG 
.CTT........
.....A.. 4 chr11 + 
71948
788 24 
  
CCCCCCCCCCACC
CCGCCCCCGG 
CC.....C....
......C. 4 chr2 - 
12924
4196 24 
  
ATCCCCCTCCACC
CCACCCCTGG 
AT..........
...A..C. 4 chr11 + 
12308
918 16 
  
ACCCCCCCCCGCC
CCGCCCCCGG 
AC.....C..G.
......C. 5 chr11 + 
73458
481 15 
  
ACCCCCCCCCCCC
CCGCCCCCGG 
AC.....C..C.
......C. 5 chr2 + 
24857
577 16 
  
CAACCCCCCCACC
CCGCTTCAGG 
C.A....C....
.....T.. 4 chr3 + 
14039
8784 11 
  
CCACCCCCCCACC
CCGCCCCTGG 
CCA....C....
......C. 5 chr20 - 
10913
955 5 
  
CACTCCCCCCACC
CCGCCCCAGG 
C..T...C....
......C. 4 chr9 - 
12613
8175 12 
  
GGACCCTCCCACC
CCACCTCAAG 
.GA...TC....
...A.... 5 chr13 - 
10062
1456 3 
  
AGGCCCCCACACC
CCGCCTCAGG 
AGG....CA...
........ 5 chr4 + 
14962
41 21 
  
CCACCCCCCCACC
CCGCCCCAGG 
CCA....C....
......C. 5 chr2 + 
17057
3334 7 
  
GACCCCCCCCACC
CCACCCCAGG 
.......C....
...A..C. 3 chr6 + 
26470
607 10 
  
CTCCCCCGCCACC
CCGCCCCAGG 
CT.....G....
......C. 4 chr17 - 
16954
846 11 
  
CATACCCCCCACC
CCGCCCCGGG 
C.TA...C....
......C. 5 chr4 - 
88419
11 8 
  
GACCCCTCCCTCC
CCACCTCAGG 
......TC..T.
...A.... 4 chr1 - 
51442
186 4 
  
AAGACCCCCCACC
CCGCCCCAGG 
A.GA...C....
......C. 5 chr19 + 
45952
038 5 
  
CCCCCCCCCCCCC
CCGCCTCCGG 
CC.....C..C.
........ 4 chr22 + 
50884
786 11 
  
CCCCACCCCCACC
CCGCCTCAGG 
CC..A..C....
........ 4 chr10 - 
11629
4250 2 
  
CTACCCCCACTCC
CCGCCTCCGG 
CTA....CA.T.
........ 6 chr10 + 
10282
1501 4 
  
TCCACCCCCCACC
CCGCCCCGGG 
TC.A...C....
......C. 5 chr7 + 
10493
3939 5 
   229 
  
GACCCCTCACACC
CCGCCCCTGG 
......TCA...
......C. 4 chr7 - 
95319
671 10 
  
GCCCCCCACCACC
CCACCTCGGG 
.C.....A....
...A.... 3 chr19 + 
13122
172 2 
  
CGCCCTCCCCACC
CCGCCTCCGG 
CG...T.C....
........ 4 chr10 + 
13514
9931 8 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr20 - 
35991
127 4 
  
AGCCCCCCCCTCC
CCGCCCCAGG 
AG.....C..T.
......C. 5 chr14 + 
10460
1192 7 
  
GGACCCCCCCCCC
CCGCCCCCGG 
.GA....C..C.
......C. 5 chr3 - 
13187
297 3 
  
GGACCCCGACGCC
CCGCCTCAGG 
.GA....GA.G.
........ 5 chr3 - 
31574
996 8 
  
CAGTCCCCCCACC
CCACCTCTGG 
C.GT...C....
...A.... 5 chr10 + 
72538
201 9 
  
ACACCCCCCCACC
CCACCCCAGG 
ACA....C....
...A..C. 6 chr2 - 
22153
5826 4 
  
GACCCTGTCCACC
CCACCTCAGG 
.....TG.....
...A.... 3 chr1 + 
87532
1 3 
  
GACCCGCCCCGCC
CCGCCTCTGG 
.....G.C..G.
........ 3 chr1 + 
11714
529 2 
  
CCCCCCCACCACC
CCGCCCCGGG 
CC.....A....
......C. 4 chr8 - 
18041
540 4 
  
GGCCCTCTCCACT
CCACCTCAGG 
.G...T......
T..A.... 4 chr1 - 
17873
8721 2 
  
AGACCCCCCCACC
CCACCCCAGG 
AGA....C....
...A..C. 6 chr21 + 
47440
541 4 
  
CCCCCCTCCCACC
CCGCCTCTAG 
CC....TC....
........ 4 chr9 + 
37465
348 3 
  
GAGCTCCCCCACC
CCGCCCCGGG 
..G.T..C....
......C. 4 chr19 - 
14142
969 3 
  
CCCCCCCCCCCCC
CCGCCCCCGG 
CC.....C..C.
......C. 5 chr4 + 
54259
934 2 
  
CGGACCCCCCACC
CCGCCCCCAG 
CGGA...C....
......C. 6 chr8 + 
66934
423 3 
  
TCTCCACCCCACC
CCGCCCCTGG 
TCT..A.C....
......C. 6 chr1 - 
78245
430 2 
  
TCCCCCCCCCACC
CCGCTTTGGG 
TC.....C....
.....T.T 5 chr11 - 
64012
937 3 
  
TTCTCCCTCCTCC
CCGCCTCGGG 
TT.T......T.
........ 4 chr19 - 
42806
795 2 
  
AAGCCCCCCCACC
CCGCCCCGGG 
A.G....C....
......C. 4 chr9 - 
14026
3439 2 
  
GACACCTCCCACC
CCTTCACAGA 
...A..TC....
...TT.A. 6 chr1 + 
23078
3394 2 
  
GACCTCCACCTCC
CATGCTCAAG 
....T..A..T.
..ATG... 6 chr15 + 
29694
599 2 
  
GACCCCCCAGCCC
CCGCCTCAGG 
.......CAGC.
........ 4 chr19 + 
10163
747 2 
SpCas9WT 
   230 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 520 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 198 
OTD_TS
3_2 
TGTGGGTGAGTGT
GTGCGTGAGG 
T...G.......
........ 2 chr5 + 
11543
4659 121 
OTD_TS
3_3 
GCTGAGTGAGTGT
ATGCGTGTGG 
.C..........
.A...... 2 chr22 - 
37662
818 102 
OTD_TS
3_4 
AGAGAGTGAGTGT
GTGCATGAGG 
A.A.........
.....A.. 3 chr5 - 
89440
963 59 
OTD_TS
3_5 
TGTGAGTGAGTGT
GTGTGTGTGA 
T...........
....T... 2 chr8 - 
22932
497 18 
OTD_TS
3_6 
TGTGGGTGAGTGT
GTGCGTGAGA 
T...G.......
........ 2 chr9 - 
23824
548 8 
OTD_TS
3_7 
GGTGAGTGAGTGT
GTGTGTGAGG 
............
....T... 1 chr14 + 
10602
9015 7 
  
GCTATTTGTGTGT
GTGGGTGAAG 
.C.ATT..T...
....G... 6 chr13 + 
66489
436 2 
  
ACTGTGTGAGTGT
GTGCGTGAGG 
AC..T.......
........ 3 chr19 - 
40561
861 2 
  
GGTGAGTGTGTGT
GTGCATGTGG 
........T...
.....A.. 2 chr2 - 
17746
3420 2 
  
GATGAGTGTGTGT
GTGTGTGAGG 
.A......T...
....T... 3 chr4 - 
62067
613 2 
  
TGTGGATGTCTGT
GTGTGTGGGG 
T...GA..TC..
....T... 6 chr5 - 
16840
2464 2 
  
GATGAGTGAGTGA
GTGAGTGGGG 
.A..........
A...A... 3 chr6 - 
15707
8321 2 
  
GGTTAGTGAGAAG
CTGTGTGGGA 
...T......AA
GC..T... 6 chr9 - 
13324
4355 2 
  
AGGGAGTGAGTGT
GAGAGTGCGG 
A.G.........
..A.A... 4 chr6 + 
14445
8274 3 
  
GGTGTGTGAGTGT
GTGTGTGTGA 
....T.......
....T... 2 chr7 + 
39341
109 3 
  
GTAGAGTGAGTGT
GTGTGTGTGG 
.TA.........
....T... 3 chr8 + 
48997
789 3 
  
GGTGAGTGAGTGA
GTGAGTGAGG 
............
A...A... 2 chr10 - 
10937
8061 4 
  
GGTGAGTCAGTGT
GTGAGTGAGG 
.......C....
....A... 2 chr2 - 
73317
044 4 
  
AGTGAGTGAGTGT
GAGTGCGGGG 
A...........
..A.T.C. 4 chr8 - 
67579
421 4 
  
AGTGAGTGAGTGT
GTGTGTGTGA 
A...........
....T... 2 chr16 + 
12264
596 5 
  
TGTGAGTGAGTGT
GTGTGTGTGA 
T...........
....T... 2 chr19 + 
61090
16 6 
  
AGTGTGTGAGTGT
GTGCGTGTGG 
A...T.......
........ 2 chr20 - 
20178
278 8 
   231 
  
GGTGAGAGAGTGT
GTGCACGGGG 
......A.....
.....AC. 3 chr22 + 
43939
280 8 
  
AGTGAATGAGTGT
GTGTGTGTGG 
A....A......
....T... 3 chr3 - 
19399
3878 9 
  
GTTGAGTGAATGT
GTGCGTGAGG 
.T.......A..
........ 2 chr10 - 
98760
582 10 
  
AGTGGGTGAGTGA
GTGCGTGCGG 
A...G.......
A....... 3 chr11 + 
68851
122 11 
  
GGTGAGAGAGTGT
GTGCGTAGGA 
......A.....
.......A 2 chr16 - 
74898
114 12 
  
AGCGAGTGGGTGT
GTGCGTGGGG 
A.C.....G...
........ 3 chr14 + 
74353
480 14 
  
TGTGAGTGAGTGT
GTGTATGGGG 
T...........
....TA.. 3 chr5 - 
29367
373 16 
  
TGTGAGTAAGTGT
GTGTGTGTGG 
T......A....
....T... 3 chr14 - 
62078
767 17 
SpCas9MT3-ZFP 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 140 
OTD_TS
3_8 
GGTGAGAGCGAGG
GTTGGTGTGG 
......A.C.A.
G..TG... 6 chr11 - 
57254
546 5 
OTD_TS
3_9 
TGTGTGTGTGTGT
GTGTTTTGAG 
T...T...T...
....TT.T 6 chr1 - 
29261
945 4 
  
ATAGAGTGTGGGT
GTGGGTGTGG 
ATA.....T.G.
....G... 6 chr10 + 
71425
390 3 
  
TGAGAGAGAGAGT
TTGCCTGAGG 
T.A...A...A.
.T...C.. 6 chr16 - 
73573
395 2 
SpCas9MT3-TAL 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 175 
OTD_TS
3_12 
GGTGAGGGAGTAT
CGGGGAGTGA 
......G....A
.CG.G.A. 6 chr7 - 
25201
94 30 
  
TGTGTGTGTGTGT
GTGTGTTTGG 
T...T...T...
....T..T 5 chr14 - 
92959
300 2 
  
AGAGAGTGAGTGT
GTGGCAGAAG 
A.A.........
....GCA. 5 chr2 - 
49171
03 2 
Split-SpCas9WT-NLS 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 231 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 62 
   232 
OTD_TS
3_2 
TGTGGGTGAGTGT
GTGCGTGAGG 
T...G.......
........ 2 chr5 + 
11543
4659 30 
OTD_TS
3_3 
GCTGAGTGAGTGT
ATGCGTGTGG 
.C..........
.A...... 2 chr22 - 
37662
818 50 
OTD_TS
3_4 
AGAGAGTGAGTGT
GTGCATGAGG 
A.A.........
.....A.. 3 chr5 - 
89440
963 17 
OTD_TS
3_5 
TGTGAGTGAGTGT
GTGTGTGTGA 
T...........
....T... 2 chr8 - 
22932
497 5 
OTD_TS
3_6 
TGTGGGTGAGTGT
GTGCGTGAGA 
T...G.......
........ 2 chr9 - 
23824
548 2 
  
AGCGAGTGGGTGT
GTGCGTGGGG 
A.C.....G...
........ 3 chr14 + 
74353
480 9 
  
TGTGAGTAAGTGT
GTGTGTGTGG 
T......A....
....T... 3 chr14 - 
62078
767 6 
  
AGTGGGTGAGTGA
GTGCGTGCGG 
A...G.......
A....... 3 chr11 + 
68851
122 6 
  
AGTGTGTGAGTGT
GTGCGTGTGG 
A...T.......
........ 2 chr20 - 
20178
278 6 
  
AGTGAATGAGTGT
GTGTGTGTGG 
A....A......
....T... 3 chr3 - 
19399
3878 4 
  
AGTGAGTGAGTGA
GTGAGTGAGG 
A...........
A...A... 3 chr4 + 
58326
591 4 
  
GATGAGTGTGTGT
GTGTGTGAGG 
.A......T...
....T... 3 chr4 - 
62067
613 3 
  
TGTGAGTGAGTGT
GTGTATGGGG 
T...........
....TA.. 3 chr5 - 
29367
373 2 
  
GGTGAGTGAGTGA
GTGAGTGAGG 
............
A...A... 2 chrX - 
41726
212 2 
Split-SpCas9MT3-ZFPTS3-NLS 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 239 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 6 
OTD_TS
3_15 
AGTGCGTGTGTGC
GTGCGCCAGG 
A...C...T...
C.....CC 6 chr16 + 
67283
108 4 
OTD_TS
3_16 
TGTGTGTGTGTGT
GTGTGTGTGA 
T...T...T...
....T... 4 chr8 + 
41273
263 3 
OTD_TS
3_6 
TGTGGGTGAGTGT
GTGCGTGAGA 
T...G.......
........ 2 chr9 - 
23824
548 2 
OTD_TS
3_10 
TGTGTGTGTCTGT
GTGTGTGTGA 
T...T...TC..
....T... 5 chr14 + 
98411
510 2 
OTD_TS
3_17 
TGTGTGTGTGTGT
GTGTGTGTGA 
T...T...T...
....T... 4 chrX - 
11651
7683 2 
OTD_TS
3_18 
GGTGGCCGCATGG
GTGCGTGAGG 
....GCC.CA..
G....... 6 chr16 + 
30845
953 2 
OTD_TS
3_19 
AGTGACTGAATGG
GTGAGGGGAG 
A....C...A..
G...A.G. 6 chr2 - 
20421
958 2 
OTD_TS
3_20 
TGTGTGTGCATGT
GTGTTTGGAG 
T...T...CA..
....TT.. 6 chr2 + 
13999
2438 2 
   233 
OTD_TS
3_21 
GATGTGGTGGTGT
GTGCCTGTAG 
.A..T.GTG...
.....C.. 6 chr4 - 
11009
4379 2 
SplitCas9MT3-TALETS3 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 99 
OTD_TS
3_13 
TGTGTGTGTGTGT
GTGCATTAAG 
T...T...T...
.....A.T 5 chr3 - 
68073
944 3 
SpCas9MT3-DD-ZFPTS3 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 145 
OTD_TS
3_11 
TGTGTGTATGTGT
GTCTGTGTAG 
T...T..AT...
...CT... 6 chr9 - 
24270
033 8 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 5 
OTD_TS
3_10 
TGTGTGTGTCTGT
GTGTGTGTGA 
T...T...TC..
....T... 5 chr14 + 
98411
510 3 
OTD_TS
3_6 
TGTGGGTGAGTGT
GTGCGTGAGA 
T...G.......
........ 2 chr9 - 
23824
548 2 
OTD_TS
3_25 
TCTGGGTGTGTGT
CTGTGTGGGG 
TC..G...T...
.C..T... 6 chr2 - 
43351
368 2 
SpCas9MT3-DD-TALETS3 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 175 
OTD_TS
3_14 
GGGCAGTGTGTGT
GTGGCGGGGG 
..GC....T...
....GCG. 6 chr16 + 
79840
707 9 
OTD_TS
3_10 
TGTGTGTGTCTGT
GTGTGTGTGA 
T...T...TC..
....T... 5 chr14 + 
98411
510 7 
OTD_TS
3_22 
GGTGGGTGGGGGT
GGGGGGGGGG 
....G...G.G.
..G.G.G. 6 chr21 + 
40664
046 7 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 4 
OTD_TS
3_5 
TGTGAGTGAGTGT
GTGTGTGTGA 
T...........
....T... 2 chr8 - 
22932
497 3 
OTD_TS
3_23 
GATGAGTGTGGCT
GAGGGTGGGG 
.A......T.GC
..A.G... 6 chr14 + 
76796
338 2 
OTD_TS
3_24 
GGAGAGTGGGTTT
TTGGCTGAGA 
..A.....G..T
.T..GC.. 6 chr20 - 
47227
171 2 
  
GGAGAGAGAGAGA
GGGGGTGGGG 
..A...A...A.
A.G.G... 6 chr4 + 
11204
4802 2 
  
TGTGTGTGTGTAT
GTGTGTGTGA 
T...T...T..A
....T... 5 chr6 + 
14339
2920 2 
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TGGGATTGGGGGT
GTGTGTGGGG 
T.G..T..G.G.
....T... 6 chr8 - 
27807
865 2 
Split-SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
mismatc
h 
Chrom
osome 
Str
and 
Start 
position 
Peak 
Score 
TS3 
GGTGAGTGAGTGT
GTGCGTGTGG 
............
........ 0 chr6 + 
43737
454 195 
OTD_TS
3_1 
AGTGAGTGAGTGT
GTGTGTGGGG 
A...........
....T... 2 chr14 - 
65569
153 31 
OTD_TS
3_3 
GCTGAGTGAGTGT
ATGCGTGTGG 
.C..........
.A...... 2 chr22 - 
37662
818 19 
OTD_TS
3_4 
AGAGAGTGAGTGT
GTGCATGAGG 
A.A.........
.....A.. 3 chr5 - 
89440
963 14 
OTD_TS
3_2 
TGTGGGTGAGTGT
GTGCGTGAGG 
T...G.......
........ 2 chr5 + 
11543
4659 10 
  
GGTGGGTAAGTGG
GAGCTTGGGG 
....G..A....
G.A..T.. 5 chr2 - 
20062
8256 4 
OTD_TS
3_7 
GGTGAGTGAGTGT
GTGTGTGAGG 
............
....T... 1 chr14 + 
10602
9015 3 
  
AGTGTGTGAGTGT
GTGCGTGTGG 
A...T.......
........ 2 chr20 - 
20178
278 3 
  
TGTGTGTGTGTGT
GTGTGTGTGG 
T...T...T...
....T... 4 chr20 + 
47519
599 3 
OTD_TS
3_10 
TGTGTGTGTCTGT
GTGTGTGTGA 
T...T...TC..
....T... 5 chr14 + 
98411
510 2 
  
TGTGTGTATGTGT
GTGCGAAGGA 
T...T..AT...
......AA 6 chr11 - 
32522
389 2 
  
TGTGTGTTTGTGT
GTGCAAGAGA 
T...T..TT...
.....AA. 6 chr4 + 
11981
2483 2 
 
  
   235 
Appendix 2.3  GUIDE-seq data in Chapter 4 
SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
TS3 
GGTGAGTGAGTGTGT
GCGTGTGG 
...........
......... 0 chr6 + 
4373
7454 472 
OT3-4 
GCTGAGTGAGTGTAT
GCGTGTGG 
.C.........
..A...... 2 
chr2
2 - 
3766
2818 381 
OT3-18 
TGTGGGTGAGTGTGT
GCGTGAGG 
T...G......
......... 2 chr5 + 
1154
3465
9 305 
OT3-20 
AGAGAGTGAGTGTGT
GCATGAGG 
A.A........
......A.. 3 chr5 - 
8944
0963 239 
OT3-2 
AGTGAGTGAGTGTGT
GTGTGGGG 
A..........
.....T... 2 
chr1
4 - 
6556
9153 218 
OT3-3 
AGTGTGTGAGTGTGT
GCGTGTGG 
A...T......
......... 2 
chr2
0 - 
2017
8278 188 
OT3_Sp_ne
w 
AGTGGGTGAGTGAGT
GCGTGCGG 
A...G......
.A....... 3 
chr1
1 + 
6885
1122 186 
OT3-21 
AGCGAGTGGGTGTGT
GCGTGGGG 
A.C.....G..
......... 3 
chr1
4 + 
7435
3480 182 
OT3-6 
TGTGGGTGAGTGTGT
GCGTGAGA 
T...G......
......... 2 chr9 - 
2382
4548 117 
OT3-17 
GTTGAGTGAATGTGT
GCGTGAGG 
.T.......A.
......... 2 
chr1
0 - 
9876
0582 98 
GUIDEseq_
HF1 
AGTGAATGAGTGTGT
GTGTGTGG 
A....A.....
.....T... 3 chr3 - 
1939
9387
8 90 
Zhang_VEG
FA1-OT7 
TGTGAGTAAGTGTGT
GTGTGTGG 
T......A...
.....T... 3 
chr1
4 - 
6207
8767 82 
  
GGTGAGTGTGTGTGT
GCATGTGG 
........T..
......A.. 2 chr2 - 
1774
6342
0 74 
  
GATGAGTGAGTGAGT
GAGTGGGG 
.A.........
.A...A... 3 chr6 - 
1570
7832
1 53 
  
GGGGAATGAGTGTGT
GCATGGAG 
..G..A.....
......A.. 3 chr1 + 
2126
3976
1 51 
  
GGTGAGTAAGTGTGA
GCGTAAGG 
.......A...
...A....A 3 
chr1
8 + 
7410
3158 51 
OT3-19 
ACTGTGTGAGTGTGT
GCGTGAGG 
AC..T......
......... 3 
chr1
9 - 
4056
1861 51 
  
CGCGAGTGAGTGTGT
GCGCGGGG 
C.C........
.......C. 3 chr3 - 
7163
2803 50 
VEGF3_new
2 
AGCGAGTGAGTGTGT
GTGTGGGG 
A.C........
.....T... 3 chr9 - 
1873
3629 49 
OT3-22 
AGGGAGTGACTGTGT
GCGTGTGG 
A.G......C.
......... 3 
chr1
0 + 
1302
2833
7 44 
   236 
  
AGTGAGTGAGTGAGT
GAGTGAGG 
A..........
.A...A... 3 chr7 - 
1526
7137
2 34 
  
TGTGAGTGAGTGTGT
GTGTGTGA 
T..........
.....T... 2 chr8 - 
2293
2497 34 
  
GGTGAGAGAGTGTGT
GCGTAGGA 
......A....
........A 2 
chr1
6 - 
7489
8114 33 
  
GGTGGGTGAATGGGT
GCGTGGGG 
....G....A.
.G....... 3 
chr1
7 + 
1914
1553 30 
  
GATGAGTGTGTGTGT
GTGTGAGG 
.A......T..
.....T... 3 chr4 - 
6206
7613 29 
OT3-1 
GGTGAGTGAGTGTGT
GTGTGAGG 
...........
.....T... 1 
chr1
4 + 
1060
2901
5 28 
  
CTGGAGTGAGTGTGT
GTGTGTGG 
CTG........
.....T... 4 
chr1
9 - 
4773
2486 28 
  
TGTGAGTGAGTGTGT
GTGTGTGA 
T..........
.....T... 2 
chr1
9 + 
6109
016 26 
Zhang_VEG
FA1-OT10 
CGTGAGTGAGTGTGT
ACCTGGGG 
C..........
....A.C.. 3 
chr2
0 + 
5072
4388 24 
  
AGGGAGTGAGTGTGA
GAGTGCGG 
A.G........
...A.A... 4 chr6 + 
1444
5827
4 24 
VEGF3_new
1 
GTAGAGTGAGTGTGT
GTGTGTGG 
.TA........
.....T... 3 chr8 + 
4899
7789 24 
  
GGTGAGTGAGTGAGT
GAGTGAGT 
...........
.A...A... 2 chr4 + 
5832
6587 23 
  
GGTGTGTGAGTGAGT
GTGTGTAT 
....T......
.A...T... 3 chr5 - 
2936
7377 23 
  
GGAGAGTGAGTGTGT
GCATGTGC 
..A........
......A.. 2 chr1 + 
1815
5718
7 22 
  
TGTGAGTGAGTGTGT
GCGTGTGA 
T..........
......... 1 
chr1
6 + 
8001
6314 22 
  
GGGGAATGAGTGTGT
GTGTGGGG 
..G..A.....
.....T... 3 chr3 - 
4036
9878 22 
  
GGTGTGTGAGTGTGT
GTGTGTGG 
....T......
.....T... 2 
chr2
2 + 
4973
9984 21 
  
GGTGAGTCAGTGTGT
GAGTGAGG 
.......C...
.....A... 2 chr2 - 
7331
7044 21 
  
GGGGGGTGAGTGTGT
GTGTGGGG 
..G.G......
.....T... 3 chr1 + 
3273
8747 19 
  
GGTGTGTGAGTGTGT
GTGTGTGA 
....T......
.....T... 2 chr7 + 
3934
1109 18 
  
AGTGAGTGAGTGTGA
GTGCGGGG 
A..........
...A.T.C. 4 chr8 - 
6757
9421 17 
  
AGTGAATGAGTGTGT
GCATGTGA 
A....A.....
......A.. 3 chrX + 
1056
1439
8 17 
  
AGAGAGTGAGTGTGT
GTGTTGGG 
A.A........
.....T..T 4 
chr1
0 + 
1078
6736
2 16 
   237 
  
TGTGAGTGAGTGTGT
GTGTGGAG 
T..........
.....T... 2 
chr1
9 - 
1656
9481 16 
  
GGTGAGCAAGTGTGT
GTGTGTGG 
......CA...
.....T... 3 chr2 - 
2305
0623
5 14 
  
AGTGAGTGAGTGTGT
GTGTGAGA 
A..........
.....T... 2 chr3 - 
5104
934 14 
  
GGTGAGTGAGTGAGT
GAGTGAGG 
...........
.A...A... 2 chrX - 
4172
6212 14 
  
TGTGGGTGAGTGTGT
GTGTGTGG 
T...G......
.....T... 3 chr1 - 
4830
5032 13 
  
AGTGAGAAAGTGTGT
GCATGCGG 
A.....AA...
......A.. 4 chr2 + 
1869
6208 13 
  
GGTGAGTAGGTGTGT
GTGTGGGG 
.......AG..
.....T... 3 
chr1
1 - 
7625
789 12 
  
TGTGAGTGAGTGTGT
GTGTGTGA 
T..........
.....T... 2 
chr1
5 - 
9286
4206 12 
  
GGTGAGTGAGAGTGT
GTGTGTGG 
..........A
.....T... 2 chr5 + 
1502
2470
4 12 
  
AGTGAGTGAGTGTGT
GTGTGTGA 
A..........
.....T... 2 
chr1
6 + 
1226
4596 11 
  
GGTGAGTGCGTGTGT
GCGTGCGC 
........C..
......... 1 
chr1
6 + 
6728
3104 11 
  
GGTGAGTGAGTGAGT
GAGTGAGG 
...........
.A...A... 2 
chr1
0 - 
1093
7806
1 10 
  
GGAGAGTGAGTATGT
GTGTGTGT 
..A........
A....T... 3 
chr1
0 - 
5749
655 10 
  
AGTGAGTGAGTGAGT
GAGTGAGT 
A..........
.A...A... 3 
chr1
1 + 
7917
8502 10 
  
TGTGAGTGAGTGTGT
GTGTGTGA 
T..........
.....T... 2 
chr1
4 + 
5811
8427 10 
  
ATTGAGTGAGTATGT
GTGTGAGG 
AT.........
A....T... 4 
chr1
1 + 
6336
6325 9 
  
GGAGAGTGAGTGTGT
GTGTGAGA 
..A........
.....T... 2 chr5 - 
1308
5759
6 9 
  
AGGGTGTGAGTGAGT
GCATGTGT 
A.G.T......
.A....A.. 5 chr5 - 
1787
4653
7 9 
  
GGTGTGTGAGTGTGT
GCATTGGG 
....T......
......A.T 3 chr6 + 
3902
8625 9 
  
AATGAGTGAGTGTGT
GAGTGAAG 
AA.........
.....A... 3 chr1 + 
1164
8562
7 8 
  
AGTGTGTGTGTGTGT
GGTTTTTT 
A...T...T..
.....GT.T 6 
chr1
1 + 
9076
2704 8 
  
GGTGGGTGAGTGAGT
GAGTGAGG 
....G......
.A...A... 3 
chr1
2 + 
1311
9665
0 8 
   238 
  
AGAGAGTGAGTGTGT
GTGTGAGA 
A.A........
.....T... 3 chr1 - 
2450
4846
1 8 
  
GGTGAATGAGTGTGT
GCTCTGGG 
.....A.....
......TCT 4 
chr1
6 - 
8403
2640 8 
  
ACTGAGTGAGTGTGA
GTGTGAGG 
AC.........
...A.T... 4 chr3 + 
1940
7363
5 8 
  
GATGAGTGAGTGTGT
GAGTGAGA 
.A.........
.....A... 2 chr5 - 
1495
0168
8 8 
  
TGTGAGAGAGAGTGT
GCGTGTGG 
T.....A...A
......... 3 chr1 - 
4769
0888 6 
  
AATGAGTGAGTGTGT
GTGTGTGA 
AA.........
.....T... 3 
chr1
6 + 
7358
5909 6 
  
TGTGAGTGAGTGTGG
GTGTGTGG 
T..........
...G.T... 3 chr1 + 
2362
1605
9 5 
OT3-24 
CATGAGTGAGTGTGT
GGGTGGGG 
CA.........
.....G... 3 
chr1
9 + 
1716
775 5 
  
GGCAGGGAAGTGTGT
GCATGGAT 
..CAG.GA...
......A.. 6 chr5 + 
1726
3554
8 5 
  
AGTGTGTGAGTGTGT
GAGTGAGG 
A...T......
.....A... 3 
chr1
3 - 
9170
6950 4 
  
AGAGAGTGAGTGTGT
GTGTGAGA 
A.A........
.....T... 3 
chr1
7 + 
3500
6783 4 
  
AGAGAGAGAGTGTGT
GTGTGGGG 
A.A...A....
.....T... 4 chr3 - 
1693
7909
9 4 
  
GATGAGCGAGTGTGT
GTGTATGG 
.A....C....
.....T..A 4 chrX - 
3960
6143 4 
  
GGTGAGTGGGTGTGT
GTGTTGGG 
........G..
.....T..T 3 
chr1
3 + 
6068
3006 3 
  
TGTGAGTGAGTGGGT
GAGTGTGT 
T..........
.G...A... 3 
chr1
6 - 
7287
7916 3 
  
TGTGAGTGGGTGTGT
GCATGTGG 
T.......G..
......A.. 3 
chr2
1 + 
4417
9960 3 
  
GGTGAGAGAGTGTGT
GCACGGGG 
......A....
......AC. 3 
chr2
2 + 
4393
9280 3 
SpCas9MT3-dSaCas9 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
TS3 
GGTGAGTGAGTGTGT
GCGTGTGG 
...........
......... 0 chr6 + 
4373
7454 479 
OT3-2 
AGTGAGTGAGTGTGT
GTGTGGGG 
A..........
.....T... 2 
chr1
4 - 
6556
9153 77 
  
GGAGAGTGAGTGTGT
GCATGTGC 
..A........
......A.. 2 chr1 + 
1815
5718
7 13 
   239 
OT3-18 
TGTGGGTGAGTGTGT
GCGTGAGG 
T...G......
......... 2 chr5 + 
1154
3465
9 9 
OT3-6 
TGTGGGTGAGTGTGT
GCGTGAGA 
T...G......
......... 2 chr9 - 
2382
4548 7 
SpCas9MT3-dNmCas9 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
TS3 
GGTGAGTGAGTGTGT
GCGTGTGG 
...........
......... 0 chr6 + 
4373
7454 84 
  
AGTGAGTGAGTGTGT
GTGTGTGT 
A..........
.....T... 2 chr3 + 
1365
2162
5 8 
  
TGTGTGAGAGTGTCT
GTGTTCCA 
T...T.A....
..C..T..T 6 
chr1
7 + 
5972
994 4 
  
TGTTAGTGAGTGTTT
AACTGGCT 
T..T.......
..T.AAC.. 6 chr9 + 
2731
0251 4 
  
TGGGAGTGGGAGTGG
GGGTGGAG 
T.G.....G.A
...G.G... 6 chr2 + 
1613
5053
0 3 
SpCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
BCL11A_TS
7,10,11_S
p 
GCTAGTCTAGTGCAA
GCTAACAG 
...........
......... 0 chr2 - 
6072
2412 79 
NmCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
BCL11A_TS
7_NmCas9 
CAGGCTCCAGGAAGG
GTTTGGCCTCTGATT 
...........
........... 0 chr2 - 
6072
2370 256 
  
GAGGGGAAGGGAAGG
GGATGGGGGTGGTTA 
G...GGAAG..
.....GA...G 9 chr7 + 
2158
4864 41 
  
GTGGTGGCAGGATGG
CTTGAGCCCAGGCCG 
GT..TGG....
.T..C..GA.. 9 
chr1
1 + 
1896
2094 3 
  
ATGACCCCAGGGAGG
TTTTTATATGGGACT 
AT.A.C.....
G...T...TAT 9 
chr1
1 - 
6619
6236 3 
SpCas9WT-NmCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
BCL11A_TS
7_NmCas9 
CAGGCTCCAGGAAGG
GTTTGGCCTCTGATT 
...........
........... 0 chr2 - 
6072
2370 177 
  
CAGCCTCCAGAGCAG
CTGGGACCACAGGTG 
...C......A
GCA.C.GG.A. 9 chr6 + 
1519
9993
8 8 
   240 
  
CAGCCTCCAGGGAGA
ACCTCCAGACTGCAG 
...C.......
G..AACC.CCA 9 
chr1
3 - 
8476
5515 3 
  
CAGGCTAAAGGTGTG
GAGAGGAAAAGGTAA 
......AA...
TGT..AGA..A 9 chr8 - 
8810
9044 3 
SaCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
BCL11A_TS
9_SaCas9 
CTTTTATCACAGGCT
CCAGGAAGGGT 
...........
......... 0 chr2 - 
6072
2383 1704 
BCL11A_TS
11_SaCas9 
CCTCTGATTAGGGTG
GGGGCGTGGGT 
...........
......... 0 chr2 - 
6072
2353 1248 
BCL11A_TS
10_SaCas9 
GTTTGGCCTCTGATT
AGGGTGGGGGC 
...........
......... 0 chr2 - 
6072
2359 662 
  
CCCCTGATTAGGGTG
AAGGGCTGGGG 
..C........
....AA..G 4 
chr1
5 + 
7087
2512 380 
  
CCTCTCACCAGGGTG
GGGCTGTGAGT 
.....C.CC..
.......CT 5 chr1 - 
3360
5885 374 
  
CCTTTGAATAAAGTG
GGGGCATGGGG 
...T...A..A
A........ 4 
chr1
6 + 
5541
0314 357 
  
CCTCTCATTAGGGTA
GAGACAAGAAT 
.....C.....
...A.A.A. 4 
chr1
1 + 
9900
6985 111 
  
CCTCTGCTCACGGTG
GGGGCATGGGG 
......C.C.C
......... 3 
chr2
0 + 
5829
7869 71 
  
TCTCTGACAAGAGAG
GAGGCAAGGGT 
T......CA..
A.A..A... 6 chr1 - 
1513
1640
3 69 
  
CCTTTGACTGGGGTG
GGGGGTGGGGT 
...T...C.G.
........G 4 chr1 + 
4870
3020 54 
  
CTTCTGCTTAGGGTG
GAGGCATGAGG 
.T....C....
.....A... 3 chr4 - 
8880
8529 48 
  
CCTCAGATAAGAGTG
GGGACCAGGAG 
....A...A..
A......A. 4 
chr1
3 - 
5172
9736 46 
  
CTTCTGACAAAGATG
GGGGCGGGGGT 
.T.....CA.A
.A....... 5 
chr1
5 + 
4622
1458 36 
  
CCTCTGAGGAGGGTG
AGGGCAGGAGG 
.......GG..
....A.... 3 chr9 + 
1364
9857
8 34 
  
CATCTGATGGGGGTG
GGGGCTTGAGG 
.A......GG.
......... 3 
chr1
9 + 
3893
2084 26 
  
CCTTTGAGAGAGGTG
GGGGCAGGGGT 
...T...GAGA
......... 5 chr4 + 
3873
0629 26 
  
CTTCTGACCAAGGCA
GGGGCTTGAGC 
.T.....CC.A
..CA..... 6 
chr1
2 + 
5442
1154 22 
  
CCTTTGGTTAGGATG
GGGGTAGGGGT 
...T..G....
.A......T 4 chr1 - 
1171
5319
4 20 
  
CCTTTGGTTAGGATG
GGGGTAGGGGT 
...T..G....
.A......T 4 chr2 + 
9193
0605 20 
  
CCTCTGATTAGGGTT
GGGTCGTGGAG 
...........
...T...T. 2 chr1 + 
2362
2871
2 19 
   241 
  
CCTCTGGTAGGGGTA
GGGGTCAGGGT 
......G.AG.
...A....T 5 
chr1
4 - 
5238
9234 18 
  
CACCTGAAAAAGGTG
AGGGCAGGAGT 
.AC....AA.A
....A.... 6 
chr1
2 - 
2447
9594 17 
  
ACCCTAATTAGAGGA
GGGGCCTGGTA 
A.C..A.....
A.GA..... 6 chr3 - 
2544
9995 15 
  
CCTATGATTTGGGTG
GGGGCATGAAG 
...A.....T.
......... 2 chr8 - 
1174
7581
8 14 
  
CCTCTGGCATGGGTG
AGGGCATGGGC 
......GCAT.
....A.... 5 chr2 + 
6751
5306 13 
  
CCTCTCACTAGGGTG
AGGGCTGGGCT 
.....C.C...
....A.... 3 
chr1
2 + 
6447
61 12 
  
CCTCTGGTCGGGGCG
GGGGCGGGGGC 
......G.CG.
..C...... 4 
chr1
9 - 
4984
1518 12 
  
TCTCTGACCAGGGTG
GGGGCTAGCCA 
T......CC..
......... 3 chr1 - 
1905
3367 11 
  
CCTCAGCTTAGGATG
GGGGCTGGAGA 
....A.C....
.A....... 3 chr8 - 
1397
7141
1 10 
  
CCTCTGCATAGGGTG
AGGGCTAGATG 
......CA...
....A.... 3 chr8 - 
2142
8232 10 
  
CCTCTGACCTTGGAG
GGGGCCAGAGT 
.......CCTT
..A...... 5 chr9 - 
1163
5152
9 10 
  
CCTCTGAACAAAGTG
GGGGCTGGAAC 
.......AC.A
A........ 4 chr8 + 
1333
5142
1 9 
  
CTGCTGATTAGGGTG
AGGGTTAGGGT 
.TG........
....A...T 4 
chr1
0 - 
1189
3032
6 8 
  
CCTCTGACCAGGGTG
GAGTAGTGGGT 
.......CC..
.....A.TA 5 chr9 - 
3728
9531 8 
  
CCTGTGAGTAGAGTG
AGGGCAGGAGG 
...G...G...
A...A.... 4 
chr1
1 + 
7516
6399 7 
  
CCCCTGACTGGGGCG
GGGGCGTGGTA 
..C....C.G.
..C...... 4 
chr1
9 + 
3663
0408 7 
  
CCCCTGACTAGGGTG
GGAGCATGGCA 
..C....C...
......A.. 3 chr3 - 
1496
3659 7 
  
CCTCTGACGGGGATG
GGGATGGGGGT 
.......CGG.
.A.....AT 6 chr5 + 
6160
2772 7 
  
CCACTCATTAGGGTG
GAAACAGGAGT 
..A..C.....
.....AAA. 5 chrX + 
8277
7389 5 
  
CCTCTGATTAGGGTG
GAGGTGAGAGA 
...........
.....A..T 2 
chr1
1 + 
2221
7343 4 
  
CCTCTGTCTAGGGTG
GACACTTGAGT 
......TC...
.....ACA. 5 
chr1
1 + 
3318
9658 4 
  
TCTCTGACTAGGAAA
GGGGCCAGAGT 
T......C...
.AAA..... 5 chr1 + 
3486
0363 4 
  
CCTCTGAGTGGGGTG
AAGGCCAGGGG 
.......G.G.
....AA... 4 
chr1
5 + 
5057
1952 4 
   242 
  
CTTCTGATGAGGGTG
GAGGCTGGACA 
.T......G..
.....A... 3 
chr1
6 - 
8005
4318 3 
  
CCTCGGATTAAAGTG
GGGGCTGGGCA 
....G.....A
A........ 3 
chr1
8 - 
5600
8669 3 
  
CCCCTCATCATGGTG
GAGGCTGGGGT 
..C..C..C.T
.....A... 5 chr6 + 
3757
2942 3 
SpCas9WT-NmCas9WT 
Name Sequence 
Alignment to 
target 
# of 
misma
tch 
Chro
moso
me 
Str
an
d 
Start 
positio
n 
Peak 
Score 
BCL11A_TS
9_SaCas9 
CTTTTATCACAGGCT
CCAGGAAGGGT 
...........
......... 0 chr2 - 
6072
2383 1809 
BCL11A_TS
9_SpCas9 
CCAGGGTCAATACAA
CTTTGAAG 
...........
......... 0 chr2 - 
6072
2434 1809 
BCL11A_TS
11_SaCas9 
CCTCTGATTAGGGTG
GGGGCGTGGGT 
...........
......... 0 chr2 - 
6072
2353 210 
BCL11A_TS
10_SaCas9 
GTTTGGCCTCTGATT
AGGGTGGGGGC 
...........
......... 0 chr2 - 
6072
2359 116 
  
CCCCTGATTAGGGTG
AAGGGCTGGGG 
..C........
....AA..G 4 
chr1
5 + 
7087
2512 100 
  
CCTTTGAATAAAGTG
GGGGCATGGGG 
...T...A..A
A........ 4 
chr1
6 + 
5541
0314 82 
  
CCTCTCACCAGGGTG
GGGCTGTGAGT 
.....C.CC..
.......CT 5 chr1 - 
3360
5885 81 
  
CCTCTGCTCACGGTG
GGGGCATGGGG 
......C.C.C
......... 3 
chr2
0 + 
5829
7869 19 
  
TCAGGGTCAAGACAA
CTTTGAGG 
T.........G
......... 2 chr3 + 
1521
7629 16 
  
CTTCTGCTTAGGGTG
GAGGCATGAGG 
.T....C....
.....A... 3 chr4 - 
8880
8529 15 
  
CTTTTATCAGAAGTT
CCAGGGAGGGT 
.........G.
A.T...... 3 chrX + 
6823
4110 12 
  
CCTCTCATTAGGGTA
GAGACAAGAAT 
.....C.....
...A.A.A. 4 
chr1
1 + 
9900
6985 12 
  
CCTCTGAGGAGGGTG
AGGGCAGGAGG 
.......GG..
....A.... 3 chr9 + 
1364
9857
8 12 
  
TCTCTGACAAGAGAG
GAGGCAAGGGT 
T......CA..
A.A..A... 6 chr1 - 
1513
1640
3 11 
  
CCTTTGACTGGGGTG
GGGGGTGGGGT 
...T...C.G.
........G 4 chr1 + 
4870
3020 11 
  
CCTCTGACCTTGGAG
GGGGCCAGAGT 
.......CCTT
..A...... 5 chr9 - 
1163
5152
9 11 
  
CCTCAGATAAGAGTG
GGGACCAGGAG 
....A...A..
A......A. 4 
chr1
3 - 
5172
9736 9 
  
CCAGGGTCAGCACCT
TCTTGGCT 
.........GC
..CTTC... 6 chr3 - 
5174
3062 8 
  
CCTTTGGTTAGGATG
GGGGTAGGGGT 
...T..G....
.A......T 4 chr1 - 
1171
5319
4 8 
   243 
  
CTTTTATTGCAGCCT
CCAGGTGGAAT 
.......TG..
.C....... 3 
chr1
7 + 
1782
6167 6 
  
AGAGGGCCAATACAA
CTTTAGGG 
AG....C....
........A 4 
chr1
0 + 
5694
7264 5 
  
CCTCAGCTTAGGATG
GGGGCTGGAGA 
....A.C....
.A....... 3 chr8 - 
1397
7141
1 4 
  
CCTTTGGTTGGGGCA
GGGGCAGGAAT 
...T..G..G.
..CA..... 5 chr6 - 
3669
6690 4 
  
CTTCTGCGTGGGGGG
GGGGGGGGGGT 
.T....CG.G.
..G.....G 6 
chr1
2 - 
1194
1890
7 3 
  
CATTTGACAAGGGGG
GGGGGGGGGAG 
.A.T...CA..
..G.....G 6 
chr1
7 + 
9191
405 3 
  
CCCCTGAGCAAGGTG
GAGGCTGGATT 
..C....GC.A
.....A... 5 chr6 - 
3185
2626 3 
 
